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Preface
Retinoblastoma (RB) is the most common primary ocular malignancy of
childhood. In the previous half century, universal treatment for this tumor
has been limited to enucleation only. However, with evolving new treatment
modalities, better understanding of the genetic background of this tumor with
corresponding counseling, and improving health awareness, many specialized
centers have been able to offer conservative management with preserved functional
vision in many cases. The survival of affected children has also been dramatically
improved.
This book is the product of collective unique information that covers all major
aspects of this tumor starting from a description of the history of the disease.
The first part of the book has been designed to take you on an interesting
journey over history, including the distribution of RB throughout the world
with epidemiological information and a brief genetic description. The second
part extensively tackles the clinical presentation of the tumor highlighting the
presence of late advanced cases in spite of increasing health awareness of this
tumor. Then, within the same part of the book, readers will find a comprehensive
summary of all treatment modalities used in the previous era of management,
as well as the most recently updated therapeutic options. Diagnostic tools are
also included in that part to show the value of radiological assessment and the
importance of the histopathological careful evaluation of the tumor in enucleated
globes. Classification of the tumor according to the American Joint Commission
on Cancer is also described aiming to show its importance in the determination
of further chemotherapy and as a guideline for prognosis. The last chapters in
the second part also mention secondary malignancies and long-term follow-up in
these patients.
The book is well written in a way that allows readers to grasp and retain
the information, thus it is suitable as a baseline reference book for general 
ophthalmologists, residents under training, as well as highly specialized pediatric
ophthalmologists/oncologists who are actually dealing with these patients. It is
also of benefit to healthcare leaders who are interested in exploring the magnitude
of the morbidity that is related to this tumor in children, especially in developing 
countries, to execute plans for health awareness and genetic counseling for a
brighter future.
The collective information in this book comes from a wide range of sources with
remarkable contributions from radiologists, pediatric oncologists, senior ophthal-
mologists who are directly involved in this field and who have much experience, 
and selected junior ophthalmologists. The editor would like to acknowledge all 
contributing authors.
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Last but not least, the reader will find that the book is enjoyable and full of useful 
information with illustrations and images.
Dr. Hind Manaa Alkatan, MD
Associate Professor and Consultant,
Departments of Ophthalmology and Pathology,
Director of Postgraduate Residency and Fellowship Training Programs in 
Ophthalmology and Assistant Director for External Accreditation Unit,
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Abstract
The history of retinoblastoma (RB) goes back to 1597 when Pieter Pawius of 
Amsterdam described a tumor that resembled retinoblastoma. “Fungus haema-
todes” was the first term used to describe retinoblastoma. Later, the American 
Ophthalmological Society approved the term retinoblastoma in 1926. The reti-
noblastoma protein is encoded by the RB1 gene located at 13q14. The functioning 
model of the tumor suppressor genes was first proposed by Alfred Knudson in 
the 1970s who precisely explained the hereditary mechanism of retinoblastoma. 
If both alleles of this gene are mutated, the protein is inactivated and this results 
in the development of retinoblastoma. One mutation can be either germline or 
somatic and the second one is always somatic. Differentiation between sporadic 
and germline retinoblastoma variants requires the identification of the RB1 germ-
line status of the patient. This identification is important for assessing the risk of 
additional tumors in the same eye, the other eye, and the risk of secondary tumors. 
Thus, genetic testing is an important component of the management of all children 
diagnosed with retinoblastoma. In this chapter, we will go over the history, genetics, 
and counseling for patients with retinoblastoma.
Keywords: history, genetics, two-hit hypothesis, RB1 gene, tumor suppressor, 
epigenetics, Knudson, allele, germline, somatic
1. History
1.1 Introduction
Different tumors that resembled retinoblastoma were described in the past, the 
first of which was by Pieter Pawius of Amsterdam in 1597 [1]. The Dutch anatomist 
described a malignancy involving the left eye, temporal bone, and cranium [1]. 
Pawius described the tumor as “filled with substance like brain tissue mixed with 
thick blood and like crushed stone.” The crushed stone may have represented 
retinoblastoma classic calcifications. Then, in 1767, Hayes described another case 
of a child who had presented with the appearance “cat’s eyes in the dark” [2]. This 
was the first description of leukocoria in the scientific literature. In the last two 
centuries, retinoblastoma had different names. “Fungus haematodes” was the 
term used in the early 1800s. This term was used to describe a fungating vascular 
tumor that affected different parts of the body including the globe. Before the era 
of ophthalmoscopy, no one thought the tumor originated from the globe except 
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James Wardrop who had a different opinion. He believed “fungus haematodes” of 
the globe originated from the retina and should be recognized as a distinct entity 
[3]. Wardrop, who was a Scottish surgeon, reached this conclusion based on his 
dissections. However, at that time, Wardrop’s explanation and observation were 
not acknowledged. Wardrop was also the first surgeon to perform enucleation for 
retinoblastoma [3]. In 1854, Virchow suggested the term “glioma of the retina” [4]. 
Flexner and later Wintersteiner noticed tumor rosettes on histopathology which 
resembled the photoreceptors of the retina [5, 6]. Flexner proposed the name 
neuroepithelioma, and both thought that the photoreceptors were the origin of 
the tumor [5]. Finally, in 1922, Verhoeff coined the term retinoblastoma after he 
noticed the histologic similitude between the disease and embryonic retina [7]. 
Four years later, the American Ophthalmological Society decided to adopt the term 
retinoblastoma. In 1970, Tso described the appearance of fleurettes which represent 
advanced photoreceptor differentiation [8].
1.2 Retinoblastoma variants
Hirschberg categorized the disease per its growth into endophytum and 
exophytum [9]. In 1960, Schofield described few cases who had presented with 
hypopyon and no macroscopic evidence of retinoblastoma [10]. After enucleation, 
histological exam showed malignant cells and rosettes were found within the retina. 
He described the cases as having “diffuse infiltrating retinoblastoma” [10]. He gave 
the credit to Ashton who first used the term in 1958 after personal communication 
with him. Schofield stressed on including retinoblastoma as part of the differential 
diagnosis of hypopyon. In 1998, Grossniklaus was the first to use the name “anterior 
variant of diffuse retinoblastoma” [11]. He reported a case that was misdiagnosed 
as anterior uveitis. After the eye was enucleated, the tumor was found to be in the 
peripheral retina, iris, ciliary body, and anterior vitreous. In 1982, Bader et al. 
described three cases of trilateral retinoblastoma [12]. He found out retinoblas-
toma-like tumors in the suprasellar or parasellar region few months before the 
detection of intraocular retinoblastoma in each of the three cases. He concluded 
the association was more than a coincidence and having retinoblastoma gene may 
confer the risk of having other “ectopic” malignancies.
1.3 The history of genetics
In the 1800s, retinoblastoma was thought to be an autosomal dominant heredi-
tary disease. Alfred Knudson, a cancer geneticist, had observed that patients with 
hereditary retinoblastoma developed multiple tumors in both eyes, while patients 
with the non-hereditary form had unilateral tumors. In 1971, Knudson proposed 
the two-hit hypothesis. It states that a second sporadic mutation should occur in 
patients with hereditary retinoblastoma before the development of retinoblastoma 
[13]. The other type described by Knudson was non-hereditary retinoblastoma. In 
non-hereditary retinoblastoma, two sporadic mutations in both alleles of retinal 
cells should take place. In 1986, RB gene was the first tumor suppressor gene to be 
identified in medical history.
1.4 The treatment history
Wardrop advocated enucleation in 1809 as the only treatment [3]. However, 
Wardrop’s patients failed to survive despite enucleation. Von Graefe suggested 
the optic nerve should be excised during enucleation. This resulted in better 
survival rates. One of the major turn points in the history of retinoblastoma was 
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introduction of ophthalmoscope, which allowed earlier detection of retinoblas-
toma. Retinoblastoma was a fatal disease, so the primary was aim to save life of 
affected patients. The first radiation treatment for retinoblastoma was reported, in 
1903, by Hilgartner in Texas [14]. Hilgartner reported the survival of the patient 
but not the eye following a series of X-rays. Verhoeff, in 1921, used radiotherapy to 
cure retinoblastoma [15]. However, 60 years following radiation therapy, Verhoeff ’s 
patient developed lid basal cell carcinoma and recurrence of retinoblastoma [16]. 
In 1930, Moore used surgically inserted radioactive radon seed to cure retinoblas-
toma [17]. Weve introduced the use of diathermy for treating retinoblastoma [18]. 
However, it resulted in major complications including large chorioretinal scarring 
and scleral thinning. Then, Stallard established plaque brachytherapy [19]. External 
beam radiotherapy (EBRT) was used and resulted in improvement in eye survival 
rates [20]. However, EBRT cause second cancers in patients with germline muta-
tions by causing the second hit described by Knudson [21, 22].
Schwickerath used xenon arc photocoagulation to treat retinoblastoma [23]. 
Harvey Lincoff developed cryotherapy for the treatment of small retinoblastoma 
tumors [24]. In 1953, Kupfer was the first to use chemotherapy, nitrogen mustard, 
along with radiotherapy for retinoblastoma [25]. To decrease systemic side effects 
of chemotherapy, the idea of local chemotherapy came up. Kaneko used intra-
arterial chemotherapy for retinoblastoma, which resulted in substantially higher 
drug concentration in the eye [26, 27]. Retinoblastoma mortality rate decreased 
substantially from 100 to 2% in the last 50 years [25]. Indeed, retinoblastoma is a 
story of success and there is still more to come.
2. Genetics of retinoblastoma
2.1 Introduction
Retinoblastoma (RB) is the most common intraocular malignancy in children 
affecting 1 in 18,000 live births which occurs as a result of biallelic inactivation of 
RB1 gene [28]. Hereditary RB is due to heterozygous germline mutation in one copy 
of the RB1 gene, hence is inherited as an autosomal dominant trait. In this form, all 
body cells have a dysfunctional RB1 allele and, thus, are vulnerable to neoplasia. 
The non-hereditary form of RB is consequent to somatic mutations, which is known 
to affect both RB1 alleles in retinal cells [29].
In these patients, RB development requires a second, somatic, mutation in the 
same cells that renders the other allele nonfunctional. The cumulative incidence 
rates of non-ocular tumors reach up to 90% at 30 years in patients who were 
exposed to radiation vs. 68% at 32 years in patients without radiation exposure [30].
The aim of this chapter is to provide a valuable summary of retinoblastoma 
genetics that is essential for genetic counseling and estimation of short-term (mul-
tifocal and bilateral ocular tumors) and long-term (secondary tumors) risks with an 
overall improvement of healthcare planning and management of our patients.
2.2 The RB1 gene and protein function
The RB1 gene located on the long arm of chromosome 13 (13q14) is a negative 
regulator element in the cell cycle process and was the first tumor suppressor gene 
identified [31]. This gene codes for the RB protein which has multiple cellular func-
tions; it prevents the dividing cells from uncontrollable cycles in the mitosis stage 
and has a role in genomic stability, apoptosis, and differentiation [32]. Inactivation 
of the RB protein is usually caused by deletions and nonsense mutations [33].
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2.3 Inheritance of retinoblastoma
Retinoblastoma is an autosomal dominant inherited disease. Thus, there is a 
50% risk of inheriting a germline mutation for each child born to a patient with a 
germline RB1 mutation. However, 90% of the children with a germline RB1 muta-
tion will develop retinoblastoma with an overall risk of having a child with heredi-
tary retinoblastoma of 45%. The remaining 10% of children with the mutated RB1 
gene will be unaffected carriers [34].
More than 900 mutations have been identified in the RB1gene. Different types 
of mutations have been identified in RB1 gene; deletions and gene rearrange-
ments represent majority of mutations (http://www.hgmd.cf.ac.uk/ac/gene.
php?gene=RB1). Additionally, de novo mutation is considered to be present in most 
children with heritable retinoblastoma, as a positive family history is elicited in only 
10% of all affected children, which is then transmissible in subsequent generations. 
In these children, in whom a germline mutation is present with a negative family 
history, 30% have bilateral disease and 60% develop unilateral RB [35]. A germline 
RB1 mutation is present in 15% of children diagnosed with a unilateral RB [34].
The “2-hit” hypothesis, which was first proposed by Knudson, described two 
complementary mutations that are essential for the development of hereditary and 
non-hereditary forms of retinoblastoma. The first “hit,” or mutation, in heritable 
retinoblastoma is a germline mutation affecting all body cells. The second mutation 
is a somatic mutation occurring in many retinoblasts with subsequent multifocal or 
bilateral lesion. On the other hand, the first and second mutations in non-heritable 
retinoblastoma occur somatically in a single retinoblast presenting as a unilateral 
and unifocal retinoblastoma [36].
2.4 Epigenetics of RB
Epigenetics is the study of heritable changes occurring in gene activity and 
expression of a specific phenotype. These changes do not cause alterations in the 
DNA sequence, external and/or environmental factors might affect cellular and 
physiological phenotypic traits [37].
RB1 gene has been linked to the regulation of numerous epigenetic processes. 
These processes include DNA methylation, histone modification, and microRNA 
regulation [38–43]. In addition, dysfunction of RB1 gene causes deregulations in 
many tumor suppressor pathways. Tumorigenesis requires this epigenetic deregula-
tion against which new therapeutic options can be invented. Retinoblastoma was 
the first tumor discovered to be showing the actions of epigenetics on the pathogen-
esis of cancer [44].
2.4.1 MicroRNAs in RB
MicroRNAs are small, conserved, single-stranded, and non-coding RNA that 
comprise 1–5% of the human genome and are involved in regulating at least 30% of 
protein-coding genes [45–49]. MicroRNAs play an essential role in the regulation 
of gene expression governing various cellular and metabolic pathways [50–56]. 
MicroRNAs’ deregulation has been linked to the development of RB and other 
human diseases [57–59]. Thus, microRNA studies on RB have offered novel under-
standings of the disease mechanisms. Messenger RNA (mRNA), a large family of 
RNA molecules that convey genetic information from DNA to ribosome, was also 
studied in cases of RB. A three-fold increase was noted in mRNA levels of ACVR1C/
ALK7 in retinoblastomas invading the optic nerve. This suggests that ACVR1C/
SMAD2 pathway has a function in promoting invasion and growth of RB [60].
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2.4.2 DNA methylation
DNA methylation involves the addition of methyl groups to the DNA molecule. 
This process can change the DNA segment activity without altering its sequence. 
When this segment is located in a gene promoter, DNA methylation usually acts 
to block gene transcription. The role for promoter methylation in retinoblastoma 
development was discovered when there was methylation of a CpG island (CpG 106) 
that overlapped the RB1 promoter [61]. This has resulted in a decreased gene expres-
sion confirming the epigenetic factor in retinoblastoma tumorigenesis [44, 62–64].
Methylation of DNA segment was also reported in tumor suppressor genes 
beyond RB1. These genes include RASSF1A (RAS-associated domain family 1A) 
that was methylated in 59% of tumors analyzed and adenomatous polyposis coli 
(APC) in 6% [65]. Furthermore, hypermethylation of O6-methylguanine-DNA 
methyltransferase (MGMT) was detected in 15% of RB tumors. This was associated 
with advanced-stage RB suggesting that the presence of methylated MGMT is a 
poor prognostic indicator [66].
2.5 Features of heritable RB
2.5.1 13q deletion syndrome
Children with this syndrome may present with characteristic dysmorphic 
features, developmental delay, and intellectual disability. Interstitial chromo-
some deletion or translocation of region 13q14 was found in approximately 6% of 
patients with RB [67]. The larger the size of chromosomal deletion, the more severe 
the associations. Dysmorphic facial features include high and broad forehead, 
short nose, prominent philtrum, and a thick everted lower lip [67]. Karyotype or 
chromosomal microarray is usually performed to detect chromosomal deletions, 
translocations, and copy number alteration [68].
2.5.2 Trilateral RB
Trilateral retinoblastoma indicates the concomitant presence of a heritable 
retinoblastoma and a midline tumor or a pineoblastoma [12, 69]. Around 5–13% of 
patients with RB develop trilateral retinoblastoma [70]. Therefore, in children with 
heritable retinoblastoma, a brain magnetic resonance imaging with gadolinium 
contrast every 6 months is recommended until the age of 5 years [71].
2.5.3 Secondary malignant neoplasms
As patients with heritable RB age, the risk of non-ocular malignancies signifi-
cantly increases. These tumors include osteosarcoma, soft tissue sarcoma, epithelial 
cancers, and melanoma. It has been suggested that a greater risk for second cancers 
occurs in patients with familial RB compared with those with a de novo RB1 muta-
tion [72]. External beam radiation therapy for patients with heritable disease has a 
further increased risk of developing second malignancies.
2.5.4 Low-penetrant retinoblastoma
In a typical “null” germline mutation, there is a 90% chance that patient 
will develop RB. In a few families, however, the penetrance is far less than 90% 
with subsequent reduced expressivity and an increased proportion of unilateral 
RB. Some patients will be carriers with no tumors [73]. These low-penetrant 
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mutations are usually missense mutations. Moreover, a low level of RB protein 
production due to mutations in the promoter region can occur without total absence 
of the protein [33].
2.6 Genetic testing
2.6.1 Clinical context
Heritability of retinoblastoma is confirmed if a proband with retinoblastoma has 
a family history of retinoblastoma. In the absence of family history of RB, genetic 
testing is required to identify heterozygous germline RB1 pathogenic variants. This 
will allow early diagnosis and identification of potential carriers of the heritable 
RB1 mutations which eventually will improve disease management and family 
counseling.
The following staging system has been proposed to facilitate description of one’s 
genetic risk of possessing germline RB1 pathogenic variant: [74, 75]
2.6.2 Single-gene testing
For bilateral, unilateral familial, and unilateral multifocal retinoblastoma, 
peripheral blood DNA should be tested initially using sequence analysis and gene-
targeted deletion/duplication analysis of RB1. If blood testing did not reveal any 
mutation, molecular analysis of tumor DNA (if either eye was enucleated) should 
subsequently be done. Mosaicism can be assumed if germline mutation was not 
found in this group of patients [76].
For unilateral unifocal non-familial retinoblastoma, the chance of carrying 
RB1 germline mutation is 15%. And, with the high sensitivity of RB1 mutation 
detection techniques which reach up to (95%), testing blood from unilateral 
patients, extracted at the time of the first examination under anesthesia may 
confirm the diagnosis of germline RB1 mutation. If blood DNA testing did not 
reveal any mutation, molecular analysis of tumor DNA (if the eye was enucle-
ated) should subsequently be done. If pathogenic variants were detected in the 
tissue, the blood DNA should be re-tested looking for these specific variants or 
any large rearrangements within the RB1 gene. If tumor tissue was unavailable, a 
negative blood result will reduce the chance of possessing a mutation to less than 
1%. With such very low risk of RB development, the proband needs no additional 
exam under anesthesia and frequent examination in the clinic is sufficient. The 
same conclusion also applies to the offspring.
It has been previously reported by Rushlow et al. that retinoblastoma is not 
exclusively caused by mutations in RB1 gene; mutations in MYCN oncogene has 
been predicted to be responsible for 18% of cases diagnosed with non-familial 
unilateral RB in children less than 6 months of age. They reported group of patients 
who harbored mutations in MYCN amplification and no RB1 mutations. An addi-
tional 1.5% of patients with unilateral non-familial RB were found to have normal 
RB1 and MYCN genes [77].
HX Unknown or insufficient evidence of a constitutional (germline) RB1 pathogenic variant
H0 Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays
H0* Normal RB1 in blood with <1% residual risk for mosaicism
H1 Bilateral retinoblastoma, trilateral retinoblastoma (retinoblastoma with intracranial CNS midline 
embryonic tumor), family history of retinoblastoma, or RB1 pathogenic variant identified in blood
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2.6.3 Chromosomal microarray (CMA)
Chromosomal microarray analysis (CMA) is a technology used for the detection 
of clinically significant microdeletions or duplications and genetic rearrangement 
(including RB1), with a high sensitivity for submicroscopic aberrations [78]. It can 
be utilized in retinoblastoma patients with dysmorphic features, developmental 
delay, and/or other congenital anomalies [79, 80].
2.7 Genetic counseling
Genetic testing and counseling are essential parts of RB disease management; 
they help delineate heritable RB for non-heritable ones. The increased knowledge 
of molecular basis of RB allowed for better understanding and management of the 
disease. Genetic evaluation and counseling should be done in collaboration with a 
geneticist and genetic counselor [81]. The aim of the geneticist is to implement the 
proper test to detect the underlying disease causing mutation and communicate with 
the genetic counselor who will educate patients and their families about their condi-
tion in general, discuss anticipated risk of developing subsequent tumors, and con-
struct the appropriate screening plan for the affected individual and their relatives.
At first encounter of a patient and family of retinoblastoma, detailed family his-
tory should be obtained and family pedigree should be drawn with special attention 
to relatives at risk. Then, genetic testing is offered after discussion about purpose, 
possible outcome, and limitations. Specimens are then collected and sent to a spe-
cialized laboratory for analysis. Another counseling session is arranged to convey 
and interpret the reported results. Accordingly, additional testing and counseling 
should be offered to the relatives at risk.
2.7.1 Prenatal screening
In the presence of family history of retinoblastoma and when a specific RB1 
mutation is detected, a pregnancy at risk can be tested by chorionic villus sampling 
or amniocentesis. Prenatal testing and preimplantation genetic diagnosis are 
indicated as approximately 30% of newborns with an RB1 mutation will harbor a 
vision-threatening tumor [82, 83].
Amniocentesis can be used to screen the fetus for carrying RB1 gene using the 
above-mentioned methods. If an RB1 pathogenic variant was identified, then fetal 
ultrasonography may be used to identify intraocular tumor as small as 2–3 mm in 
size [84]. If tumors are present, preterm delivery to allow early treatment may be 
indicated. Alternatively, early term delivery (i.e., 36–38 weeks gestation) can be 
induced even if no intraocular tumor can be detected as this was found to improve 
the visual outcome and reduce the need for invasive tests and therapies in the 
postnatal period [83, 85].
Prenatal testing and management may raise several ethical issues especially if it 
involved termination of pregnancy. A generally accepted approach is to discuss all 
options with the parents and leave them to decide on further steps.
2.7.2 Genetic screening and counseling after birth
Genetic testing should be performed carefully especially when the propand’s 
blood is found negative for pathogenic mutations. It remains possible that large 
genetic rearrangement is being missed or they are mosaicism for RB1 mutation.
Carriers of RB1 pathogenic variants should be frequently examined for develop-
ment of new tumors whether under anesthesia or in the outpatient setting until they 
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reach 9 years of age and the frequency of follow-ups should be reduced thereafter. 
For relatives who do not carry the mutation, no additional monitoring is required 
[86]. However, proband’s offspring will always be at risk of developing RB and be 
tested for the RB1 pathogenic mutation identified and proper counseling and clinical 
monitoring should be implemented. Additionally, all retinoblastoma survivors 
should have life-long surveillance for other lethal secondary tumors [21, 87, 88].
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Abstract
Retinoblastoma (Rb) is the most common primary intraocular malignancy of 
childhood. The incidence of Rb is stable worldwide at one case per 16,000–18,000 
live births. It is estimated that 7800–8800 Rb cases were newly diagnosed globally 
in 2017. Over 80% of these are in low- and middle-income countries (LMICs) in 
Asia and Africa. So far, there is no validated evidence that retinoblastoma incidence 
is associated with gender, ethnicity or geographical factors. A link between human 
papillomavirus (HPV) and Rb is being investigated to establish its role in the patho-
physiology of the sporadic form of the disease. Survival rates for Rb vary greatly 
between countries: while almost all Rb cases from high-income countries survive, 
cases in LMICs have a mortality rate of up to 70%.
Keywords: retinoblastoma, incidence, RB1, hereditary
1. Introduction
Retinoblastoma (Rb) is the most common intraocular malignancy of childhood, 
but a relatively rare disease, occurring in approximately 1: 16,000–18,000 live 
births [1]. Its incidence is uniform across populations, with no known gender, racial 
or ethnic predilection. Rb develops in early childhood, with the vast majority of 
cases that present before the age of 5 years. The disease can involve one or both eyes 
and can be inherited from an affected parent or developed de novo in a child with 
no family history of Rb. This chapter discusses the epidemiological aspects of Rb, 
including basic concepts in Rb development, incidence and prevalence, age, sex and 
racial considerations, associated environmental factors, trilateral Rb and secondary 
non-Rb malignancies.
2. Genetic considerations
Rb can be inherited by an affected parent or developed de novo in a child with no 
known family history of Rb (i.e., sporadic). The neoplasm can involve one or both 
eyes and may present in an asymmetrical manner, with different grades in each eye 
at presentation or even initially appearing as unilateral and becoming bilateral in the 
course of the disease. The disorder, which is believed to originate from an immature 
cone photoreceptor cell early in childhood, is initiated in most cases by a mutation in 
the RB1 gene. RB1 loss initially produces a retinoma, the benign precursor of Rb, and 
causes genomic instability that subsequently leads to the cancerous tumor, Rb.
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In hereditary Rb cases, a single RB1 allele is mutated in most or every cell of a 
child’s body. An additional “hit” in the second allele in the retina will result in clini-
cal Rb. These cases usually present with bilateral and multifocal disease at a median 
age of 15 months, but can present also in unilateral disease, albeit less frequently. 
Between 30 and 37% of Rb cases are bilateral [2], and all bilateral cases are heredi-
tary. However, it is estimated that up to 18% of unilateral cases are also hereditary 
[3]. This emphasizes the importance of genetic testing in addition to clinical 
examination, as it has direct impact on the recommended screening frequency of 
the fellow eye and occasionally on management decisions.
Non-hereditary cases (i.e., somatic) usually present at a later age (median: 
24 months) with unilateral unifocal disease. In order for the disease to develop in 
this scenario, two consecutive “hits” occur in a retinal cell, resulting in both RB1 
alleles mutated and the development of clinical Rb.
All familial cases are hereditary, but not necessarily vice versa. A mutation 
can occur at or after conception in an individual with no family history of Rb, 
and depending on the stage at which it occurs, some of the fetus’ cells will have 
a mutated RB1 allele, resulting in mosaicism. Children with mosaicism are at 
increased risk of developing Rb. The disease in this scenario is not inherited, hence 
siblings of the proband are not at risk, but offspring potentially are, and therefore 
should be screened soon after birth.
Hereditary Rb has been associated with an increased risk of developing second-
ary non-Rb malignancies [4, 5], including sarcomas, carcinomas, malignant mela-
noma, and neuroectodermal cancers. Secondary tumors were reported to occur in 
up to 20% of cases in 10 years and the incidence was reported to directly correlate 
with the time lag from initial diagnosis. It is also well established that treatment by 
radiotherapy increases the risk of developing secondary tumors, both in and outside 
the field of radiation [6]. Draper et al. showed in a series of nearly 400 hereditary 
cases that close to 10% developed secondary malignancies, mainly osteosarcomas, 
most of which were in the field of radiation [6].
Trilateral Rb is a syndrome consisting of unilateral or bilateral hereditary Rb 
associated with an intracranial neuroblastic tumor that develops most often in the 
pineal gland (i.e., Pinealblastoma). On a meta-analysis by Kivelä [7], 2% of trilat-
eral Rb cases had a brain tumor but no intraocular Rb, 12% had unilateral Rb and 
the remaining had bilateral disease.
3. Magnitude and distribution of Rb
3.1 Global incidence and prevalence
The reported incidence of Rb is constant worldwide at one case per 16,000–
18,000 live births [8, 9]. In 2009 the estimated global annual incidence of Rb ranged 
from 7200 to 8100 children. The global birth rate has dropped since then, from 20.3 
to 18.6 births per 1000 population, but the world’s population has grown from 6593 
to 7550 million [10], resulting in an estimated 7800–8800 newly diagnosed Rb cases 
globally in 2017. The highest disease prevalence is recorded in areas with high birth 
rates, which is the case of many low- and middle-income countries (LMICs).
3.2 Global distribution and survival
Over 80% of the newly diagnosed cases are in LMICs in Asia and Africa (Table 1 
and Figure 1) [3]. These regions also show the lowest survival rate, reporting up to 
70% mortality from Rb. Only about 15% of children with Rb reside in high-income 
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countries, and their prognosis is considered to be very good, with an estimated 
disease-free survival rate of nearly 100% [11].
4. Rb determinants
4.1 Age
According to the World Health Organization’s compendium of data from 







n n n (%)
Continent
North America 273 242 258 (3.1)
Latin America and the Caribbean 669 595 632 (7.7)
Africa 2567 2282 2425 (29.5)
Asia 4656 4139 4398 (53.5)
Europe 504 448 476 (5.8)
Oceania 37 32 35 (0.4)
National income level
Low 1413 1256 1335 (16.2)
Lower-middle 4221 3752 3987 (48.5)
Upper-middle 2272 2020 2146 (26.1)
High 800 711 756 (9.2)
Table 1. 
Estimated number of newly diagnosed retinoblastoma patients in 2017.
Figure 1. 
Estimated average number of newly diagnosed Rb patients in 2017 by national income level. Income level data 
source: United Nations, Department of Economic and Social Affairs PD [10].
Retinoblastoma - Past, Present and Future
18
In hereditary Rb cases, a single RB1 allele is mutated in most or every cell of a 
child’s body. An additional “hit” in the second allele in the retina will result in clini-
cal Rb. These cases usually present with bilateral and multifocal disease at a median 
age of 15 months, but can present also in unilateral disease, albeit less frequently. 
Between 30 and 37% of Rb cases are bilateral [2], and all bilateral cases are heredi-
tary. However, it is estimated that up to 18% of unilateral cases are also hereditary 
[3]. This emphasizes the importance of genetic testing in addition to clinical 
examination, as it has direct impact on the recommended screening frequency of 
the fellow eye and occasionally on management decisions.
Non-hereditary cases (i.e., somatic) usually present at a later age (median: 
24 months) with unilateral unifocal disease. In order for the disease to develop in 
this scenario, two consecutive “hits” occur in a retinal cell, resulting in both RB1 
alleles mutated and the development of clinical Rb.
All familial cases are hereditary, but not necessarily vice versa. A mutation 
can occur at or after conception in an individual with no family history of Rb, 
and depending on the stage at which it occurs, some of the fetus’ cells will have 
a mutated RB1 allele, resulting in mosaicism. Children with mosaicism are at 
increased risk of developing Rb. The disease in this scenario is not inherited, hence 
siblings of the proband are not at risk, but offspring potentially are, and therefore 
should be screened soon after birth.
Hereditary Rb has been associated with an increased risk of developing second-
ary non-Rb malignancies [4, 5], including sarcomas, carcinomas, malignant mela-
noma, and neuroectodermal cancers. Secondary tumors were reported to occur in 
up to 20% of cases in 10 years and the incidence was reported to directly correlate 
with the time lag from initial diagnosis. It is also well established that treatment by 
radiotherapy increases the risk of developing secondary tumors, both in and outside 
the field of radiation [6]. Draper et al. showed in a series of nearly 400 hereditary 
cases that close to 10% developed secondary malignancies, mainly osteosarcomas, 
most of which were in the field of radiation [6].
Trilateral Rb is a syndrome consisting of unilateral or bilateral hereditary Rb 
associated with an intracranial neuroblastic tumor that develops most often in the 
pineal gland (i.e., Pinealblastoma). On a meta-analysis by Kivelä [7], 2% of trilat-
eral Rb cases had a brain tumor but no intraocular Rb, 12% had unilateral Rb and 
the remaining had bilateral disease.
3. Magnitude and distribution of Rb
3.1 Global incidence and prevalence
The reported incidence of Rb is constant worldwide at one case per 16,000–
18,000 live births [8, 9]. In 2009 the estimated global annual incidence of Rb ranged 
from 7200 to 8100 children. The global birth rate has dropped since then, from 20.3 
to 18.6 births per 1000 population, but the world’s population has grown from 6593 
to 7550 million [10], resulting in an estimated 7800–8800 newly diagnosed Rb cases 
globally in 2017. The highest disease prevalence is recorded in areas with high birth 
rates, which is the case of many low- and middle-income countries (LMICs).
3.2 Global distribution and survival
Over 80% of the newly diagnosed cases are in LMICs in Asia and Africa (Table 1 
and Figure 1) [3]. These regions also show the lowest survival rate, reporting up to 
70% mortality from Rb. Only about 15% of children with Rb reside in high-income 
19
Epidemiological and Genetic Considerations in Retinoblastoma
DOI: http://dx.doi.org/10.5772/intechopen.86811
countries, and their prognosis is considered to be very good, with an estimated 
disease-free survival rate of nearly 100% [11].
4. Rb determinants
4.1 Age
According to the World Health Organization’s compendium of data from 







n n n (%)
Continent
North America 273 242 258 (3.1)
Latin America and the Caribbean 669 595 632 (7.7)
Africa 2567 2282 2425 (29.5)
Asia 4656 4139 4398 (53.5)
Europe 504 448 476 (5.8)
Oceania 37 32 35 (0.4)
National income level
Low 1413 1256 1335 (16.2)
Lower-middle 4221 3752 3987 (48.5)
Upper-middle 2272 2020 2146 (26.1)
High 800 711 756 (9.2)
Table 1. 
Estimated number of newly diagnosed retinoblastoma patients in 2017.
Figure 1. 
Estimated average number of newly diagnosed Rb patients in 2017 by national income level. Income level data 
source: United Nations, Department of Economic and Social Affairs PD [10].
Retinoblastoma - Past, Present and Future
20
per million compared to <1 per million in children aged 5–9 years, and significantly 
lower beyond that age [12].
It is difficult to accurately estimate the time at which Rb tumors first develop as 
information about the biological development of the disease is essentially lacking. 
There are three important time points associated with Rb development and the time 
of Rb diagnosis. These include (1) retinal tumor growth following two RB1 mutative 
events, (2) parents/guardians noticing the first ocular sign, and (3) presentation to 
an Rb center, at which diagnosis is made and treatment given.
As discussed earlier, the median age of presentation for bilateral cases is 
15 months, while for non-hereditary cases is 24 months. Most of the available 
knowledge originates from familial cases in high income countries, where Rb 
centers commonly perform screening tests for patients at risk (i.e., siblings of 
probands). Screening allows detection of small tumors very early in the course of 
disease, relatively soon after they develop. However, since sporadic cases are not 
screened, we rely only on age of presentation at two time points. First, the time 
at which the parents/guardians notice an ocular abnormality, it is usually a white 
pupillary reflex (i.e., leukocoria). Second, the time at which the final diagnosis is 
made, which is dependent on the time it takes the patient to reach the Rb center in 
the referral pathway.
The body of knowledge on Rb is based on retrospective studies, hence, the most 
accurate data in this context reports the age of the child’s first presentation at an Rb 
center. Nevertheless, several studies have investigated the lag time from the first 
ocular sign as noticed by parents, to the presenting sign at the Rb center. In this 
respect, a huge gap exists between high-income countries and LMICs. In the UK, 
the referral time from sign onset to visiting primary care was found to be 28 days, 
primary care to ophthalmologist 3 days, and the time from local ophthalmologist 
to an Rb Unit was 6 days. In low-income countries, these time lags are considerably 
longer, and can take 6 months or more [13].
Rarely, Rb can develop in adults older than 20 years of age, with fewer than 50 
case reports found in the literature. Adult-onset Rb is quite different in its presenta-
tion compared to its pediatric form, and due to its rarity, it is usually not considered 
in the differential diagnosis, often leading to delay in diagnosis.
In trilateral Rb [7], rates of familial Rb, the age at diagnosis and laterality were 
found to be similar to ordinary hereditary Rb. Cases of suprasellar trilateral Rb, 
however, were diagnosed at an earlier age as compared to Pinealblastoma. The 
median age of Rb diagnosis was 5 months, and cases of familial Rb were diagnosed 
at an earlier age than non-familial cases.
4.2 Gender
There is no known gender predilection in Rb, and although this notion is widely 
quoted in many scientific reports in the field, it has not actually been thoroughly 
investigated. Based on data available from the Surveillance, Epidemiology, and End 
Results (SEER) program of the National Cancer Institute, Tamboli et al. calculated 
the incidence of Rb in the United States from 1974 to 1985 and found no gender dif-
ferences [14]. Gurney et al. used the same data source for similar years (1974–1989), 
but concluded that rates of Rb were higher in females [15], and Wong et al., in 
contrast, found an excess of Rb cases in males using the SEER database for the 
years 2000–2009 [8]. RB1 gene is located on chromosome 13 and there is no known 
relation to any of the sex chromosomes. There is also no evidence of an associa-
tion between sex hormones and Rb. Cases of trilateral Rb do not show any gender 
predilection either [7].
21
Epidemiological and Genetic Considerations in Retinoblastoma
DOI: http://dx.doi.org/10.5772/intechopen.86811
4.3 Race
Similar to sex, there is no known association between race and Rb, although 
some exceptions have been reported. Gurney et al. found higher rates of Rb in 
blacks as compared to whites in the United States [15]. Broaddus et al., in contrast, 
found that the overall mean age-adjusted incidence of Rb was 11.3 for Caucasians 
and 13.0 for blacks, with no significant difference between the two populations [8]. 
Krishna et al. examined the incidence of Rb using data from the International 
Agency for Research on Cancer [16], and found no significant difference between 
white populations in the United States and Europe/Australia, Hispanic popula-
tions in Spain and the United States, and Hispanic populations in Uruguay and 
the United States. They concluded that Rb incidence is similar among varied 
populations.
4.4 Environmental factors
Several studies have shown a link between human papillomavirus (HPV) and 
the development of sporadic Rb [17, 18]. Shetty et al. analyzed enucleated eyes 
with Rb and found that 70% were positive for HPV [17], suggesting that the virus 
may play a role in the development of sporadic RB. Anand et al. tested the presence 
of HPV in Rb tissue (formalin-fixed paraffin-embedded tissue and fresh-frozen 
specimens) and found that nearly a quarter of the specimens were positive for HPV 
[19]. However, the implications of the presence of HPV in Rb tissue and its role in 
carcinogenesis warrant further study. Jemal et al. investigated the relation between 
Rb incidence and ultraviolet (UV-B) radiation levels in the SEER program and 
found no statistically significant correlations [20]. To the best of our knowledge, 
there are no other reports focused on any additional environmental factors in 
association with Rb development.
5. Conclusions
Rb is the most common primary intraocular malignancy of childhood. The 
disease can involve one or both eyes and can be inherited or sporadic. The incidence 
of Rb is stable worldwide at one case per 16,000–18,000 live births. The average Rb 
incidence rate in children aged 0–4 years is >10 per million compared to <1 per mil-
lion in children aged 5–9 years, and significantly lower beyond that age. In 2017, 
globally, an estimated 7800–8800 Rb cases were newly diagnosed. Over 80% of 
these are in LMICs in Asia and Africa.
So far, there is no validated evidence that retinoblastoma incidence is associated 
with gender, ethnicity or geographical factors. Studies have shown the presence 
of HPV in sporadic Rb tissue. Its role in carcinogenesis and the development of 
sporadic Rb warrants further investigation.
We lack accurate information about the biological development of Rb which cre-
ates difficulties in estimating the time at which Rb tumors first develop. In familial 
cases from high-income countries, genetic screening is routinely conducted. 
However, in low-income countries this is not the case, and in all settings sporadic 
cases are not screened. In these cases, we rely on time of presentation, which is 
strongly influenced by the referral pathways in different settings.
Survival rates are related to the time taken for the child to present at an Rb center 
and vary greatly between countries: while almost all Rb cases from high-income 
countries survive, cases in LMICs have a mortality rate of 70%.
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respect, a huge gap exists between high-income countries and LMICs. In the UK, 
the referral time from sign onset to visiting primary care was found to be 28 days, 
primary care to ophthalmologist 3 days, and the time from local ophthalmologist 
to an Rb Unit was 6 days. In low-income countries, these time lags are considerably 
longer, and can take 6 months or more [13].
Rarely, Rb can develop in adults older than 20 years of age, with fewer than 50 
case reports found in the literature. Adult-onset Rb is quite different in its presenta-
tion compared to its pediatric form, and due to its rarity, it is usually not considered 
in the differential diagnosis, often leading to delay in diagnosis.
In trilateral Rb [7], rates of familial Rb, the age at diagnosis and laterality were 
found to be similar to ordinary hereditary Rb. Cases of suprasellar trilateral Rb, 
however, were diagnosed at an earlier age as compared to Pinealblastoma. The 
median age of Rb diagnosis was 5 months, and cases of familial Rb were diagnosed 
at an earlier age than non-familial cases.
4.2 Gender
There is no known gender predilection in Rb, and although this notion is widely 
quoted in many scientific reports in the field, it has not actually been thoroughly 
investigated. Based on data available from the Surveillance, Epidemiology, and End 
Results (SEER) program of the National Cancer Institute, Tamboli et al. calculated 
the incidence of Rb in the United States from 1974 to 1985 and found no gender dif-
ferences [14]. Gurney et al. used the same data source for similar years (1974–1989), 
but concluded that rates of Rb were higher in females [15], and Wong et al., in 
contrast, found an excess of Rb cases in males using the SEER database for the 
years 2000–2009 [8]. RB1 gene is located on chromosome 13 and there is no known 
relation to any of the sex chromosomes. There is also no evidence of an associa-
tion between sex hormones and Rb. Cases of trilateral Rb do not show any gender 
predilection either [7].
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4.3 Race
Similar to sex, there is no known association between race and Rb, although 
some exceptions have been reported. Gurney et al. found higher rates of Rb in 
blacks as compared to whites in the United States [15]. Broaddus et al., in contrast, 
found that the overall mean age-adjusted incidence of Rb was 11.3 for Caucasians 
and 13.0 for blacks, with no significant difference between the two populations [8]. 
Krishna et al. examined the incidence of Rb using data from the International 
Agency for Research on Cancer [16], and found no significant difference between 
white populations in the United States and Europe/Australia, Hispanic popula-
tions in Spain and the United States, and Hispanic populations in Uruguay and 
the United States. They concluded that Rb incidence is similar among varied 
populations.
4.4 Environmental factors
Several studies have shown a link between human papillomavirus (HPV) and 
the development of sporadic Rb [17, 18]. Shetty et al. analyzed enucleated eyes 
with Rb and found that 70% were positive for HPV [17], suggesting that the virus 
may play a role in the development of sporadic RB. Anand et al. tested the presence 
of HPV in Rb tissue (formalin-fixed paraffin-embedded tissue and fresh-frozen 
specimens) and found that nearly a quarter of the specimens were positive for HPV 
[19]. However, the implications of the presence of HPV in Rb tissue and its role in 
carcinogenesis warrant further study. Jemal et al. investigated the relation between 
Rb incidence and ultraviolet (UV-B) radiation levels in the SEER program and 
found no statistically significant correlations [20]. To the best of our knowledge, 
there are no other reports focused on any additional environmental factors in 
association with Rb development.
5. Conclusions
Rb is the most common primary intraocular malignancy of childhood. The 
disease can involve one or both eyes and can be inherited or sporadic. The incidence 
of Rb is stable worldwide at one case per 16,000–18,000 live births. The average Rb 
incidence rate in children aged 0–4 years is >10 per million compared to <1 per mil-
lion in children aged 5–9 years, and significantly lower beyond that age. In 2017, 
globally, an estimated 7800–8800 Rb cases were newly diagnosed. Over 80% of 
these are in LMICs in Asia and Africa.
So far, there is no validated evidence that retinoblastoma incidence is associated 
with gender, ethnicity or geographical factors. Studies have shown the presence 
of HPV in sporadic Rb tissue. Its role in carcinogenesis and the development of 
sporadic Rb warrants further investigation.
We lack accurate information about the biological development of Rb which cre-
ates difficulties in estimating the time at which Rb tumors first develop. In familial 
cases from high-income countries, genetic screening is routinely conducted. 
However, in low-income countries this is not the case, and in all settings sporadic 
cases are not screened. In these cases, we rely on time of presentation, which is 
strongly influenced by the referral pathways in different settings.
Survival rates are related to the time taken for the child to present at an Rb center 
and vary greatly between countries: while almost all Rb cases from high-income 
countries survive, cases in LMICs have a mortality rate of 70%.
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Spencer T. Langevin and Brian P. Marr
Abstract
Retinoblastoma was initially described in a case series by Dr. James Wardrop in 
1809. Since then, the evaluation and diagnosis of retinoblastoma has progressed 
significantly, thus providing a framework for successful therapy with up to 97% 
survival rate in developed nations. Here we outline the presentation, evaluation, 
and detailed diagnostic steps of any child presenting with signs and symptoms 
of retinoblastoma (RB). We detail the questions and pertinent history to obtain, 
describe in detail the examination under anesthesia, ancillary testing, and recom-
mendations for both anesthesia and neuroimaging. We also cover the differential 
diagnosis of retinoblastoma and the most common simulating lesions to present 
to an ophthalmologist. We describe the ways to determine if a patient has retino-
blastoma or some simulating lesion, and the characteristics associated with each 
possibility. Finally, we briefly address genetic counseling and the next steps after 
diagnosis.
Keywords: retinoblastoma, intraocular tumors, oncology, children,  
b-scan ultrasonography, leukocoria, evaluation, diagnosis
1. Introduction
Pawius of Amsterdam is the first physician credited with recognizing retinoblas-
toma in the autopsy of a young child in 1597 [1]. In 1809, a Scottish surgeon from 
Edinburgh, James Wardrop, published a monograph entitled “Observations on the 
fungus haematodes, or soft cancer, in several of the most important organs of the human 
body”. His monograph included clinical histories of 15 children diagnosed with an 
intraocular tumor at the age of 1–6 years [2]. Dr. Wardrop described the tumors as 
“white in colour and brain-like in substance”, and he concluded as well that they 
were of retinal origin. He even went so far as to recommend enucleation to save 
the life of the children, in which his peers did not agree with him at the time. The 
first case in American literature was by Dr. Steven at New York Hospital in 1818 [3]. 
At the time, retinoblastoma was known at fungus haematodes which was initially 
described by Dr. Hey of Leeds, England [4]. Virchow in 1845 renamed the entity 
glioma of the retina [5]. Hirschberg further described the glioma into exophytum 
and endophytum [6]. Flexner described the histologic findings of cellular rosettes 
in the tumor in 1891 [7]. In 1897, Wintersteiner described the lumen of the rosette 
[8]. Finally Verhoeff named the tumor retinoblastoma which was adopted by the 
American Ophthalmological Society in 1926, thus arriving at the terminology we 
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1. Introduction
Pawius of Amsterdam is the first physician credited with recognizing retinoblas-
toma in the autopsy of a young child in 1597 [1]. In 1809, a Scottish surgeon from 
Edinburgh, James Wardrop, published a monograph entitled “Observations on the 
fungus haematodes, or soft cancer, in several of the most important organs of the human 
body”. His monograph included clinical histories of 15 children diagnosed with an 
intraocular tumor at the age of 1–6 years [2]. Dr. Wardrop described the tumors as 
“white in colour and brain-like in substance”, and he concluded as well that they 
were of retinal origin. He even went so far as to recommend enucleation to save 
the life of the children, in which his peers did not agree with him at the time. The 
first case in American literature was by Dr. Steven at New York Hospital in 1818 [3]. 
At the time, retinoblastoma was known at fungus haematodes which was initially 
described by Dr. Hey of Leeds, England [4]. Virchow in 1845 renamed the entity 
glioma of the retina [5]. Hirschberg further described the glioma into exophytum 
and endophytum [6]. Flexner described the histologic findings of cellular rosettes 
in the tumor in 1891 [7]. In 1897, Wintersteiner described the lumen of the rosette 
[8]. Finally Verhoeff named the tumor retinoblastoma which was adopted by the 
American Ophthalmological Society in 1926, thus arriving at the terminology we 
use to this day [9].
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2. Presentation, evaluation, and diagnosis
2.1 Clinical presentation
The initial signs and symptoms of retinoblastoma (RB) are usually noticed by 
friends or family members, or at times from an abnormal “red reflex”, more specifi-
cally, a white reflex or (leukocoria) from a photograph. Medical professionals, such 
as pediatricians during a routine examination, or a pediatric ophthalmologist, may 
also notice signs and symptoms consistent with RB, however less often. In very 
rare circumstances the intraocular mass may be picked up on head imaging for 
non-ophthalmic reasons. In developed nations such as the United States, the most 
common presenting finding for intraocular retinoblastoma is leukocoria or “cats 
eye reflex” (43%), followed by strabismus (22%), pseudo cellulitis, (9%), microph-
thalmia (5%), routine screening examination (17%), and rarely the presence of an 
intraocular mass on non-ophthalmic imaging (<1%) [10].
On average the ophthalmic oncologist is the third medical professional to 
evaluate a child suspicious for having RB. According to a large study on referral 
patterns there is an average delay of 1.1 months between initial symptoms and 
evaluation with any medical professional, and 2.0 months before an appointment 
with an ophthalmic oncologist [10]. As of 2014, mortality from retinoblastoma in 
the United States is approximately 3%, however in developing countries is close 
to 60%. Although our treatment has improved greatly, in many parts of the world 
access to care is a large barrier to successful therapy. Mean age at diagnosis in Asia 
is 22 months, compared to North America and Europe which are 12 and 9 months, 
respectively. On a more significant note, there are approximately 3000 new cases 
of retinoblastoma in Asia compared to only 300 new cases in North America, even 
further highlighting the need for improved access to care. As there are relatively 
few specialists and centers who treat such a rare condition, it is important to use 
the internet, telemedicine, and other social services to help train ancillary staff and 
improve access to triage services to improve prognosis for children.
2.2 Misdiagnosis and differential diagnosis
A review of the literature demonstrates a historic misdiagnosis rate of 
11–40% based on histopathologic analysis of enucleated specimens, and a clini-
cal misdiagnosis rate from 16 to 53% [10]. Fortunately the accuracy in diagnosis 
at specialized ophthalmic oncology centers in the United States is believed to 
exceed 99%. In a recent review of referring physician patterns the most common 
simulating lesions (>5% of analyzed lesions) were: Persistent fetal vasculature, 
Coat’s Disease, Astrocytic Hamartoma, Intraretinal hemorrhage, and retinal 
detachment. Retinopathy of prematurity and congenital cataract were previously 
misdiagnosed often, but increased awareness of these conditions and better 
examination practices are likely the cause of reduced misdiagnosis of these two 
entities. Misdiagnosis of RB may be due to the fact that the condition is exceed-
ingly rare, large differential diagnosis, and the challenges of examining children. 
Thus, any suspicion for the condition should warrant prompt referral to special-
ized care [11].
2.3 Evaluation and diagnosis of retinoblastoma
We will describe an organized approach in a stepwise manner for evaluating 
and properly diagnosis of RB. This will consist of: detailed history, initial office 
examination, ultrasonographic testing, examination under anesthesia, and current 
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consensus on imaging and genetic testing. Modifications dependent on specific 
patient encounters should be left to the treating physician.
2.3.1 History
For any child with suspicion of retinoblastoma, a very detailed history is the 
most useful step in establishing an appropriate differential diagnosis and accurate 
examination, and in cases may establish the diagnosis. History should be taken 
prior to examination to ensure an appropriate focused examination. It should 
include details of the pregnancy, labor, and delivery of the child. History of birth 
weight, birth trauma, maternal infection, history of prematurity, oxygen therapy, 
and whether leukocoria was present at birth or developed later. Also, history of 
hearing abnormalities at birth or during young childhood should be taken into 
consideration as well. History of animal/pet exposure should also be elicited. 
These questions should help direct the clinician to the diagnosis of cataract, 
retinopathy of prematurity, persistent fetal vasculature, toxocariasis, and con-
genital rubella, which all can mimic retinoblastoma. The time course of when 
parents or clinicians first noticed an abnormality and the course of their visits 
with other health care providers should be carefully elicited. Most children with 
retinoblastoma do not have an obvious ocular abnormality at birth. They tend to 
develop signs such as esotropia, visual disturbances, or other strabismus between 
6 months and 2 years of age. Leukocoria is also unlikely to be present at birth and 
will occur around the same time frame as the strabismus. For children suspected 
to have retinoblastoma a detailed family history including number and health of 
their siblings should be noted, along with any history of family medical condi-
tions. A history of poor vision, blindness, or loss of an eye should be requested. 
A positive history of retinoblastoma in parents should point to the diagnosis, as 
simulating lesions do not usually occur in patients with a positive family history. 
If the child’s parents or siblings have not had recent dilated fundus examinations 
they should be performed as soon as possible [12]. About 1% of patients with 
history of retinoblastoma may develop spontaneous regression with retinoma/
retinocytoma present on dilated examination [13]. Some parents may be unaware 
that they were treated for retinoblastoma as children and examination may be 
able to elicit this finding.
2.3.2 Office examination
The initial examination of the child should occur while history taking, by 
watching the child’s behavior, visual interaction with the world, and evaluating 
for any abnormalities in size of the child, proportions, or for any facial abnormali-
ties. The external examination of a child with retinoblastoma should be otherwise 
normal except for the ocular exam unless the child has a 13q deletion syndrome. 
Before the formal examination, the ability to notice leukocoria, decreased visual 
function, strabismus, or periorbital swelling should be noted upon gross examina-
tion. Assessment of vision is obviously dependent on age of patient, and his or her 
individual cooperation, but the size and symmetry of each eye should be recorded, 
as asymmetric size can suggest other diagnoses as well as retinoblastoma. Presence 
or absence of heterochromia should be noted during this portion of the examina-
tion as well [12]. Pupil response should also be documented. Using a direct ophthal-
moscope or retinoscope, the pupillary light reflex should be noted in both eyes and 
leukocoria can be noted at that time.
The next step should be instillation of dilating eyedrops (0.5% tropicamide and 
2.5% phenylephrine). Cyclopentolate is not necessary for this examination. If the 
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as pediatricians during a routine examination, or a pediatric ophthalmologist, may 
also notice signs and symptoms consistent with RB, however less often. In very 
rare circumstances the intraocular mass may be picked up on head imaging for 
non-ophthalmic reasons. In developed nations such as the United States, the most 
common presenting finding for intraocular retinoblastoma is leukocoria or “cats 
eye reflex” (43%), followed by strabismus (22%), pseudo cellulitis, (9%), microph-
thalmia (5%), routine screening examination (17%), and rarely the presence of an 
intraocular mass on non-ophthalmic imaging (<1%) [10].
On average the ophthalmic oncologist is the third medical professional to 
evaluate a child suspicious for having RB. According to a large study on referral 
patterns there is an average delay of 1.1 months between initial symptoms and 
evaluation with any medical professional, and 2.0 months before an appointment 
with an ophthalmic oncologist [10]. As of 2014, mortality from retinoblastoma in 
the United States is approximately 3%, however in developing countries is close 
to 60%. Although our treatment has improved greatly, in many parts of the world 
access to care is a large barrier to successful therapy. Mean age at diagnosis in Asia 
is 22 months, compared to North America and Europe which are 12 and 9 months, 
respectively. On a more significant note, there are approximately 3000 new cases 
of retinoblastoma in Asia compared to only 300 new cases in North America, even 
further highlighting the need for improved access to care. As there are relatively 
few specialists and centers who treat such a rare condition, it is important to use 
the internet, telemedicine, and other social services to help train ancillary staff and 
improve access to triage services to improve prognosis for children.
2.2 Misdiagnosis and differential diagnosis
A review of the literature demonstrates a historic misdiagnosis rate of 
11–40% based on histopathologic analysis of enucleated specimens, and a clini-
cal misdiagnosis rate from 16 to 53% [10]. Fortunately the accuracy in diagnosis 
at specialized ophthalmic oncology centers in the United States is believed to 
exceed 99%. In a recent review of referring physician patterns the most common 
simulating lesions (>5% of analyzed lesions) were: Persistent fetal vasculature, 
Coat’s Disease, Astrocytic Hamartoma, Intraretinal hemorrhage, and retinal 
detachment. Retinopathy of prematurity and congenital cataract were previously 
misdiagnosed often, but increased awareness of these conditions and better 
examination practices are likely the cause of reduced misdiagnosis of these two 
entities. Misdiagnosis of RB may be due to the fact that the condition is exceed-
ingly rare, large differential diagnosis, and the challenges of examining children. 
Thus, any suspicion for the condition should warrant prompt referral to special-
ized care [11].
2.3 Evaluation and diagnosis of retinoblastoma
We will describe an organized approach in a stepwise manner for evaluating 
and properly diagnosis of RB. This will consist of: detailed history, initial office 
examination, ultrasonographic testing, examination under anesthesia, and current 
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consensus on imaging and genetic testing. Modifications dependent on specific 
patient encounters should be left to the treating physician.
2.3.1 History
For any child with suspicion of retinoblastoma, a very detailed history is the 
most useful step in establishing an appropriate differential diagnosis and accurate 
examination, and in cases may establish the diagnosis. History should be taken 
prior to examination to ensure an appropriate focused examination. It should 
include details of the pregnancy, labor, and delivery of the child. History of birth 
weight, birth trauma, maternal infection, history of prematurity, oxygen therapy, 
and whether leukocoria was present at birth or developed later. Also, history of 
hearing abnormalities at birth or during young childhood should be taken into 
consideration as well. History of animal/pet exposure should also be elicited. 
These questions should help direct the clinician to the diagnosis of cataract, 
retinopathy of prematurity, persistent fetal vasculature, toxocariasis, and con-
genital rubella, which all can mimic retinoblastoma. The time course of when 
parents or clinicians first noticed an abnormality and the course of their visits 
with other health care providers should be carefully elicited. Most children with 
retinoblastoma do not have an obvious ocular abnormality at birth. They tend to 
develop signs such as esotropia, visual disturbances, or other strabismus between 
6 months and 2 years of age. Leukocoria is also unlikely to be present at birth and 
will occur around the same time frame as the strabismus. For children suspected 
to have retinoblastoma a detailed family history including number and health of 
their siblings should be noted, along with any history of family medical condi-
tions. A history of poor vision, blindness, or loss of an eye should be requested. 
A positive history of retinoblastoma in parents should point to the diagnosis, as 
simulating lesions do not usually occur in patients with a positive family history. 
If the child’s parents or siblings have not had recent dilated fundus examinations 
they should be performed as soon as possible [12]. About 1% of patients with 
history of retinoblastoma may develop spontaneous regression with retinoma/
retinocytoma present on dilated examination [13]. Some parents may be unaware 
that they were treated for retinoblastoma as children and examination may be 
able to elicit this finding.
2.3.2 Office examination
The initial examination of the child should occur while history taking, by 
watching the child’s behavior, visual interaction with the world, and evaluating 
for any abnormalities in size of the child, proportions, or for any facial abnormali-
ties. The external examination of a child with retinoblastoma should be otherwise 
normal except for the ocular exam unless the child has a 13q deletion syndrome. 
Before the formal examination, the ability to notice leukocoria, decreased visual 
function, strabismus, or periorbital swelling should be noted upon gross examina-
tion. Assessment of vision is obviously dependent on age of patient, and his or her 
individual cooperation, but the size and symmetry of each eye should be recorded, 
as asymmetric size can suggest other diagnoses as well as retinoblastoma. Presence 
or absence of heterochromia should be noted during this portion of the examina-
tion as well [12]. Pupil response should also be documented. Using a direct ophthal-
moscope or retinoscope, the pupillary light reflex should be noted in both eyes and 
leukocoria can be noted at that time.
The next step should be instillation of dilating eyedrops (0.5% tropicamide and 
2.5% phenylephrine). Cyclopentolate is not necessary for this examination. If the 
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child is large enough or a portable slit lamp is available, slit lamp examination should 
be performed, care to note, presence or absence of cataract, conjunctival or scleral 
injection, anterior segment shallowing, neovascularization of the iris, iris seeding 
or iris atrophy. Evaluate for retrolental membranes to assess presence of retinopathy 
of prematurity or persistent fetal vasculature. Most patients with retinoblastoma 
have normal anterior segments but may have anterior cells or nodules on the iris. 
In exophytic tumors, visualization of retinal vasculature behind the lens may be 
possible as well. Indirect ophthalmoscopy should be performed to evaluate the 
posterior pole and fundus. Depending on the age of the child, they may cooperate or 
family members may be needed to help secure the patient in a supine position. Very 
young children may be swaddled with a blanket to secure their limbs. The indirect 
exam in the office should be used to rule out simulating lesions when possible and 
to also increase or decrease suspicion for retinoblastoma, thus determining whether 
examination under anesthesia (EUA) is needed for full evaluation and diagnosis. 
An eyelid speculum may be needed for proper dilated examination, and a topical 
anesthetic such as 0.5 or 1% proparacaine should be instilled prior to speculum 
insertion. Scleral depression may be indicated, if it can be reserved for examination 
under anesthesia it is less traumatic but can be done in the office setting.
2.3.3 Ophthalmic ultrasound
An ophthalmic ultrasound can be performed in the A and B scan mode using 
a 10 mHz transducer to evaluate for intraocular masses, retinal detachment, or 
calcification. In retinoblastoma, the ultrasound should reveal an irregular mass, 
which is more echogenic than the vitreous, and commonly has fine calcifications 
(highly reflective foci mostly with acoustic shadowing) since upon histologic study, 
95% of retinoblastoma contains calcification [14] (Figure 1). Measurements should 
be taken as a baseline to compare to in the future following treatment.
2.4 Exam under anesthesia (EUA) considerations
If EUA is warranted, general anesthesia will be needed to conduct detailed 
examination and ancillary testing at one time. Preparation of the room for EUA 
should consist of examination materials including: external photography, portable 
slit lamp, tonometry, indirect ophthalmoscope with condensing lens and scleral 
Figure 1. 
10 mHz ultrasound in A and B scan mode showing a large intraocular retinoblastoma with irregular mass and 
intrinsic calcification with acoustic shadowing.
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depressor, wide-angle hand-held fundus camera, intravenous fluorescein dye, high 
resolution ophthalmic ultrasound, ultrasound biomicroscopy, electroretinogra-
phy. When retinoblastoma is confirmed, an MRI of the brain and orbits with and 
without contrast should be ordered at the time of the EUA to assess for extrascleral 
extension, orbital anatomy, posterior portion of the optic nerve, and presence of 
pinealoblastoma in trilateral disease.
2.5 Anesthesia
The type of general anesthetic and airway support varies depending on institu-
tion and available resources. Safe anesthesia methods range from mask anesthesia, 
to laryngeal mask airway (LMA), to complete endotracheal intubation. Both 
inhaled anesthetics and intravenous anesthetics, or a combination of the two, are 
suitable for examination. General guidelines recommend that heavy fatty meals be 
discontinued 8 h prior to procedure, light meals, formula, and nonhuman milk 6 h 
prior to surgery, human milk 4 h prior to anesthesia, and clear liquids 2 h prior to 
anesthesia [15]. These recommendations will vary by location and anesthesiologist, 
and type of anesthesia administered. Recently there has been literature support for 
use of LMA without placement of intravenous lines, which reduces total time under 
anesthesia without increased anesthesia complications, all of which were managed 
successfully without long term sequelae [16].
2.6 Examination under anesthesia
2.6.1 External examination
An orderly approach to the exam should be taken to efficiently access and treat 
the patient to avoid prolonged anesthesia exposure. The overall features of the 
child should be assessed, evaluating for any abnormalities that are consistent with 
retinoblastoma and a 13Q deletion syndrome which is strongly associated with 
retinoblastoma risk (Figure 2). Patient’s with 13Q deletion syndrome may have 
hypotelorism, micrognathia, hypoplasia of midface, absent nasal bones, large ears, 
hypoplastic thumbs, cleft palate, or microcephaly [17].
2.6.2 Anterior examination
Intraocular pressures should be measured using Schiotz tonometer, tonopen, 
Perkins tonometer, or pneumotonometer. Elevated intraocular pressure in patients 
with retinoblastoma can be secondary to iris neovascularization or angle closure, 
and has been associated with increased risk of optic nerve invasion and metastatic 
disease [18].
After intraocular pressure is checked, corneal diameter should be measured with 
a caliper both in horizontal and vertical directions. Conditions such as persistent 
fetal vasculature (PFV) is associated with asymmetric corneal diameter size as 
well as eyes with congenitally elevated intraocular pressures can be associated with 
buphthalmos and increased corneal diameter.
A portable slit lamp should be used to assess the anterior segment. The clini-
cian should evaluate anterior depth, clarity of the lens, neovascularization of the 
iris or atrophy, retrolental membrane, anterior chamber cells, nodules of the iris, 
or anterior vitreous seeds seen behind the lens. Presence of a pseudohypopyon 
should raise suspicion for endophytic tumor and anterior chamber seeing of cancer. 
It may be possible to visualize retinal vascular, retrolental masses, or retrolental 
membranes. Retrolental retinal tissue should reveal blood vessel branching patterns 
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child is large enough or a portable slit lamp is available, slit lamp examination should 
be performed, care to note, presence or absence of cataract, conjunctival or scleral 
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depressor, wide-angle hand-held fundus camera, intravenous fluorescein dye, high 
resolution ophthalmic ultrasound, ultrasound biomicroscopy, electroretinogra-
phy. When retinoblastoma is confirmed, an MRI of the brain and orbits with and 
without contrast should be ordered at the time of the EUA to assess for extrascleral 
extension, orbital anatomy, posterior portion of the optic nerve, and presence of 
pinealoblastoma in trilateral disease.
2.5 Anesthesia
The type of general anesthetic and airway support varies depending on institu-
tion and available resources. Safe anesthesia methods range from mask anesthesia, 
to laryngeal mask airway (LMA), to complete endotracheal intubation. Both 
inhaled anesthetics and intravenous anesthetics, or a combination of the two, are 
suitable for examination. General guidelines recommend that heavy fatty meals be 
discontinued 8 h prior to procedure, light meals, formula, and nonhuman milk 6 h 
prior to surgery, human milk 4 h prior to anesthesia, and clear liquids 2 h prior to 
anesthesia [15]. These recommendations will vary by location and anesthesiologist, 
and type of anesthesia administered. Recently there has been literature support for 
use of LMA without placement of intravenous lines, which reduces total time under 
anesthesia without increased anesthesia complications, all of which were managed 
successfully without long term sequelae [16].
2.6 Examination under anesthesia
2.6.1 External examination
An orderly approach to the exam should be taken to efficiently access and treat 
the patient to avoid prolonged anesthesia exposure. The overall features of the 
child should be assessed, evaluating for any abnormalities that are consistent with 
retinoblastoma and a 13Q deletion syndrome which is strongly associated with 
retinoblastoma risk (Figure 2). Patient’s with 13Q deletion syndrome may have 
hypotelorism, micrognathia, hypoplasia of midface, absent nasal bones, large ears, 
hypoplastic thumbs, cleft palate, or microcephaly [17].
2.6.2 Anterior examination
Intraocular pressures should be measured using Schiotz tonometer, tonopen, 
Perkins tonometer, or pneumotonometer. Elevated intraocular pressure in patients 
with retinoblastoma can be secondary to iris neovascularization or angle closure, 
and has been associated with increased risk of optic nerve invasion and metastatic 
disease [18].
After intraocular pressure is checked, corneal diameter should be measured with 
a caliper both in horizontal and vertical directions. Conditions such as persistent 
fetal vasculature (PFV) is associated with asymmetric corneal diameter size as 
well as eyes with congenitally elevated intraocular pressures can be associated with 
buphthalmos and increased corneal diameter.
A portable slit lamp should be used to assess the anterior segment. The clini-
cian should evaluate anterior depth, clarity of the lens, neovascularization of the 
iris or atrophy, retrolental membrane, anterior chamber cells, nodules of the iris, 
or anterior vitreous seeds seen behind the lens. Presence of a pseudohypopyon 
should raise suspicion for endophytic tumor and anterior chamber seeing of cancer. 
It may be possible to visualize retinal vascular, retrolental masses, or retrolental 
membranes. Retrolental retinal tissue should reveal blood vessel branching patterns 
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extending towards the periphery of the lens which could be secondary to exophytic 
tumor, whereas the persistent tunica vasculosa lentis in PFV, vessels should be noted 
to be growing towards the center of the posterior lens in a disorganized fashion. 
Retrolental membrane without vascular pattern is suggestive of retinopathy of 
prematurity rather than RB.
Binocular indirect ophthalmoscopy should then be performed in a step by step 
fashion. Initially the vitreous should be examined in both eyes for presence of 
seeding, vitreous hemorrhage, fibrous membranes, or inflammatory debris. If the 
posterior pole is visible, optic disc and macula should be examined and abnormal 
findings documented. Examination of the periphery should be performed with 
scleral depression of the ora serrata in a clockwise or counter-clockwise fashion, 
with examination of the midperipheral retina and posterior pole for 360 degrees in 
both eyes.
Small RB lesions can be difficult to detect as there can be poor contrast between 
the small translucent tumor and the surrounding fundus. Meticulous examination 
and depression is needed to observe these tumors stereoscopically. Medium sized 
tumors become more opaque and start appearing white. Large tumors (>4–5 mm) 
in diameter will begin to have visually obvious blood supply and visually signifi-
cant feeder vessels should be noted. Many very large lesions (>6 mm) will develop 
chalky-white calcifications within the body of the tumor. The size and number of 
all tumors should be noted, with evaluation of subretinal fluid, retinal detachment, 
and presence of seeding (subretinal or vitreous) (Figure 3), and should all be 
incorporated into a detailed retinal drawing along with fundus photography [12]. 
Drawing and photography can help the clinician classify the tumor according to 
existing classification schemes at a later time.
2.6.3 Ancillary testing
2.6.3.1 Photography
It is important to obtain photographs of both the anterior segment as well as the 
vitreous cavity and posterior segment for documentation. The most useful method 
is using a wide-angle fundus camera. Photographs should be obtained during every 
EUA to help document response to therapy (Figures 4, 5A, B, and 6A, B). The 
clinician should try to standardize the photographs, so comparisons to each exam 
can be readily performed. As an example, start with a posterior pole photograph 
centered on the fovea then sequentially take peripheral photos superiorly, inferiorly, 
temporally and nasally keeping the optic nerve visible at the respective edge of the 
photograph to use as a point of reference for peripheral lesions. Then any other 
areas of special interest can be photographed separately.
Figure 2. 
External photograph of young child with leukocoria of the left eye secondary to intraocular retinoblastoma.
33
Retinoblastoma: Presentation, Evaluation, and Diagnosis
DOI: http://dx.doi.org/10.5772/intechopen.85744
2.6.3.2 Fluorescein angiography
Thanks to advances in photography as described in the above section, fluores-
cein angiography (FA) can be readily performed during an EUA and can help one 
Figure 3. 
RetCam photography of the left eye with defocusing to document free-floating vitreous seeding.
Figure 4. 
A retinoblastoma of the left eye with tumor scar showing type 3 regression.
Figure 5. 
(A) RetCam photograph of class C retinoblastoma of the right eye prior to intra-arterial chemotherapy and 
(B) RetCam photograph of the right eye showing class C retinoblastoma after treatment with intra-arterial 
chemotherapy.
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differentiate RB from simulating lesions. Firstly, subclinical neovascularization of 
the iris (NVI) can be distinguished using Retcam FA. In a recent study, eyes with 
advanced retinoblastoma, NVI was documented appearing as placoid or patchy 
areas of hyper fluorescence involving one or more sectors of the iris [19]. This find-
ing typically occurred between 1 and 2 min. Retinoblastoma in the fundus should 
show dilated and tortuous vessels, with retinal arteries which “feed” the tumor of 
the largest caliber. Also, microaneurysms, retinal hemorrhages, and arteriovenous 
shunts can also be noted. In the same study, as the tumors enlarged, the abnormal 
vascularization was no longer consistent with normal retinal anatomy, and were 
contained entirely within the tumor itself. Intrinsic vessels of the tumor had disor-
ganized and complex branching patterns, irregular caliber, and terminated early 
within the body of the tumor. This multi-level involvement of vascular abnormality 
helps the clinician readily distinguish RB from Coat’s disease which has large dilated 
vessels which remain within one level of the retina and show extensive peripheral 
non-perfusion (Figure 7A and B). Lastly, after 3 min diffuse leakage from retinal 
vessels can lead to inability to discern fine details of the fundus, so the clinician 
should try to obtain all valuable information within the first 3 min of the study.
2.6.3.3 Ophthalmic ultrasonography
During the EUA, ultrasound imaging of both eyes can be used to assess the orbit 
for extraocular extension, to measure thickness of the lesions, and to obtain axial 
lengths of the eyes to evaluate for normal size and symmetry. Ophthalmic ultrasound 
has traditionally been used for diagnosing and monitoring treatment of retinoblas-
toma and distinguishing it from simulating lesions [20, 21]. As described previously 
in the chapter, a 10 mHz transducer in the A and B scan mode should be used to image 
the posterior pole and evaluate the size and location of tumors, evaluate for retinal 
detachment, and look for extraocular extension of tumor (Figure 8). Ultrasound 
is especially useful in cases when ophthalmoscopy is limited by a poor view or in 
presence of a cataract. As described previously in this chapter, large retinoblastoma 
lesions undergo dystrophic calcification from necrosis, and these can be readily 
observed as areas of hyper-reflection with acoustic shadowing.
2.6.3.4 Ultrasound biomicroscopy
Ultrasound biomicroscopy (UBM) can also be helpful for visualizing the iris, 
pars plana, pars plicata, and ciliary body during an EUA. It is extremely helpful to 
Figure 6. 
(A) RetCam photograph of the left eye showing class D retinoblastoma prior to intra-arterial chemotherapy 
and (B) RetCam photograph of the left eye showing class D retinoblastoma after intra-arterial chemotherapy.
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assess the anterior extent of tumor burden or to obtain more information regarding 
the pars panna and ciliary body as well as anterior chamber seeding. It is especially 
important to use UBM to rule out pars plana tumor involvement in cases where 
intravitreal injections of chemotherapy are being considered to choose a proper 
injection site.
2.6.3.5 Electroretinogram
Electroretinograms (ERG) has been used to monitor retinal function before, 
during, and after therapy with intra-arterial chemotherapy. It is especially help-
ful in preverbal children who are unable to describe their level of visual function 
during the treatment course. Also it provides information regarding the cumula-
tive effects of retinal damage secondary to therapy, chemotherapy toxicity, and 
tissue destruction from treatments including radiation, laser photocoagulation, 
and cryotherapy. During the EUA, a 30-Hz flicker has been tested and shown to be 
Figure 7. 
(A) A portable wide field photograph showing a simulating lesion of retinoblastoma in the right eye 
showing a white macular lesion, close attention to the far periphery shows vascular telangiectasia  
and non-perfusion and (B) accompanying fluorescein angiogram confirming diagnosis of Coat’s  
disease in 8 year old boy, again notice vascular telangiectasias and non-perfusion within a single  
plane of the retina.
Figure 8. 
10 mHz B-scan ultrasonography of the left eye showing treated intraocular retinoblastoma with intrinsic 
calcifications and acoustic shadowing.
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assess the anterior extent of tumor burden or to obtain more information regarding 
the pars panna and ciliary body as well as anterior chamber seeding. It is especially 
important to use UBM to rule out pars plana tumor involvement in cases where 
intravitreal injections of chemotherapy are being considered to choose a proper 
injection site.
2.6.3.5 Electroretinogram
Electroretinograms (ERG) has been used to monitor retinal function before, 
during, and after therapy with intra-arterial chemotherapy. It is especially help-
ful in preverbal children who are unable to describe their level of visual function 
during the treatment course. Also it provides information regarding the cumula-
tive effects of retinal damage secondary to therapy, chemotherapy toxicity, and 
tissue destruction from treatments including radiation, laser photocoagulation, 
and cryotherapy. During the EUA, a 30-Hz flicker has been tested and shown to be 
Figure 7. 
(A) A portable wide field photograph showing a simulating lesion of retinoblastoma in the right eye 
showing a white macular lesion, close attention to the far periphery shows vascular telangiectasia  
and non-perfusion and (B) accompanying fluorescein angiogram confirming diagnosis of Coat’s  
disease in 8 year old boy, again notice vascular telangiectasias and non-perfusion within a single  
plane of the retina.
Figure 8. 
10 mHz B-scan ultrasonography of the left eye showing treated intraocular retinoblastoma with intrinsic 
calcifications and acoustic shadowing.
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informative prior to the physical examination portion of the exam [22]. One must 
be cautious to not manipulate the eyes before obtaining the ERG, as ocular manipu-
lation including scleral depression, photography, and ophthalmoscopy can affect 
the ERG readings thus confounding results [23].
2.6.3.6 Imaging for retinoblastoma
Historically computerized tomography (CT) scans were used to evaluate 
patients ocular, orbital, optic nerve, and brain involvement from the tumor, since 
CT detection of calcifications in retinoblastoma have a sensitivity of 81–96% 
and an even higher specificity [24]. Magnetic resonance imaging (MRI) however 
is currently considered to be of higher accuracy and value due to its superior 
soft-tissue contrast for determining extent of tumor into orbit, optic nerve, and 
for evaluation of the presence of pinealoblastoma in trilateral disease. CT scan-
ning is also felt to unnecessarily increase patient exposure to ionizing radiation 
with limited diagnostic value now that MRI is available. MRI of the brain and 
orbits with and without contrast is now ordered routinely on all patients with 
retinoblastoma at the time of diagnosis. The general practice among groups in the 
United States is to repeat imaging every 6–12 months for germline cases until the 
age of 5–6 years old to screen to pineal tumors. Transaxial or sagittal T1-weighted 
images will reveal an RB tumor which is slightly hyperintense with respect to 
the vitreous body. Transaxial or sagittal heavily T2-weighted imaging provides a 
low signal intensity of retinoblastoma and is helpful for detecting retinal detach-
ment. Transaxial and sagittal oblique contrast enhanced T11 weighted spin echo 
provides information of the enhancement of retinal, invasive optic nerve, invasive 
eye wall, and anterior segment lesions.
2.6.3.7 Genetic counseling
After all of the steps outlined in this chapter are followed, and a diagnosis of 
retinoblastoma is made, the clinician can hold a discussion with the family regard-
ing therapeutic options and the genetic counseling needed for the patient and their 
loved ones. A treatment plan can be devised and initiated, but is outside the scope 
of this chapter, and will be covered in other portions of this text.
3. Conclusion
Accurate and consistent diagnosis of retinoblastoma, and it’s simulating lesions 
begin with the initial consult. This involves a systematic approach starting with a 
detailed history and high level of suspicion for patients presenting with leukocoria, 
decreased vision, strabismus, periorbital swelling, or dysmorphic facial features. 
Initial examination should involve a detailed dilated fundus exam with ophthalmic 
ultrasound, which will either push the clinician towards or away from the diagnosis 
of retinoblastoma. Any suspicion should warrant an examination under anesthesia 
as outlined above to obtain all of the information needed for an accurate diagnosis. 
The examination under anesthesia should follow a consistent, careful, and repeat-
able fashion as described earlier in the chapter. The techniques above, if followed, 
should aid the clinician in consistent diagnosis of retinoblastoma and its simulating 
lesions. Once diagnosed, appropriate brain and body imaging, and referral for 
genetic counseling should be performed. Treatment of this rare condition, along 
with survival and preservation of the eye is continuing to improve and will be 
covered in other portions of this text.
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Retinoblastoma is the most common primary ocular malignancy in chil-
dren. Diagnosing retinoblastoma relies mainly on the clinical appearance of 
the lesion and not on histological description. Although histology still remains 
the gold standard in evaluation of tumor extension and progression risk fac-
tor, a tumor biopsy carries high risk of dissemination and is difficult to obtain. 
Retinoblastoma has characteristic clinical features of creamy-white mass associ-
ated with subretinal fluids and may be accompanied by retinal detachment and 
vitreous seeding. There are many factors contributing to metastatic risk factors 
like postlaminar optic nerve infiltration, scleral and choroidal invasion, and 
peribulbar fat invasion. Ancillary testing is necessary for any patient with a 
suspected retinoblastoma to assess the dimensions of the tumor as well as the 
tumor extension. An ultrasonography (B scan) will show the mass dimensions as 
well as the hyperechoic calcifications, which are commonly present with retino-
blastoma. CT scan is not the modality of choice for diagnosis of retinoblastoma 
in children because of the radiation exposure. Magnetic resonance imaging is 
considered the examination of choice to assess the tumor extension as it has high 
soft tissue contrast. The use of MRI changed the accuracy of assessing metastatic 
risk factors as the results yielded before and after the use of MRI differed. This 
chapter will address the use of radiological imaging in retinoblastoma defining 
diagnostic characteristics and identifying parameters of metastatic risk factor 
assessment. This chapter will also include evidence-based review on the efficacy 
of radiological imaging of retinoblastoma and its impact on the choice of treat-
ment and disease prognosis.
Keywords: magnetic resonance imaging, retinoblastoma, metastasis, optic nerve 
invasion, vitreous seeding, retinal detachment, calcification, prognosis
1. Introduction
Retinoblastoma is the most common primary ocular malignancy in children. 
It is usually unilateral but may be bilateral in one-third of cases. It presents in 
childhood as leukocoria or acute onset strabismus. Diagnosing retinoblastoma 
relies mainly on the clinical appearance of the lesion and not on histological 
description. Although histology still remains the gold standard in evaluation of 
tumors extension and progression risk factor, a tumor biopsy carries high risk 
of dissemination and is difficult to obtain. Retinoblastoma has characteristic 
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of dissemination and is difficult to obtain. Retinoblastoma has characteristic 
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clinical features of creamy-white mass associated with sub retinal fluids and 
may be accompanied by retinal detachment. Endophytic tumors grow inwards 
towards the vitreous cavity which may result in vitreous seeding of the tumor 
cells. Exophytic tumors grow into the sub retinal space causing progressive retinal 
detachment and subretinal seeing. There are many factors contributing to meta-
static risk factors like post laminar optic nerve infiltration, scleral and choroidal 
invasion, and peribulbar fat invasion. Ancillary testing is necessary for any 
patient with a suspected retinoblastoma to assess the dimensions of the tumor as 
well as the tumor extension.
The main ancillary tests that can be used with retinoblastoma are ultrasound 
imaging (US), computerized tomography (CT), and magnetic resonance imaging 
(MRI).
Ultrasonography (B scan) will show the mass dimensions as well the hyper-
echoic calcifications which is commonly present with retinoblastoma. These 
imaging modalities and their uses in retinoblastoma detection will be discussed in 
this chapter with the main focus on MR imaging.
2. Ultrasonography imaging in retinoblastoma
Ultrasound imaging is a cost-effective widely available modality that is non-
invasive and easy to perform. This modality is especially useful in patient when 
the ocular light-conducting media is opaque. It can detect tumor dimensions and 
characteristics as well as vitreous seeding. It is usually conducted at a 10 MHz high 
frequency probe. B scans can also visual the optic nerve which can be seen within 
the retrobulbar fat. The optic nerve is usually seen as a hypoechoic structure within 
the echogenic surrounding fat.
In case of retinoblastoma, the tumor is visualized as a hyperechoic tumor 
with irregular borders. It may present a diffuse lesion or a localized well-defined 
lesion (Figure 1). The calcium deposits are clearly visualized by ultrasonography 
as highly hyper-echoic and they are a pathognomonic feature [1]. Ultrasound 
imaging can also identify any associated retinal detachment or choroidal thicken-
ing (Figure 2). The vitreous surrounding the lesion may show hyper-reflective 
particles representing the calcified tumor seeding into the vitreous cavity. 
Figure 1. 
B scan of an eye with diffuse pattern retinoblastoma showing areas of calcification.
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Extraocular invasion of the optic nerve can also be detected once the normal 
tubular hypo-echoic nature of it is altered.
3. Computerized tomography imaging in retinoblastoma
Computerized tomography (CT) is a combination of multiple X-ray images from 
different angles producing cross sectional images. Like standard X-ray, CT depends 
on relative the radio-density of different tissue structures. CT delivers ionization 
radiation reaching to 1–10 mSv per brain CT. Retinoblastoma appears as a hyperdense 
lesion on CT in relation to the surrounding hypodense ocular vitreous (Figure 3).
CT scan is also another beneficial tool in detecting calcification which may be 
seen in a non-homogenous pattern in most large tumors (Figure 4) or in a homog-
enous pattern in smaller tumors. In certain studies, CT scan has failed to show 
calcification in small retinoblastoma tumors [2–4] CT images can also be useful to 
detect any associated metastatic brain lesions (Figure 5).
CT scan is not the modality of choice for diagnosis and follow-up of children 
with retinoblastoma due to radiation exposure (ionizing radiation) and the high 
sensitivity of MRI for soft tissue. This reduces the implantation of CT in retinoblas-
toma cases especially in areas where MR studies are accessible [3].
Figure 2. 
B scan of an eye with retinoblastoma showing an exophytic growth pattern with an associated retinal 
detachment.
Figure 3. 
CT (soft tissue window image) showing right globe hyperdense vitreous, retrolental intraocular solid mass with 
dystrophic calcification and proximal calcified optic nerve local invasion.
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4. Magnetic resonance imaging in retinoblastoma
Magnetic resonance imaging is a type of imaging that use strong magnetic fields 
and magnetic field gradients to generate anatomical images without the use of 
ionization radiation.
Magnetic resonance imaging is considered the examination of choice to assess 
the retinoblastoma tumor extension extraocularly as it has high soft tissue contrast. 
Although retinoblastoma is usually diagnosed clinically by fundoscopy examination; in 
cases of unclear ocular medium, MRI can even be used in diagnosing retinoblastoma.
Figure 5. 
A non-contrast brain CT for follow up of retinoblastoma patient, showed solid suprasellar mass with faint 
calcification suggestive of metastasis.
Figure 4. 
CT (bone window image) showing right globe enlargement, hyperdense vitreous due to hemorrhage, retrolental 
intraocular solid mass with central large dystrophic calcification and an enlarged proximal calcified optic 
nerve due to local invasion.
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The European Retinoblastoma Imaging Collaboration (ERIC) released a recom-
mended guideline protocol for MR imaging in retinoblastoma. This MR retinoblas-
toma protocol uses a 1.5 T in T1 weighted images scout view and turbo spin-echo 
T2 and PD images if the brain as well as 2 mm thick T2 images of the eye in sagittal 
cuts. Later axial T1 images and T2 with fat suppression of the orbit with contrast 
medium of 0.1 mmol/kg gadopentetate dimeglumine are obtained. The advanced 
use of high resolution three-dimensional T2 weighted imaging allows for then 
0.4 mm sections with high SNR that is sensitive to detect calcification.
In this guideline a post laminar optic nerve invasion is characterized by abnor-
mal contrast enhancement of the optic nerve that is > = 2 mm length or any  
asymmetrical thickening [5].
Sagittal and axial T1-weighted images: repetition time (TR) = 475 ms; echo 
time (TE) = 10 ms; slice thickness = 2 mm; field of view (FOV) = 150 × 150 mm; 
matrix = 256 × 179; number of excitations = 1].
Axial T2-weighted fat sat images: TR = 3600 ms; TE = 95 ms; echo train length = 15; slice 
thickness = 2.5 mm; FOV = 150 × 150 mm; matrix = 320 × 240; number of excitations = 2].
When approaching MRI images of an intraocular lesion, one of the first param-
eters to be assessed is the axial length and eye volume as well as the laterality of 
the disease. Thorough examination of the brain images is also a major step for the 
detection of any syndromic associations or intracranial metastasis. These param-
eters are very beneficial in the differentiation of similar intraocular lesions. In cases 
of persistent fetal vasculature (PFV), they can present with leukocoria or strabis-
mus as well. However, the globe size is markedly smaller in PFV cases (Figure 6).
On MRI the retinoblastoma tumor borders usually exhibit an irregular lobulated 
pattern.
The eye parameters are relatively smaller in eyes with retinoblastoma with the 
size of the tumor volume inversely proportional to the size of the globe [6].
Retinoblastoma can also be associated with retinal detachment which can be 
clearly detectable on MR images (Figure 7).
Retinoblastoma on T1 weighted MR imaging appears as relatively hyper-intense 
compared to the adjacent normal vitreous. It also contains areas of low signal inten-
sity within the hyper-intense tumor that reflects the areas of calcification (Figure 8).
Figure 6. 
Axial T2 WI image of brain and orbit showing bilateral microphthalmia, hyaloid canal, a characteristic 
finding of PFV. Images of brain cortex are characteristic of type II cobblestone lissencephaly, hydrocephaly with 
dysplastic white matter, over all finding are of Walker-Warburg syndrome.
Retinoblastoma - Past, Present and Future
44
4. Magnetic resonance imaging in retinoblastoma
Magnetic resonance imaging is a type of imaging that use strong magnetic fields 
and magnetic field gradients to generate anatomical images without the use of 
ionization radiation.
Magnetic resonance imaging is considered the examination of choice to assess 
the retinoblastoma tumor extension extraocularly as it has high soft tissue contrast. 
Although retinoblastoma is usually diagnosed clinically by fundoscopy examination; in 
cases of unclear ocular medium, MRI can even be used in diagnosing retinoblastoma.
Figure 5. 
A non-contrast brain CT for follow up of retinoblastoma patient, showed solid suprasellar mass with faint 
calcification suggestive of metastasis.
Figure 4. 
CT (bone window image) showing right globe enlargement, hyperdense vitreous due to hemorrhage, retrolental 
intraocular solid mass with central large dystrophic calcification and an enlarged proximal calcified optic 
nerve due to local invasion.
45
Uses of Radiological Imaging in Retinoblastoma
DOI: http://dx.doi.org/10.5772/intechopen.86828
The European Retinoblastoma Imaging Collaboration (ERIC) released a recom-
mended guideline protocol for MR imaging in retinoblastoma. This MR retinoblas-
toma protocol uses a 1.5 T in T1 weighted images scout view and turbo spin-echo 
T2 and PD images if the brain as well as 2 mm thick T2 images of the eye in sagittal 
cuts. Later axial T1 images and T2 with fat suppression of the orbit with contrast 
medium of 0.1 mmol/kg gadopentetate dimeglumine are obtained. The advanced 
use of high resolution three-dimensional T2 weighted imaging allows for then 
0.4 mm sections with high SNR that is sensitive to detect calcification.
In this guideline a post laminar optic nerve invasion is characterized by abnor-
mal contrast enhancement of the optic nerve that is > = 2 mm length or any  
asymmetrical thickening [5].
Sagittal and axial T1-weighted images: repetition time (TR) = 475 ms; echo 
time (TE) = 10 ms; slice thickness = 2 mm; field of view (FOV) = 150 × 150 mm; 
matrix = 256 × 179; number of excitations = 1].
Axial T2-weighted fat sat images: TR = 3600 ms; TE = 95 ms; echo train length = 15; slice 
thickness = 2.5 mm; FOV = 150 × 150 mm; matrix = 320 × 240; number of excitations = 2].
When approaching MRI images of an intraocular lesion, one of the first param-
eters to be assessed is the axial length and eye volume as well as the laterality of 
the disease. Thorough examination of the brain images is also a major step for the 
detection of any syndromic associations or intracranial metastasis. These param-
eters are very beneficial in the differentiation of similar intraocular lesions. In cases 
of persistent fetal vasculature (PFV), they can present with leukocoria or strabis-
mus as well. However, the globe size is markedly smaller in PFV cases (Figure 6).
On MRI the retinoblastoma tumor borders usually exhibit an irregular lobulated 
pattern.
The eye parameters are relatively smaller in eyes with retinoblastoma with the 
size of the tumor volume inversely proportional to the size of the globe [6].
Retinoblastoma can also be associated with retinal detachment which can be 
clearly detectable on MR images (Figure 7).
Retinoblastoma on T1 weighted MR imaging appears as relatively hyper-intense 
compared to the adjacent normal vitreous. It also contains areas of low signal inten-
sity within the hyper-intense tumor that reflects the areas of calcification (Figure 8).
Figure 6. 
Axial T2 WI image of brain and orbit showing bilateral microphthalmia, hyaloid canal, a characteristic 
finding of PFV. Images of brain cortex are characteristic of type II cobblestone lissencephaly, hydrocephaly with 
dysplastic white matter, over all finding are of Walker-Warburg syndrome.
Retinoblastoma - Past, Present and Future
46
Figure 9. 
MRI T2 weighted fat saturated image of the orbits showing low signal of retrolental mass corresponding to 
retinoblastoma tumor at left globe with mild reduction of size of globe.
A study compared the efficacy of MRI in calcification detection by compar-
ing in vivo T2 weight MRI with ex vivo high-resolution CT. It has found the 
T2WI correlated well with CT findings. Therefore, combining examination with 
Figure 7. 
MRI orbit T1 weighted fat saturated with contrast imaging showing bilateral faintly enhanced retrolental 
retinal based mass with right retinal detachment.
Figure 8. 
MRI T1 weighted image with contrast, faintly enhanced retrolental mass at left globe corresponding to 
retinoblastoma tumor core.
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ultrasonography and MRI with gradient-echo sequence is thought to be the stan-
dard diagnostic approach for any patient with retinoblastoma [4].
On T2 weighted imaging, the retinoblastoma tumor is usually darker than 
the vitreous resulting in a relative hypo-intense lesion within the vitreous with 
further patches of hypointensity within corresponding to calcification area 
(Figures 9 and 10).
5. Diffusion weighted imaging in retinoblastoma
Diffusion-weighted imaging (DWI) is a type of MR imaging that depends on 
the motion of water molecule within the tissue. Highly cellular tissue exhibits 
lower diffusion coefficients making this modality useful for tumor characteriza-
tion. DWI is wisely wised for orbital disease as well as brain malignancy. On dif-
fusion weighted imaging (P value 1000) the retinoblastoma tumor shows diffuse 
restriction.
A pulse sequence form of DWI that generates various imaging is referred to as 
ADC images (apparent diffusion coefficient) which measures the magnitude of 
diffusion resulting a numerical value. The mean ADC value of retinoblastoma was 
0.49 ± 0.12 × 10−3 mm2/s.
The low ADC values of retinoblastoma tumors are attributed to the tightly 
packed nature of high nuclear cytoplasmic ratio of the tumor (Figure 11).
The use of ADC value images has shown to be well correlated with the  
degree of tumor differentiation in a study conducted in Saudi Arabia. 
The ADC value was analyzed in different sized tumors and was shown to 
be significantly different with various sized tumors. It demonstrates an 
inverse correlation of the ADC value with the tumor size. The ADC value 
of small tumors (<10 mm) was 0.55 ± 0.09 × 10−3 mm2/s, medium tumors 
(>10–15 mm) was 0.48 ± 0.09 × 10−3 mm2/s, and large tumors (>15 mm) was of 
0.38 ± 0.11 × 10−3 mm2/s value.
In addition, the ADC value was lower in tumors with optic nerve invasion 
which may correlate with the tumor’s likelihood to be poorly differentiated and 
Figure 10. 
Axial T2 weighed MRI of the brain and orbit showing a hypointense tumor of the right globe, filling 80% if the 
globe with areas of hypo-intensity representing calcification or retinoblastoma tumor core.
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aggressive [7]. Axial diffusion weighted images: TR = 5000 ms; TE = 74 ms; number 
of diffusion matrix = 200 – 162; number of excitations = 1 with reconstruction of the 
ADC map.
6. Metastasis of retinoblastoma on MRI
Retinoblastoma tumor grows with an endophytic and/or an exophytic pat-
tern. Endophytic growth starts from the inner layers of the retina progressing 
into the vitreous cavity. As the tumor cells detach from the main tumor, they can 
float into the vitreous and cause what is known as vitreous seeding. Detection of 
vitreous seeding is crucial in the staging of retinoblastoma and is considered a 
main prognostic indicator. Although detection of vitreous seeding by ophthal-
moscopy examination is superior to MR imaging, it can be clearly identified in 
63% of patient on MRI. It is usually identified as bright patches on T1 weighted 
imaging and dark patches on T2 weighted imaging within the vitreous cavity [5, 8] 
(Figure 12).
Exophytic growth pattern starts at the outer retinal layers and progress into the 
sub-retinal space causing a retinal detachment and sub-retinal tumor seeding [9].
MR imaging can detect choroidal invasion of retinoblastoma tumor at a sensitiv-
ity of 74% and a specificity of 72%. (Brisse relevance) Scleral invasion of retino-
blastoma tumor can also be assessed by MR imaging with 88% sensitivity and 99% 
specificity [2] (Figure 7).
Another more aggressive pattern of retinoblastoma tumor growth is diffuse 
infiltrating growth pattern. In this pattern, the tumor grows along the retina as 
a placoid mass which subsequently results in ocular inflammation and hemor-
rhages. This may be seen as severe AS inflammation and a pseudohypopyon. MR 
images can help assess the anterior segment for the presenter absence if abnormal 
enhancement.
Diffuse infiltrative growth pattern is very rare (1–2%) and occurs with older 
age children with a male predilection of 8:1. It is usually difficult to diagnose as 
there are no discrete mass borders and it usually lacks the characteristic reti-
noblastoma calcification. A retinal detachment is commonly associated and is 
often evident on MRI especially on FLAIR sequence (Fluid attenuated inversion 
recovery) [10].
Figure 11. 
ADC (apparent diffusion coefficient) MR image of the brain and orbit showing bilateral ocular lesions with 
low ADC values represented tumor core representing bilateral retinoblastoma.
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7. MRI’s uses in the staging and prognosis of retinoblastoma
Although MRI can aid in the diagnosis of retinoblastoma by the aforementioned 
characteristics, it is more widely used for the staging of retinoblastoma. Like all 
other malignancies, tumor staging in retinoblastoma is essential for the prognosis 
predictions.
The use of MRI has changed the accuracy of assessing metastatic risk factors as 
the initial retinoblastoma staging of patients before the use of MRI varied after MR 
imaging were obtained.
The extension of retinoblastoma is usually by direct extension into adjacent 
structures. Intraocular extension of the tumor can easily be visualized during 
examination in patients with good posterior pole visualization. MR imaging has 
Figure 12. 
MRI of the spine showing areas of diffuse leptomeningeal enhancement of the spinal cord representing areas of 
CSF seeding.
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been widely used to evaluate the extra-ocular and intracranial extension and can 
also aid in the evaluation of intraocular tumor extension [11].
Intraocular extension can be detected by choroidal irregularities. Choroidal 
invasion identification is important in the prognosis of the disease. It changes the 
prognosis of retinoblastoma by increasing the mortality rate up to 24–65% depend-
ing on the severity of invasion [12].
In the assessment of extra-ocular retinoblastoma extension, the most important 
structure to evaluate is the optic nerve. Involvement of the optic nerve in reti-
noblastoma alters the prognosis and the management of the disease. The overall 
mortality rate of retinoblastoma without optic nerve invasion is 10%. If the inva-
sion of the optic nerve reaches through the lamina cribrosa, the mortality may rise 
up to 15%. Moreover, if the extension is posterior to the lamina cribrosa the mortal-
ity rises up to 44%. This makes the optic nerve assessment by MR imaging crucial 
in any retinoblastoma case with proper identification of the level of optic nerve 
invasion. On MRI, the affected optic nerve appears thickened and irregular with 
high enhancement of the nerve itself and the area surrounding it [11].
A study showed that the specificity of MRI in detecting optic nerve invasion past 
the lamina cribrosa to reach up to 80% and a sensitivity of 74%. This makes MR 
imaging the most superior non-invasive method in the detection of retinoblastoma 
optic nerve invasion [13] (Figures 13 and 14).
Ophthalmic surgeons require extra measurements of the invasion to take extra 
precautions during the enucleation of the affected eye. It is important for the MR 
image to demonstrate if the retrolaminar optic nerve invasion extends more than 
5 mm posteriorly. This is particularly crucial to identify prior to surgical interven-
tion as the tumor may be cut through during the enucleation. If such complication 
happens, the distal part of the tumor that remains is connected to the brain and 
may progress to brain metastasis. In such cases, the surgeon might consider doing 
an orbitotomy to be able to reach further posterior and dissect at least 10 mm from 
Figure 13. 
MRI T2 weighted image of brain and orbit showing right globe retrolental hypo-intense tumor core, retro 
bulbar extension and extensive long segment right optic nerve invasion resulting in right globe proptosis.
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the suggested tumor margin. Despite the advancement of MRI, it has limitations 
in detecting microscopic optic nerve invasion. Studies have shown a discrepancy 
between histological results in optic nerve assessment (gold standard) and MRI 
results [14]. This dictates the need for thorough histopathological assessment of the 
optic nerve regardless of MR findings.
An important disease entity in retinoblastoma is the trilateral retinoblastoma 
disease. It refers to rare disease that is characterized by bilateral ocular RB and a 
primitive midline neuroectodermal tumor in the pineal region or the suprasellar 
cistern. It represents 1.5–5% of all RB patients [15].
8. Conclusion
Retinoblastoma is the most common primary ocular malignancy in children. 
Diagnostic imaging has changed the accuracy of diagnosing and staging retino-
blastoma. There are many imaging modalities that are currently in use for retino-
blastoma tumor like ultrasonography, computerized tomography and magnetic 
resonance imaging. MR images of the brain and spinal cord need to be obtained 
routinely in retinoblastoma patients in institutes where MRI is accessible. They aid 
in the diagnosis and prognosis of the disease. As the retinoblastoma tumor seeding 
may spread via cerebrospinal fluid and reach the intracranial resulting in brain 
metastasis, MRI can clearly delineate these metastatic lesions, which eventually 
alters the management plan.
MRI can show retrolaminar optic nerve and choroidoscleral infiltration and spread 
of tumor into the brain and spine more accurately than other diagnostic imaging.
A purely ocular tumor confined within the globe reaches a survival rate of 90% 
AT 5-years whereas a tumor that has extended outside the globe has a mortality rate 
of over 90%.
Figure 14. 
MRI T1 weighted image with contrast of the same patient delineating the retrobulbar extension, enhanced 
and enlarged right optic nerve, leptomeningeal enhancement due to direct extension and CSF seeding of 
retinoblastoma.
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Diagnostic imaging has changed the accuracy of diagnosing and staging retino-
blastoma. There are many imaging modalities that are currently in use for retino-
blastoma tumor like ultrasonography, computerized tomography and magnetic 
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routinely in retinoblastoma patients in institutes where MRI is accessible. They aid 
in the diagnosis and prognosis of the disease. As the retinoblastoma tumor seeding 
may spread via cerebrospinal fluid and reach the intracranial resulting in brain 
metastasis, MRI can clearly delineate these metastatic lesions, which eventually 
alters the management plan.
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This drastic difference makes staging and the use of ancillary testing vital for the 
prognosis and survival rate estimation which further guides the treatment decision.
It is now currently recommended for any newly diagnosed patient with retino-
blastoma to undergo an MRI [13].
MRI can also offer hope for future advancement of early diagnosis. It has 
recently shown to aid in very early fetal diagnosis of retinoblastoma in a fetus with 
high-risk of RB and may be implemented as a part of future screening protocol in 
high risk population [16].
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This drastic difference makes staging and the use of ancillary testing vital for the 
prognosis and survival rate estimation which further guides the treatment decision.
It is now currently recommended for any newly diagnosed patient with retino-
blastoma to undergo an MRI [13].
MRI can also offer hope for future advancement of early diagnosis. It has 
recently shown to aid in very early fetal diagnosis of retinoblastoma in a fetus with 
high-risk of RB and may be implemented as a part of future screening protocol in 
high risk population [16].
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Abstract
Retinoblastoma (Rb) is the most common primary intraocular malignancy in 
children with an incidence from 1:15,000 to 1:20,000 live births. It can present as 
a unilateral or bilateral involvement of the eyes. It is generally induced by biallelic 
mutation of the RB1 tumor suppressor gene that leads to malignant transformation 
of primitive retinal cells. The most common presentation is leukocoria, followed by 
strabismus. The initial assessment and future treatment of such tumor should be 
based on the laterality, the stage of the tumor, and the presenting age of the child. 
In general, the primary target of therapy is to preserve the child’s life. However, pre-
serving the globe and preserving vision should be achieved whenever it’s possible. 
Retinoblastoma treatment has evolved from enucleating the affected globe to also 
involving external beam radiation therapy, cryotherapy, laser photocoagulation, 
thermotherapy, brachytherapy, and chemotherapy (intravitreal, intra-arterial, and 
systematic). This chapter is intended to discuss briefly the clinical presentation of 
Rb, as well as a comprehensive review about the evolution and current treatment 
modalities with a focus on cases with low-risk features.
Keywords: retinoblastoma, management, enucleation, 
external beam radiation therapy, brachytherapy, thermotherapy,  
laser photocoagulation, cryotherapy, chemotherapy
1. Clinical presentation and diagnosis
The clinical presentation of retinoblastoma can be variable depending on the 
stage of the tumor. However, the most common presenting symptom overall is 
abnormal white reflection from one or both pupils [1]. This can be observed grossly 
by the naked eye and is termed as leukocoria. The second most common presen-
tation of retinoblastoma is strabismus, which results from sensory deprivation 
when the tumor involves the central vision [2]. Less commonly, uveitis, glaucoma, 
hyphema, iris heterochromia, and orbital cellulitis can also be presenting signs for 
retinoblastoma [3]. A more advance and late presentation may result in proptosis 
and orbital swelling [4]. Any of the mentioned clinical presentations in a child 
should prompt detailed clinical exam including dilated fundus examination. 
Typically, it shows unifocal or multifocal white vascularized retinal mass with or 
without tumor seeding. Different imaging modalities can be performed to aid in 
the diagnoses of retinoblastoma. The most easy and readily available modality is 
ultrasound. It can be helpful in the detection of intraocular mass characteristic 
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(height, thickness, and depth) and the presence of heterogeneity and calcification. 
Computed tomography (CT) is more sensitive in detecting intraocular calcifica-
tion and delineating the mass. However, CT scan raises the concern of developing 
secondary malignancies in cases with germ line mutation due to radiations [5]. 
Magnetic resonance imaging (MRI) is currently the preferred imaging modality of 
choice for most ophthalmologists. MRI is considered the best for detecting optic 
nerve involvement and extraocular extension [6]. Other diagnostic procedures like 
cerebrospinal fluid (CSF) analysis and cytology are particularly performed when 
there is evidence of optic nerve involvement grossly or microscopically based on 
histopathologic examination after enucleation. Bone marrow biopsy is indicated 
for bone marrow metastasis based on clinical exam or blood work-up. Diagnosis 
of retinoblastoma should be based on clinical examination that is supported by 
imaging techniques. However, differentiating retinoblastoma from other condi-
tions like persistent hyperplastic primary vitreous (PHPV), Coats’ disease, or 
toxocariasis can be challenging [7–11]. Different classifications have been proposed 
for retinoblastoma staging throughout the past decades, including TNMH (tumor, 
node, metastasis, heritable trait) cancer staging for the American Joint Committee 
on Cancer (AJCC), Reese-Ellsworth classification system (R-E), and International 
Intraocular Retinoblastoma Classification (IIRC) [12–16]. The International 
Intraocular Retinoblastoma Classification or International Classification of 
Retinoblastoma (ICRB) have been widely accepted by ophthalmologists since they 
were first introduced in 2003, to predict the outcomes following chemoreduction 
for retinoblastoma [15, 16] (Table 1 and Figure 1).
Group Subgroup Reference Features
A Very low 
risk
Small tumor • RB ≤3 mm (in basal dimension)
• Al least 3 mm away from the foveola and 1.5 mm 
from the optic nerve
• No vitreous or subretinal seeding is present




• RB >3 mm (in basal dimension)
• Macular location (≤3 mm to foveola)
• Juxtapapillary location (≤1.5 mm to optic nerve)
• Additional subretinal fluid (≤3 mm from margin)
• No vitreous or subretinal seeding is present
C Moderate 
risk
Focal seeds • Focal subretinal and/or vitreous seeds ≤3 mm from 
the tumor
D High risk Diffuse seeds • Diffuse subretinal and/or vitreous seeds >3 mm 
from the tumor




• Extensive retinoblastoma occupying >50% of globe 
or any of the following:
• Secondary neovascular glaucoma
• Tumor anterior to anterior vitreous face or touching 
the lens
• Diffuse infiltrating retinoblastoma
• Massive intraocular hemorrhage
• Aseptic orbital cellulitis
• Phthisis bulbi
Table 1. 
International intraocular retinoblastoma classification.
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2. Management
Management of retinoblastoma is complex and requires a multidisciplinary team 
approach that includes an ophthalmologist, pediatric oncologist, radiation oncolo-
gist, pathologist, geneticist, social worker, nurses, and others. The primary goal of 
treatment is to save the child’s life and then to salvage the globe and optimize the 
vision if possible. A multimodal therapeutic option for retinoblastoma is avail-
able, which ranges from focal therapies like laser photocoagulation, cryotherapy, 
thermotherapy, and plaque radiotherapy to enucleation or chemotherapy for more 
advance cases. The decision for choosing a treatment option is depending on several 
factors including the laterality, tumor size and histopathologic feature, the age and 
general health of the child, and the family desires.
3. Enucleation
Enucleation is the preferred option for most children presenting with advance 
tumor (group E eyes), especially if unilateral [17–21]. Other indications for enucle-
ation are failure of all possible effective therapies, active tumor in an eye with no 
visual potential, anterior segment invasion, secondary neovascular glaucoma, 
and when the visualization of the tumor is compromised due to corneal opacity, 
cataract, or vitreous hemorrhage [22]. Enucleation is rarely indicated for bilateral 
retinoblastoma due to devastating functional limitation that follows such decision. 
The goal during enucleation is to obtain as much optic nerve as possible (usu-
ally 8–12 mm) to make sure that the surgical margin is free from tumor [23, 24]. 
Surgeons should avoid perforation of the globe during the procedure to minimize 
the potential risk of tumor seeding into the orbital tissue [25]. Histopathologic 
evaluation post enucleation allows for evaluation of high-risk features that requires 
additional chemotherapy. These features include retrolaminar optic nerve invasion, 
Figure 1. 
Retinoblastoma tumors, according to the international intraocular retinoblastoma classification, and their 
response to treatments.
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choroidal invasion, scleral and orbital invasion, and anterior chamber seeding 
[26–28]. At the time of enucleation, an orbital implant is placed to ensure proper 
growth of the orbit and allows for free movement of the prosthesis when attaching 
the extraocular muscles to the implant [4, 29]. Many different orbital implants can 
used and are generally divided to porous and nonporous implants. The most com-
monly used are porous implants, hence allowing vascular growth in the tiny pores 
within the implant. This can serve in the stabilization of the implant while minimiz-
ing the risk of exposure and extrusion or infection [4, 25].
4. External beam radiation therapy (EBRT)
External beam radiation therapy is an important modality used in the treatment 
of retinoblastoma. However, due to serious adverse effects, it has fallen out of use 
and became preserved for moderately advanced disease where retinoblastoma is 
refractory or progressive after chemotherapy to salvage the eye from enucleation. 
EBRT techniques have improved overtime, and new methods aim to eliminate the 
disease and minimize normal tissue exposure to avoid any adverse effects [30–33].
The main EBRT techniques used in treating retinoblastoma are photon or elec-
tron radiation therapy (ERT), intensity-modulated radiation therapy (IMRT), and 
proton radiation therapy (PRT). IMRT and PRT allow for more conformal radiother-
apy options in addition to a unique physical property of PRT. Rather than traversing 
the target, protons stops at energy-dependent depth and with a reduced exit dose to 
almost zero where it reduces the injury to uninvolved structures and limit the radia-
tion beams to a specific area. This physical property has shown to decrease unwanted 
adverse effects, making PRT become superior to photon therapy [30, 31].
EBRT treatment sessions are usually scheduled over a period of weeks where 
multiple small fractions of radiation are delivered via an external machine targeting 
the lesion. This increases tumor sensitivity to radiation by allowing time for reoxy-
genation and reassortment of cell cycle. It also spares normal tissues by allowing 
time for repair in between fractions. Conversely, PRT is delivered in one or a few 
large fractions, but to small discrete volumes, hence minimizing the volume of 
surrounding irradiated normal tissue [30, 34].
The outcome of patients who were treated with EBRT has been studied over the 
past decades. Enucleation was ultimately required in 18–37.5% of eyes, and local 
failure after radiotherapy was similar between PRT and ERT. Vision was preserved 
in most of the cases with an outcome showing up to 70% of patients having no or 
mild visual impairment. Moderate visual impairment is seen in 10–23% of eyes, 
whereas poor or no useful vision was in 20–41.7% of non-enucleated eyes. The best 
visual outcomes are noted in patients with early stages that spared the optic disc, 
macula, and fovea, suggesting that the location of tumors has an impact of visual 
outcome even after PRT [35–38].
Acute toxicities that can be seen after therapy sessions include local erythema of 
the skin, hyperpigmentation, erythema of the conjunctiva, and loss of eyelashes. 
Patients treated with PRT had a similar rate of acute toxicities, compared to patients 
treated with ERT. Cataracts were the most common long-term complication in eyes 
treated with EBRT. Other ocular complications noted are radiation retinopathy, 
glaucoma, neovascularization, vitreous hemorrhage, retinal detachment, strabis-
mus, and less common toxicities [35–38].
The hypothalamus-pituitary axis is known to be affected in EBRT as it is exposed 
to radiation beams. Growth hormone deficiency and thyroid-stimulating hormone 
abnormality are noted in patients treated with EBRT. However, due to PRT physical 
properties that eliminate the radiation to midline structures, these adverse effects 
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are noted to be less than in conventional radiation therapy. Therefore, endocrinopa-
thies were almost limited in patients treated with PRT [38, 39].
Another adverse effect reported is craniofacial deformities where the facial and bony 
structures tend to be affected in EBRT. These include hypoplasia, hyperpigmentation, or 
soft tissue fibrosis. Long-term dentofacial anomalies have also been reported [36, 38, 40].
Risk of new cancers is a major concern in retinoblastoma patients treated with 
radiotherapy. The cumulative incidence of a second cancer at 50 years after diag-
nosis of retinoblastoma was 36% for hereditary retinoblastoma. Bone, nasal cavity, 
connective and soft tissue, and other neoplasms have been associated in retino-
blastoma survivors who received EBRT. Osteosarcomas and soft tissue sarcomas 
are the most common tumors reported in irradiated patients reaching up to 76% 
of all cancer in ages younger than 25 years old. On the other hand, in unilateral 
retinoblastoma patients who did not receive radiation, sarcomas did not occur. In 
addition, the subsequent risk of cancer was noted to be higher in irradiated patients 
than nonirradiated whether the patients had hereditary or non-hereditary disease. 
Also, elevated doses of radiation were associated with increased risk of subsequent 
tumors. However, no subsequent cancers were noted among hereditary patients 
treated with chemotherapy. Furthermore, a comparison between photon and 
proton radiotherapy techniques was done and it showed that the 10-year cumulative 
incidence of malignancies was significantly higher in photon therapy compared 
to proton therapy. Therefore, patients treated with radiotherapy should have long 
follow-ups regardless of the modality used [32, 33, 41].
Lastly, the quality of life was observed, and no difference was noted between 
children and their parents regarding the quality-of-life outcomes compared to the 
general population [38].
5. Brachytherapy
Brachytherapy is a form of radiotherapy where a source of radiation is placed 
inside or next to the treatment area. In retinoblastoma the radioactive implant is 
placed on the sclera corresponding to the tumor base and fixed surgically to irradiate 
the tumor. Implantation technique requires excellent surgical skills and is applied 
under general sedation where the implant is fixed on the sclera and maintained 
for few days and removed with the patients remaining in the hospital during the 
entire treatment [42]. Iodine-125 and Ruthenium-106 are the most common radio-
active agents to be used in intraocular lesions. Other agents can be used such as 
Ruthenium-106, Palladium-103, Strontium-90, Cobalt-60, and Iridium-192 [42, 
43]. Like EBRT, the use of brachytherapy has been limited to progressive disease and 
to preserve the eye from enucleation. However, brachytherapy offers less spread of 
radiation, and its complications that can be associated with EBRT can be prevented 
where damage of normal tissue can be minimized which can lead to deformities 
and more importantly reduce the risk of radiation-induced second cancers [42, 44, 
45]. Brachytherapy can be used as primary modality to treat retinoblastoma where 
the tumor is found solitary and located anterior to the equator as per the American 
Brachytherapy Society-Ophthalmic Oncology Task Force (ABS-OOTF) recommenda-
tions. As for secondary treatment where retinoblastoma failed to respond to other 
treatment modalities, it can be used irrespective of its location [43]. Brachytherapy is 
also an effective method that can be used post enucleation to prevent recurrence [46].
Plaque brachytherapy achieved tumor control in 83–89% of cases in some stud-
ies reaching up to 88% when used as a primary modality and appears to be the best 
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or chemoreduction, but it is less successful in patients who failed EBRT [45, 47, 48]. 
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are noted to be less than in conventional radiation therapy. Therefore, endocrinopa-
thies were almost limited in patients treated with PRT [38, 39].
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Reirradiation of local recurrence with brachytherapy can be considered as an option 
to salvage the eye from enucleation, and it may provide tumor control and eye pres-
ervation [48]. Complications related to radiation included radiation retinopathy, 
maculopathy, papillopathy, cataract, and glaucoma. Fortunately, no second cancers 
related to plaque brachytherapy were reported in the literature [45, 47–50].
Visual acuity in patients was found to be good in 64% and poor in 24–32% of 
non-enucleated eyes who were treated with plaque radiotherapy. The poor visual 
outcome was mainly associated with macular lesions, macular edema, vitreous 
hemorrhage, and phthisis bulbi. It appears that there is no significant difference 
whether brachytherapy was used as a primary or secondary modality in visual 
outcome [45, 47].
In many centers, Iodine-125 is used as the standard isotope for plaque brachy-
therapy. This is due to the physical properties like its half-life, low energy, adequate 
dose distribution, and ease of shielding [42, 43]. In a study, the use of Iodine-125 
as salvage treatment in 84 recurrent lesions after chemoreduction is reported. It 
showed 95% control in those who failed chemoreduction and 100% control in 
patients who failed a combination of chemoreduction and EBRT. Complications 
were higher in patients who received EBRT and included papillopathy, vitreous 
hemorrhage, cataract, and neovascularization [50].
Ruthenium-106 has some advantages over Iodine-125 where it’s lower in cost, 
has longer half-life, and is safer in terms of radioprotection. It has shown tumor 
control achievement up to 73%, and some studies achieved eye preservation 
in 89% of cases. Local recurrence with Ruthenium-106 is noted to reach 6.3%. 
Complications of Ruthenium-106 are generally similar to those found in other 
radiation modalities such as proliferative retinopathy which can lead to vitreous 
hemorrhage, radiation maculopathy radiation optic neuropathy, exudative retinal 
detachment, neovascularization, neovascular glaucoma, and cataracts. Previous 
treatment with EBRT was shown to be associated with increased risk of some com-
plications such as optic neuropathy, retinal detachment, and cataracts. However, 
studies of efficacy of Ruthenium-106 in retinoblastoma compared to Iodine-125 are 
limited in the literature [51–54].
6. Focal therapy
Focal therapy in treatment of retinoblastoma is used either alone in small retino-
blastomas (group A or B) (1, 2 laser) or after chemoreduction, usually after two or 
three cycles, or for small recurrent tumors or subretinal seeds [55–57].
7. Transpupillary thermotherapy (TTT)
Thermotherapy is based on increasing the tissue temperature from 45 to 60°C to 
induce a cytotoxic effect, through applying an 810-nm diode laser below the coagu-
lative threshold to prevent retinal vessels from coagulation, and it can be used alone 
for small retinoblastomas that are 3 mm in diameter without vitreous or subretinal 
seeds [57, 58]. In a study of 91 tumors, 92% of the tumors that were 1.5 mm in diam-
eter were controlled with thermotherapy alone [59]. Out of 188 treated by thermo-
therapy, complete regression of the tumor was achieved in (85%) 161 tumors, where 
the mean tumor size is 3.0 mm base and 2.0 mm thickness [60]. Complications of 
transpupillary thermotherapy include iris atrophy, cataracts, tumor seeding into the 
vitreous, retinal fibrosis, transition, and vascular occlusion.
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8. Laser photocoagulation
Laser photocoagulation is aimed to diminish blood supply of tumor. This type of 
treatment is used for small (4 mm in diameter and 2 mm in thickness) and posterior 
tumors. Argon or diode laser or a xenon arc is used but not directly on tumor tissue; 
instead it is aimed to coagulate the blood vessels that supply the tumor.
Retinal detachment, retinal vascular occlusion, retinal traction, and preretinal 
fibrosis can be a complication of this type of treatment [61–63].
9. Cryotherapy
Cryotherapy induces rapid decrease (freeze) of tumor tissue, and this will cause 
damage to the tumor blood vessel endothelium and lead to vascular thrombosis, 
which results in tumor ischemia and infarction. It is used as primary treatment for 
small equatorial and peripheral retinal tumors (<3.5-mm base and <2-mm thick-
ness). Treatment protocol is based on three applications for each session every 
4–6 weeks until complete regression of the tumor. Complications of cryotherapy 
include retinal tears and detachment, proliferative vitreoretinopathy, and chorio-
retinal atrophy. Cryotherapy can be used 2–3 hours before chemotherapy adminis-
tration, and that can increase the permeability of blood retinal barrier and increase 
the effect of chemotherapy [61, 63].
10. Chemotherapy
Chemotherapy is considered as one of the most important modalities used to 
treat retinoblastoma. It has been used as a main therapeutic modality achieving 
tumor control in up to 78% with the elimination of the need for enucleation as well 
as EBRT and its risk of developing second new cancers [64]. Chemotherapeutic 
agents can be delivered via four main routes which are intravenous chemotherapy, 
intra-arterial chemotherapy (IAC), intravitreal chemotherapy, and periocular 
chemotherapy. The most common chemotherapeutic agents used are vincristine, 
etoposide, and carboplatin. This (VEC) regimen is the most popular combination 
preferred by many experts, and this stems from its proven effect on neuronal 
tumors in the pediatric age group as well as its good penetration into the eye [65]. 
Melphalan is considered as the best and most effective agent in intra-arterial 
chemotherapy, and it is the most commonly used [66]. Tumor control, chemo-
reduction, and outcome differ from one modality and route of administration to 
another. Outcome also depends on the ICRB where chemotherapy can be success-
ful in 100% in group A and it drops as low as 50% in groups D and E. Visual out-
come can be maintained with a visual acuity of 6/60 or better in around two-thirds 
of patients [16, 67]. Adverse effects of chemotherapy observed are different from 
one modality to another. For instance, common side effects seen with systemic 
chemotherapy include transient pancytopenia, fever, and alopecia. Intra-arterial 
chemotherapy complications are attributed either to the procedure itself or to the 
chemotherapeutic agent. It can result in endovascular complications, allergy, and 
hematoma at the site of entry. IAC can also result in ocular vascular complications. 
Neutropenia is another important complication noted in IAC. Among the most 
frequent side effects of intravitreal chemotherapy are retinal pigment epithelium 
changes, iris depigmentation and atrophy, chorioretinal atrophy with vitreous 
hemorrhage, and retinal detachment. Fortunately, second primary malignancy 
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Abstract
The treatment of children with retinoblastoma (RB) has evolved from primarily 
enucleation of the eye(s) to highly selective methods of chemotherapy administra-
tion and approach. Indulgent and comprehensive understanding of the multitude 
of factors including accurate classification and grading of disease, timing and 
response to therapy, when to consolidate with local methods of therapy, combina-
tion regimens to control systemic disease and prevent relapse while minimizing 
risk of secondary cancers are crucial factors in the management of children with 
retinoblastoma. Chemotherapy was introduced in the 1950s and has become an 
integral component in management of RB. Methods of administration range from 
systemic to locally directed therapy including; intravitreal, periocular and intra-
arterial chemotherapy. This chapter is intended to discuss the evolution and current 
chemotherapeutic agents with various routes of administration. The indications, 
adverse occurrences, short- and long-term complications of both local and systemic 
treatments will be elucidated.
Keywords: chemotherapy, retinoblastoma, metastasis, intravenous, intra-arterial, 
intravitreal, periocular, vitreous seeds
1. Introduction
The treatment of retinoblastoma is challenging, as the governing objectives are 
preserving life, protecting from pineoblastoma, decreasing the lifetime incidence of 
secondary tumors and salvaging useful vision without exposing the patient to sig-
nificant and serious side effects that may endanger the patient’s survival and quality 
of life. The treatment of retinoblastoma evolved steadily during the past decades, 
and multiple modalities of treatment were introduced including chemotherapy. At 
one time, chemotherapy was used mainly to manage metastatic retinoblastoma, 
but later the interest of scientists and clinicians shifted to the use of this treatment 
strategy for non-metastatic retinoblastoma. As the interest of experts grew and 
the demand for better overall outcome increased, multiple interesting treatment 
strategies were developed and refined. Now, four main routes of administration of 
chemotherapy are present, and these are: intravenous chemotherapy (IVC), intra-
arterial chemotherapy (IAC), intravitreal chemotherapy (IVitC) and periocular 
chemotherapy (POC).
Today, chemotherapy is regarded as one of the indispensable pillars of treatment 
of retinoblastoma. In fact, retinoblastoma is currently one of the most commonly 
curable childhood malignant tumors universally. In developed countries, the rates 
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lower due to the limited healthcare resources [1]. The different chemotherapy 
treatment strategies outlined above will be discussed thoroughly in the upcoming 
sections.
2. Intravenous chemotherapy for retinoblastoma
The era of chemotherapeutic treatment for retinoblastoma began in 1953 when 
Carl Kupfer reported the successful use of intravenous nitrogen mustard along with 
irradiation to treat a child with recurrent retinoblastoma [2]. Thereafter, the use 
of triethylene melamine, a chemotherapeutic alkylating agent, via different routes 
(oral, intramuscular, intravenous and intra-arterial) became more widespread 
between clinicians until the late 1960s given that it allowed the reduction of radio-
therapy dose which was associated with multiple potential side effects [3–6]. In the 
following years, the use of systemic chemotherapy fluctuated until the early 1990s 
when the use of systemic chemotherapy was popularized and strongly advocated 
by the leading retinoblastoma treatment centers worldwide and the use of external 
beam radiation was restricted in favor of chemotherapy due to the considerable risk 
of secondary tumors in patients receiving radiotherapy.
The management of retinoblastoma should be carried out by an experienced 
team as these children need meticulous bilateral ocular examination, usually 
under anesthesia, in parallel with systemic evaluation by a pediatric oncologist 
with experience in ocular oncology and appropriate systemic imaging by magnetic 
resonance imaging (MRI) must be standardly performed to rule out metastasis. 
These steps are vital to accurately classify the disease in accordance with the more 
recent International Classification of Retinoblastoma (ICRB). This will direct the 
treatment to either systemic chemotherapy or local therapies (thermal, cryotherapy 
and chemotherapy) or a combination of both.
Understating the effect of systemic chemotherapy on the different forms of 
retinoblastoma (solid tumor, subretinal tumor and vitreous seeds) is essential as 
it helps in guiding the treatment. Moreover, the likely complications and systemic 
toxicities of IVC are important to be looked at carefully before commencement as 
this will help in individualizing the treatment in this vulnerable subset of patients 
so as to reduce systemic morbidities without jeopardizing the treatment success 
[7]. In this section, we will highlight the principal characteristics of this treatment 
modality.
2.1 Indications
The use of IVC varies slightly between different treatment centers worldwide; 
but generally speaking, the umbrella of IVC usage encompasses its use in patients 
with intraocular disease only and in patients with or at high risk of extraocular 
disease. When the disease is limited to the eyes, IVC aims at shrinking the size of 
the tumor to expedite cure and lessen the damage induced by consolidating local 
therapies to follow, especially when the tumor involves sensitive retinal areas such 
as the macula. This has been termed chemoreduction and it had been shown to 
achieve adequate tumor control (alone or along with focal consolidating therapies) 
and eliminate the need for enucleation or external beam radiation (EBR) in more 
than 75% of patients in a large series (n = 457, group A–D). The risk of recurrence 
in this series was 22% and these were usually detected in the first year after starting 
the treatment; yet; none occurred by 4 years of follow up [8, 9]. This is probably the 
most important concern arising with the use of chemoreduction; though continu-
ous surveillance of these children partly helps in overcoming this shortcoming. 
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Moreover, one study suggested that the administration of chemoreduction might 
minimize the risk of pineoblastoma where none of the children (n = 147) receiving 
this therapy developed trilateral retinoblastoma [10].
IVC is used also as an adjuvant therapy after enucleation in patients with 
extraocular disease (metastasis) as well as patients with intraocular disease associ-
ated with high-risk histopathological features (e.g., optic nerve invasion beyond the 
lamina cribrosa and choroid invasion >3 mm) demonstrated on histopathological 
examination of the enucleated eye [11]. It is speculated that patients with high-risk 
features might presumably have micro-metastasis and administering systemic 
chemoprophylaxis helps in improving their prognosis. Evidence in the literature 
supports the use of prophylactic IVC in high-risk patients where it was shown that it 
is safe and effective in decreasing the risk of metastasis [12, 13].
Patients with extraocular disease receiving IVC can be divided into three 
categories: those with orbital and/or regional spread to the preauricular lymph 
nodes or optic nerve cut, those with central nervous system (CNS) dissemina-
tion and those with distant extracranial metastasis [14]. In patients presenting 
with orbital retinoblastoma, IVC is a valuable treatment. This holds true when it 
is predominantly administered in combination with other therapies (multimodal 
therapy: surgery, radiotherapy and chemotherapy) as its effect is usually inad-
equate when given alone [15]. Patients who have CNS involvement usually have a 
very poor prognosis with low survival rate. The usual approach to these patients 
consists of platinum-based IVC with agents having good CNS penetration along 
with focal CNS treatments such as radiotherapy. Some studies suggested using high 
doses of IVC followed by autologous hematopoietic progenitor cell rescue; yet, this 
technique is controversial [16]. Distant metastasis usually occurs to the bone and a 
small series (n = 14) on stage 4A patients showed promising results using intense 
induction chemotherapy followed by high dose consolidating chemotherapy and 
autologous hematopoietic progenitor cell rescue [17].
2.2 Chemotherapeutic protocol
Over the past decades, multiple chemotherapeutic agents were used, and 
multiple chemotherapy protocols were implemented, some of which are now 
outdated. In the meantime, the most commonly employed IVC therapy is the VEC 
protocol consisting of three main chemotherapeutic agents (Vincristine, Etoposide, 
Carboplatin) in standard doses based on the body weight. Higher doses may be used 
in patients with more advanced disease (bilateral group D or E) [7, 18]. This three-
drug regimen is the most popular combination preferred by many experts and this 
stems from its proven effect on neuronal tumors in the pediatric age group as well 
as its good penetration into the eye [19]. The patient usually receives 6–9 cycles on a 
monthly basis and once the tumor shrinks in size, then focal consolidating treat-
ments can follow [7].
2.3 Complications
Common side effects, which are usually observed with any systemic chemo-
therapy, include transient pancytopenia owing to bone marrow suppression, fever 
and alopecia. The occurrence of these side effects is usually limited to the treatment 
period. Although carboplatin, a platinum based agent, had been linked to ototoxic-
ity and nephrotoxicity, these serious side effects are rare as they are dose-dependent 
[20, 21]. There was an underlying concern that etoposide may induce acute myelog-
enous leukemia especially with high multiple doses; yet, the results of several 
studies on this topic were reassuring [7, 22]. With regards to secondary tumors, it 
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does not seem that IVC increases the risk ominously. A long term follow-up study 
demonstrated that the rate of secondary tumors in germline retinoblastoma patients 
treated with systemic chemotherapy was 4%, which is less than expected for this 
vulnerable subset of patients [23].
2.4 Outcomes and success rate
The introduction of systemic chemotherapy resulted in an improved eye salvage 
rate, not to mention the enhanced visual outcome. Chemoreduction success can 
be predicted in patients with retinoblastoma following the ICRB classification as 
following: 100% in group A, 93% in group B, 90% in group C and <50% in group D 
and E [24]. The success rate in the advanced stages can be augmented when combin-
ing IVC with other modalities of treatment such as IAC or IVitC. Long-term studies 
have shown that chemotherapy with or without adjunctive therapies maintains 
ambulatory vision of ≥6/60 in almost two-thirds of the patients, particularly those 
with multiple tumors and/or no foveolar tumors [25]. Furthermore, IVC seems to 
exert a protective effect against pineoblastoma as its occurrence is usually very low 
in patients receiving it [26].
The effect of systemic chemotherapy as a monotherapy appears to be satisfac-
tory especially in patients with less advanced disease whereas in patients with 
advanced disease, its remedial action is complementary to the selective recent 
therapies. A recently published meta-analysis comparing IVC to the more selective 
IAC revealed that both methods are equivalent in terms of tumor recurrence and 
metastasis. IAC evidently had a higher total success rate and ocular sparing effect 
in group D patients compared to IVC [27]. Despite this, we believe that IVC will 
continue to be an integral part of the treatment regimen of retinoblastoma.
3. Intra-arterial chemotherapy for retinoblastoma
Intra-arterial chemotherapy (IAC), also known as ophthalmic artery chemo-
surgery (OAC), is an important treatment strategy for retinoblastoma that evolved 
rapidly and gained popularity worldwide. Today, this modality of treatment is being 
performed in many retinoblastoma treatment centers located in more than 45 coun-
tries across the globe [28]. This treatment modality was initially explored by Reese 
et al. [3] who directly injected the alkylating agent triethylene melamine (TEM) 
into the internal carotid artery; nevertheless, it was not until 2006 when Abramson 
and Gobin introduced the novel technique of super-selective ophthalmic artery 
catheterization via transfemoral artery approach which allowed immediate and 
effectual delivery of the administered agent (melphalan) into the diseased eye [29]. 
Thereafter, many oncology centers adopted this technique and started publishing 
their experience. In this section, we will be shedding the light on the important 
aspects and most recent results of IAC.
3.1 Indications
IAC opened the door to a new era in the treatment of retinoblastoma. The key 
exciting factor behind this local therapy is its ability to achieve adequate therapeutic 
intraocular concentrations of the delivered chemotherapeutic agents while minimiz-
ing the systemic toxicity induced by these infused drugs such as neutropenia and 
secondary tumors [30]. In view of this, IAC is utilized mainly in treating patients 
with intraocular disease without local or systemic spread. Previous studies on IAC 
have shown that it can be used successfully as a primary retinoblastoma treatment in 
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naïve eyes (no previous therapy employed) or as a secondary treatment in eyes with 
recurrent or residual tumor after trying other treatment modalities such as systemic 
chemotherapy, external beam radiotherapy and others [29, 31–37]. Currently, the 
common indications for IAC in retinoblastoma patients include unilateral retino-
blastoma that cannot be halted by local treatments alone (e.g., cryotherapy or laser 
photocoagulation) and advanced unilateral retinoblastoma (such as group D and 
E based on the ICRB) [30]. Several studies had previously reported the following 
advantages of using IAC in patients with group D retinoblastoma: better eye conser-
vation rates and greater visual acuity compared to systemic chemotherapy, shorter 
treatment period and ability to repeat the therapy several times using multiple agents 
without endangering the patients’ life and vision [28, 38]. It is also noteworthy to 
mention that IAC can save naïve eyes with advanced retinoblastoma from enucle-
ation particularly when subretinal seeding is present (2 year ocular survival rate of 
83%) [39]. Furthermore, IAC has a proven benefit even in patients presenting with 
advanced disease such as those having retinoblastoma-induced total or partial retinal 
detachment in which it can successfully achieve retinal re-attachment and thus help 
in preserving the eye and the life with the least possible side effects [40, 41].
Simultaneous IAC (tandem therapy) to both eyes consecutively is also a valu-
able and safe treatment method in patients with bilateral germline retinoblastoma 
whether used primarily or secondarily. This was demonstrated in two recent stud-
ies, which reported excellent globe salvage rates (ocular survival rate > 90%) even 
in patients with advanced disease. Despite that the safety profile of this simultane-
ous therapy was considerably high where no treatment-associated deaths occurred, 
these children were still at risk of secondary tumors such as pineoblastoma and this 
is probably attributed to their inherent genetic predisposition [42, 43].
3.2 IAC technique
The technique of IAC is carried out on patients who are generally anesthetized and 
is usually coordinated by a specialized and experienced oncology/radiology team. The 
common femoral artery on the ipsilateral treatment side is usually used to gain access 
to the internal carotid artery and then the ophthalmic artery (OA) is selectively cath-
eterized under fluoroscopic guidance at its ostium (origin) while heparin is infused 
intravenously to prevent coagulation. Then, in order to verify the proper placement 
of the microcatheter, selective angiography is done by contrast infusion to delineate 
the vascular anatomy and ocular perfusion. Due to the variability of vascular territory 
anatomy and blood flow patterns, OA catheterization might fail and other routes are 
available, however, this is out of the scope of this chapter [34].
3.3 Chemotherapeutic agents
The most commonly used intra-arterial chemotherapeutic agent is melphalan, 
a potent alkylating agent. Melphalan is by far the strongest chemotherapeutic 
drug acting effectually against human retinoblastoma cells [44]. It is very safe 
when administered locally but very toxic when infused systemically due to the 
resultant severe myelosuppression [45]. In fact, it is currently considered an ideal 
agent due to its favorable safety profile, short half-life and ability to be used in 
combination with other agents to achieve greater tumor control when needed 
[34, 46]. Topotecan, a topoisomerase inhibitor, and carboplatin, an alkylating 
agent, are other agents that have been used alone or as a part of a multi-drug 
regimen in advanced cases that fail to respond to melphalan solitarily or in 
bilateral tandem therapy where the dose of melphalan is decreased to prevent 
systemic side effects [34].
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advanced disease such as those having retinoblastoma-induced total or partial retinal 
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in preserving the eye and the life with the least possible side effects [40, 41].
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able and safe treatment method in patients with bilateral germline retinoblastoma 
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ies, which reported excellent globe salvage rates (ocular survival rate > 90%) even 
in patients with advanced disease. Despite that the safety profile of this simultane-
ous therapy was considerably high where no treatment-associated deaths occurred, 
these children were still at risk of secondary tumors such as pineoblastoma and this 
is probably attributed to their inherent genetic predisposition [42, 43].
3.2 IAC technique
The technique of IAC is carried out on patients who are generally anesthetized and 
is usually coordinated by a specialized and experienced oncology/radiology team. The 
common femoral artery on the ipsilateral treatment side is usually used to gain access 
to the internal carotid artery and then the ophthalmic artery (OA) is selectively cath-
eterized under fluoroscopic guidance at its ostium (origin) while heparin is infused 
intravenously to prevent coagulation. Then, in order to verify the proper placement 
of the microcatheter, selective angiography is done by contrast infusion to delineate 
the vascular anatomy and ocular perfusion. Due to the variability of vascular territory 
anatomy and blood flow patterns, OA catheterization might fail and other routes are 
available, however, this is out of the scope of this chapter [34].
3.3 Chemotherapeutic agents
The most commonly used intra-arterial chemotherapeutic agent is melphalan, 
a potent alkylating agent. Melphalan is by far the strongest chemotherapeutic 
drug acting effectually against human retinoblastoma cells [44]. It is very safe 
when administered locally but very toxic when infused systemically due to the 
resultant severe myelosuppression [45]. In fact, it is currently considered an ideal 
agent due to its favorable safety profile, short half-life and ability to be used in 
combination with other agents to achieve greater tumor control when needed 
[34, 46]. Topotecan, a topoisomerase inhibitor, and carboplatin, an alkylating 
agent, are other agents that have been used alone or as a part of a multi-drug 
regimen in advanced cases that fail to respond to melphalan solitarily or in 
bilateral tandem therapy where the dose of melphalan is decreased to prevent 
systemic side effects [34].
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3.4 Complications
Despite being a less invasive therapeutic intervention, IAC does carry some 
risk of complications, as it would be expected with any medical interventional 
procedure. Complications occurring after IAC are attributed either to the procedure 
itself or to the chemotherapeutic agent/agents or both. Complications developing 
from the procedure include endovascular complications occurring intraoperative, 
allergy to iodine and hematoma at the site of entry into the femoral artery. Systemic 
thromboembolic and hemorrhagic events (stroke, limb ischemia) are possible but 
their current reported overall occurrence is extremely scarce [30, 44]. Up to date, 
no procedure-related deaths had been reported. Theoretically speaking, since IAC 
targets chiefly the intraocular pathology, the risk of metastasis and secondary 
neoplasms remains unchanged or even might be increased, as this treatment is not 
intended to reach the systemic circulation in high concentrations. Experts studied 
the incidence of death due to retinoblastoma-associated metastasis in a cohort of 
patients treated over a 10-year period by IAC primarily or secondarily and found it 
to be negligible (<1%) [47]. Likewise, IAC was not associated with an increased rate 
of second primary malignancies (SPM) in a group of patients with germline reti-
noblastoma from one treatment center studied over a 10-year period (2006–2016) 
[48]. However, IAC is relatively a recent therapy; therefore, it is still premature 
to derive definite conclusions regarding the potential risk and studies with longer 
follow up periods are required.
Neutropenia is another important complication that should be recognized and 
managed early to prevent devastating complications. The local distribution of the 
drug has helped in limiting its occurrence to <15% [34, 49]. On the other hand, 
minor ocular side effects are common and these include: lids edema, blepharoptosis, 
temporary loss of the eyelashes and forehead hyperemia along the distribution of 
the supratrochlear artery [50]. Ocular vascular complications are among the univer-
sally feared local side effects. A recent review of 16 published studies reported that 
<2.5% had ophthalmic artery obstruction or occlusion, choroidal ischemia or atro-
phy and vasospasm [49]. These vascular events should be interpreted in the context 
of the clinical case given that these are usually sick eyes that might have received 
other local treatments that might contribute to the occurrence of such events. A 
recently published study looked at the incidence of vascular events and the variabil-
ity of their occurrence when IAC is given primarily or secondarily and reported the 
following: overall vascular complications occur in 5% of eyes per infusion and no 
difference was observed when IAC is used as a primary or secondary therapy [51].
3.5 Outcomes and success rate
The body of evidence in the literature supporting the use of IAC has been 
growing persistently in the past decade. Impressively, the reported globe salvage 
rate is currently exceeding 90% without compromising patient’s survival and the 
enucleation rate dropped to <10% [35, 52–54]. Even the rate of orbital recurrence 
was significantly higher in patients with advanced disease treated with enucleation 
compared to IAC and this further emphasizes the gainful outcome of IAC [55].
A major concern about the risk of recurrence after IAC treatment remains in 
spite of the success achieved by this treatment modality. A recent study from one of 
the pioneering centers utilizing IAC with 10 years experience reported that around 
25% of eyes treated primarily with IAC might develop recurrence. The recurrence 
of the disease was observed to occur mainly in the first 12 months post-treatment; 
and therefore, close follow up with serial meticulous examination is recommended 
during this period. Surprisingly, the rate of recurrence was higher in eyes that 
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received the drug through routes other than OA and in eyes with widely spaced 
treatments more than 4 weeks. The risk of recurrence was <10% by 2 years in eyes 
remaining disease free in the first year after IAC [52].
4. Intravitreal chemotherapy for retinoblastoma
Intravitreal chemotherapy (IVitC) is another well-established targeted therapy 
accounting for one of the important current treatment modalities for retinoblas-
toma manifesting vitreous seeds. Initial reports on IVitC date back to the 1960s 
where thiotepa was injected into the vitreous cavity of six eyes with retinoblastoma; 
yet the results were inconclusive due to the limited number of treated eyes [56]. 
Later, this method was revived by Kaneko and Suzuki who injected melphalan 
intravitreally in 41 eyes along with ocular hyperthermia to cure vitreous seed-
ing with a notable resultant eye preservation rate of 51.3% [57]. The choice of 
melphalan was essentially based on in-vitro testing of 12 anti-neoplastic drugs, 
and melphalan proved to be the most effective against retinoblastoma cells [45]. 
Implementing this technique into current practice took several years and perhaps 
the major limiting factor was the fear of disseminating the cancer cells during injec-
tion with the risk of subsequent extraocular spread causing metastasis and death. 
This section will elaborate on the key qualities of this relatively new therapy.
4.1 Indications and contraindications for intravitreal chemotherapy
This local therapeutic technique is intended essentially to achieve the highest 
concentration of the delivered tumoricidal drug into the confined intraocular space 
adjacent to the tumor. IVitC is used as an adjunctive therapy to chemoreduction 
with systemic chemotherapy and IAC. The main indications for this treatment 
modality are the presence of active vitreous seeds that are either refractory to stan-
dard therapy or recurrent after pervious standard therapy [7]. The use of IVitC had 
also expanded lately to include patients with retinal and subretinal tumors where it 
had been shown to be successful in salvaging the globe of such patients [58].
On the other hands, contraindications preventing the execution of this pro-
cedure include tumors involving the ciliary body or extending up to the anterior 
segment, tumors filling the globe, retinal detachment and vitreous hemorrhage.
4.2 Intravitreal chemotherapy technique
Before proceeding with this treatment, it is critical to meticulously evaluate the 
pars plana clinically in all quadrants 360° looking for any tumor foci as that could 
pose a threat to safety if present due to the risk of spread while injecting. If visual-
ization is difficult, then ultrasound biomicroscopy can be used to help in detection 
and affirmation [59].
The procedure is usually carried out in the operating room under sterile condi-
tions while the child is under general anesthesia. The anti-cancerous drug, typically 
melphalan, is injected through the pars plana 3–3.5 mm from the limbus into the 
vitreous cavity using a small needle, preferably a 32 gauge-needle. This creates the 
smallest needle track that helps in reducing the risk of dissemination. The injection 
is rather done in a seed-free quadrant, 2 o’clock hours away from vitreous seeds to 
prevent the undesirable exteriorization of tumor cells. Furthermore, some experts 
advocate reducing the pressure inside the eye by paracentesis before inserting the 
needle to prevent the possible risk of microscopic tumor seeding. After injecting the 
drug and before exiting the tumor-harboring globe, triple freeze-thaw cryotherapy 
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melphalan was essentially based on in-vitro testing of 12 anti-neoplastic drugs, 
and melphalan proved to be the most effective against retinoblastoma cells [45]. 
Implementing this technique into current practice took several years and perhaps 
the major limiting factor was the fear of disseminating the cancer cells during injec-
tion with the risk of subsequent extraocular spread causing metastasis and death. 
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tions while the child is under general anesthesia. The anti-cancerous drug, typically 
melphalan, is injected through the pars plana 3–3.5 mm from the limbus into the 
vitreous cavity using a small needle, preferably a 32 gauge-needle. This creates the 
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should be carried out concurrently at the injection site while withdrawing the 
needle. Then, uniform intraocular distribution of the drug is achieved by gentle 
shaking of the eye using forceps. Examination is usually performed at the end of the 
procedure to rule out possible acute complications such as retinal detachment and 
bleeding. The ocular surface is then washed with balanced salt solution to remove 
any remnant chemotherapeutic agent that could be toxic. The child is usually dis-
charged in the same day and the family is instructed to avoid touching the eye [59]. 
The procedure may vary minimally between different specialized treatment centers.
4.3 Chemotherapeutic agents
Melphalan hydrochloride is the principal drug injected into the vitreous cav-
ity in retinoblastoma patients. It is a cytotoxic nitrogen mustard derivative that 
inhibits the synthesis of DNA and RNA together [59]. Its effective dosage range was 
studied and set at 20–30 μg per injection as low doses (8 μg) were not adequate to 
control and eradicate the disease while high doses (50 μg) controlled the disease 
but resulted in local toxicity (cataract, posterior segment hemorrhage, hypotony 
and phthisis bulbi) [60]. The number of injections is governed by the response. 
In general, Shields et al. proposed giving a total of six injections weekly or every 
2 weeks [7].
Topotecan, a topoisomerase-1 inhibitor, is another potent intravitreal agent 
that had been employed in the treatment of retinoblastoma with vitreous seeds. 
Experimental animal studies showed that topotecan produce high and stable levels 
in the vitreous [61]. One of the distinguishable advantages of topotecan is its ability 
to attain a vitreous-to-plasma concentration five times more than melphalan [62]. 
Previous studies have shown that it is an effective anti-tumor drug with good safety 
profile and low ocular toxicity [63]. It had been used intravitreally in combination 
with melphalan in humans with encouraging results where this multi-agent regimen 
managed to achieve notable vitreous seeds regression with fewer injections [64]. 
Topotecan can also be used effectively in patients with recurrent or resistant viable 
vitreous seeds according to a recent study on 17 eyes which demonstrated control 
of these seeds in all treated eyes (100%) in the absence of ocular or systemic side 
effects and with a lower number of injections [65].
4.4 Complications
Extraocular tumor dissemination through the needle track with subsequent 
metastasis was perhaps the most feared serious event limiting the use of this treat-
ment modality in the past. However, a meta-analysis examining published studies 
on this matter revealed that the risk of systemic spread is very low (two cases out 
of 1304 injections, proportion of extraocular spread secondary to injections was 
0.007) especially when the appropriate safety enhancing injection techniques 
are applied. Therefore, IVitC can be utilized unreservedly whenever needed after 
proper patient selection [66].
Ocular side effects are generally uncommon in patients receiving IVitC. The 
major factor influencing the risk of complications and local ocular toxicity is the 
dose of administered medication where toxicity is more likely with melphalan doses 
higher than 30 μg [67]. Among the most frequent side effects is retinal pigment 
epithelium changes (salt and pepper retinopathy), which is believed to represent a 
form of chemical burn to the retinal at the area where the drug is concentrated the 
most [68, 69]. Retinal function decline due to toxicity, usually highlighted on elec-
troretinography (ERG), is a possible complication of melphalan although the results 
are conflicting in the literature where one study showed no effect on ERG (dose: 
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20–30 μg) while another reported non-progressive decreased ERG amplitudes of 
approximately 5 μV (equivalent to 5% retinal response) with every 30 μg melphalan 
injection [70–72]. ERG can actually be a useful tool to monitor these patients for 
cumulative retinal toxicity.
Other major ocular complications that were highlighted in a systematic review 
with a total of 1287 intravitreal injections given to 306 eyes include: iris depigmen-
tation and atrophy, chorioretinal atrophy with vitreous hemorrhage and retinal 
detachment [67]. Fortunately, there are no reports of endophthalmitis after IVitC; 
nonetheless, all protective measures should be taken to prevent this possible devas-
tating complication.
With regards to serious systemic side effects, namely significant neutropenia 
of grade 3 and 4, these were not observed when analyzing 46 blood samples with-
drawn from patients receiving IVitC (despite some patients received concurrent 
IAC) [71]. Again, this accentuates the benefit of local therapies in these young 
children.
4.5 Outcomes and success rate
Treating retinoblastoma with vitreous seeding can be really challenging due to 
the avascular nature of the vitreous; and therefore, drug delivery through systemic 
routes may not be sufficient sometimes. Besides this, it tends to be resistant to 
external radiation and systemic chemotherapy [68, 73]. In the past two decades, a 
quantum leap forward in the management of advanced retinoblastoma was reached 
with the help of IVitC. The reported vitreous seeding control rates of IVitC (mel-
phalan with or without topotecan) ranges between 60 and 100% [60, 68, 71, 72, 
74]. Additionally, the attained globe salvage rates are also impressive reaching up to 
100% as reported in one study on 11 eyes receiving a total of 55 intravitreal melpha-
lan injections [69].
5. Periocular chemotherapy for retinoblastoma
Periocular chemotherapy (POC) administration was designed to allow deliv-
ery of a higher concentration of the tumoricidal drugs locally. This route was 
firstly tested in retinoblastoma animal models using carboplatin and it had been 
shown that this route produces vitreous concentrations 8–10 folds more than the 
intravenous route [75, 76]. These preclinical results led to the conduction of a trial 
in which children with retinoblastoma were treated using subconjunctival carbo-
platin and the results were promising [77]. Thereafter, POC grew in popularity 
and it was consequently incorporated into the multimodal treatment algorithm 
of retinoblastoma. Currently, it is a part of the prospective multicenter Children’s 
Oncology Group trials for retinoblastoma. In this section, POC will be tackled 
comprehensively.
5.1 Indications for periocular chemotherapy
POC is used predominantly as an adjunctive therapy to systemic chemotherapy 
as presently there is no evidence promoting it as a stand-alone therapy [78]. It is 
indicated principally in patients with recurrent localized tumor and in advanced 
disease (group D and E) where chemotherapy can be desirably infused in higher 
concentrations without exposing the patient to increased systemic toxicity [7]. It can 
also be utilized in patients who are not fit to receive systemic chemotherapy as well as 
patients with recurrent or persistent viable non-calcified vitreous seeds [78].
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of retinoblastoma. Currently, it is a part of the prospective multicenter Children’s 
Oncology Group trials for retinoblastoma. In this section, POC will be tackled 
comprehensively.
5.1 Indications for periocular chemotherapy
POC is used predominantly as an adjunctive therapy to systemic chemotherapy 
as presently there is no evidence promoting it as a stand-alone therapy [78]. It is 
indicated principally in patients with recurrent localized tumor and in advanced 
disease (group D and E) where chemotherapy can be desirably infused in higher 
concentrations without exposing the patient to increased systemic toxicity [7]. It can 
also be utilized in patients who are not fit to receive systemic chemotherapy as well as 
patients with recurrent or persistent viable non-calcified vitreous seeds [78].
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5.2 Chemotherapeutic agents
The common chemotherapeutic agents that are mostly used are carboplatin and 
topotecan. Experimental work showed that carboplatin peaks in the vitreous after 
30 min of periocular injection and lasts for hours. Its concentration in the vitreous 
is approximately seven times more than that achieved by intravenous chemotherapy 
[76]. Several periocular drug administrative devices were explored and these 
include: plain liquid, Lincoff balloon, fibrin sealant, nanoparticles and iontophore-
sis [76, 79–81].
5.3 Complications
This treatment modality fortunately has no systemic side effects. Ocular 
complications do occur, and these mostly affect the periorbital tissue possibly 
owing to local toxicity. The most common observed side effects are lid edema, 
lid erythema, periorbital pseudocellulitis, ptosis, orbital fat atrophy, optic nerve 
atrophy and muscle fibrosis causing ocular motility changes [7, 77, 78, 82, 83]. 
Concerns were raised regarding the toxic effect on the extraocular muscles; yet, 
a study examining the effect of sub-tenon topotecan on the extraocular muscles 
of 10 eyes concluded that it had no toxic effect on the muscles and it is a safe and 
effective alternative [84].
5.4 Outcomes and success rate
Although the number of studies on POC is limited overall, it had been shown 
that POC is principally effective when combined with other modalities of anti-
neoplastic therapies. One long-term follow up study demonstrated that 39% 
(n = 33 eyes) of the enrolled eyes were saved when treated with POC in addition 
to other concurrent treatment modalities. The same report indicated that two 
eyes treated by POC as monotherapy were cured and remained disease free on 
follow up [82].
6. Conclusions
In the last two decades, significant new approaches have been employed in 
the treatment of retinoblastoma which is a curable disease when diagnosed early. 
Modalities to avoid enucleation and minimize the short and long term effects of 
exposure to systemic chemotherapy and radiation therapy continue to evolve and 
now set the platform in the treatment of retinoblastoma. Despite new techniques 
such as selective intra-arterial and intravitreal chemotherapy, it is paramount to 
individualize therapy according to multiple factors including patient age, tumor 
location, stage of disease, size, and extension, along with realistic visual expecta-
tions. Personalized medicine will be able to tailor therapy with the best response 
and safety in children with retinoblastoma.
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location, stage of disease, size, and extension, along with realistic visual expecta-
tions. Personalized medicine will be able to tailor therapy with the best response 
and safety in children with retinoblastoma.
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Abstract
Retinoblastoma (RB) is the most common intraocular tumor in children. It arises 
from the nuclear layer of the retina, with different growth patterns: endophytic, 
exophytic, and mixed. Retinoblastoma also has characteristic histopathological 
appearance with areas of viable tumor, necrosis, and calcifications. The tumor dif-
ferentiation can be determined by the presence of rosettes—Flexner-Wintersteiner 
rosettes as well as fleurettes—and tends to become less differentiated with age. 
Histopathological risk factors are used as prognostic indicators and will be dis-
cussed in this chapter together with the typical tissue diagnostic features. These 
will include optic nerve/choroidal invasion, extraocular extension, and anterior 
segment involvement. Other prognostic factors with less impact will be discussed 
as well including the amount of necrosis, mitotic figures, and grading of anaplasia. 
Furthermore, we will briefly discuss different regression patterns and posttreat-
ment findings in enucleated globes.
Keywords: retinoblastoma, pathological prognostic indicators, optic nerve invasion, 
choroidal invasion, pathological classification
1. Introduction
Retinoblastoma was first ever described by Petras Pawius from Amsterdam in 
1597, and it wasn’t until 1809 when James Wardrop of Edinburgh established its 
origination from the retina and recommended enucleation as a primary treatment 
method for saving lives [1–3]. Nine years later, the first case of fungus hematodes, 
old name of retinoblastoma, was reported in the American literature [2, 4]. In the 
following three decades when the microscope was introduced, Virchow, the well-
known pathologist, claimed that this tumor is a glioma as it arises from glial cells  
[2, 5]. Nevertheless, both the pathologist Simon Flexner (1891) and ophthalmolo-
gist Hugo Wintersteiner (1897) believed independently that this tumor is actually a 
neuroepithelioma due to the presence of cellular rosettes harboring a central lumen 
histologically. In fact, the Flexner-Wintersteiner rosettes that are diagnostic for 
retinoblastoma are named after these two physicians [2, 6, 7]. Later in the nine-
teenth century, the American pathologist Verhoeff confirmed that undifferentiated 
retinal cells are the original nidus of this tumor; thus, he called it retinoblastoma. 
This term was first adopted by the American Ophthalmology Society in 1926, and it 
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1. Introduction
Retinoblastoma was first ever described by Petras Pawius from Amsterdam in 
1597, and it wasn’t until 1809 when James Wardrop of Edinburgh established its 
origination from the retina and recommended enucleation as a primary treatment 
method for saving lives [1–3]. Nine years later, the first case of fungus hematodes, 
old name of retinoblastoma, was reported in the American literature [2, 4]. In the 
following three decades when the microscope was introduced, Virchow, the well-
known pathologist, claimed that this tumor is a glioma as it arises from glial cells  
[2, 5]. Nevertheless, both the pathologist Simon Flexner (1891) and ophthalmolo-
gist Hugo Wintersteiner (1897) believed independently that this tumor is actually a 
neuroepithelioma due to the presence of cellular rosettes harboring a central lumen 
histologically. In fact, the Flexner-Wintersteiner rosettes that are diagnostic for 
retinoblastoma are named after these two physicians [2, 6, 7]. Later in the nine-
teenth century, the American pathologist Verhoeff confirmed that undifferentiated 
retinal cells are the original nidus of this tumor; thus, he called it retinoblastoma. 
This term was first adopted by the American Ophthalmology Society in 1926, and it 
has been in use since then [2, 8].
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2. Gross pathology
The first step of grossing an enucleated eye in preparation for histopathological 
microscopic examination is establishing the laterality. Several anatomical landmarks 
provide useful cues to orient the globe properly, and these include the cornea, 
oblique muscles, and ciliary arteries. The corneal horizontal diameter is larger than 
its vertical diameter by around 1 mm, and this produces an oval shape (Figure 1A). 
The insertion of the superior oblique muscle tendon after originating from the 
trochlea is in the superior outer (temporal) quadrant just behind the insertion of 
the superior rectus muscle tendon. The inferior outer (temporal) quadrant receives 
the insertion of inferior oblique muscle, just lateral to the optic nerve (Figure 1B). 
Locating the horizontal planes can be done affirmatively by identifying the long 
posterior ciliary arteries that run horizontally at 3 and 9 o’clock [9].
In the past, the enucleated eye was grossed and processed to produce one pupil-
optic nerve (PO) section, which is then studied histopathologically. This practice 
was abandoned following the consensus of the International Retinoblastoma 
Staging Working Group (IRSWG) in 2009 where the efforts of 85 members from 
Figure 1. 
Grossing an enucleated eye with retinoblastoma: (A) vertical corneal measurements; (B) inferior oblique 
muscle insertion located temporal (lateral) to the optic nerve (asterisk); (C, D) pupil-optic nerve (PO) 
section; (E) cassettes containing both calottes cut in bread-loaf pattern (red arrows), while the PO section is 
submitted in a separate cassette.
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24 different countries were joined to establish guidelines for tissue processing and 
handlining as well as staging. They concluded that the entire enucleated globe 
should be examined microscopically. This can be achieved by dividing the eye into 
four blocks. The optic nerve, tumor, and anterior chamber structures are included 
in the central pupil-optic nerve (PO) section composing one block as demonstrated 
in (Figure 1C, D). Two mirrored blocks composed of the calottes, representing the 
remaining eye tissue after harvesting the PO section, are usually cut consecutively 
in a bread-loaf fashion and embedded on edge to increase the examined surface 
area of the choroid, and this will subsequently improve the chances of detection 
of choroidal involvement (Figure 1E). The last block comprises the optic nerve 
margin cross section, and this is usually taken initially before cutting the eye. 
The optic nerve head, lamina cribrosa, and optic nerve posterior to the lamina 
cribrosa in a single section plane are usually displayed in the PO section as shown 
in (Figure 1D) [9].
Enucleation of the eye not only enables histopathological diagnosis, but it also 
yields fresh ocular tissue on which molecular and genetic testing can be carried 
out. Such tests are of paramount importance as their results are needed for family 
counseling and prognosis prediction. To facilitate this, guidelines and protocols 
were proposed to ensure preservation of the harvested ocular tissue for examination 
to obtain the best histopathological and molecular testing results. This guideline 
states that the enucleated globe should be processed and opened soon after surgery 
in order to prevent proteins and nucleic acid denaturation. Then, the optic nerve 
length is measured and documented in mm, and this is followed by preparing the 
block of the optic nerve margin cut section before proceeding with opening the eye. 
The next step involves opening the globe with the aid of transillumination, which is 
helpful in localizing the margins of the intraocular mass in addition to planning the 
collection of the PO section. Opening the eye can be accomplished using one of two 
techniques. The first proposed technique involves creating a window opening in the 
sclera adjacent to the edge of the bulk of the tumor. This scleral window is ideally 
created using a trephine. The second method is done utilizing a large bore 22-gauge 
needle that is used under sterile conditions to aspirate fresh tumor cells/tissue. The 
needle is inserted obliquely under direct visualization via the sclera into the poste-
rior chamber behind the lens, and aspiration takes place once it is inside the tumor 
mass. Finally, the globe is fixed in an adequate amount of formalin for a minimum 
of 48 hours [10].
Figure 2. 
(A) Gross photo showing the encephaloid appearance of the tumor. (B) White flecks representing the 
calcification.
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oblique muscles, and ciliary arteries. The corneal horizontal diameter is larger than 
its vertical diameter by around 1 mm, and this produces an oval shape (Figure 1A). 
The insertion of the superior oblique muscle tendon after originating from the 
trochlea is in the superior outer (temporal) quadrant just behind the insertion of 
the superior rectus muscle tendon. The inferior outer (temporal) quadrant receives 
the insertion of inferior oblique muscle, just lateral to the optic nerve (Figure 1B). 
Locating the horizontal planes can be done affirmatively by identifying the long 
posterior ciliary arteries that run horizontally at 3 and 9 o’clock [9].
In the past, the enucleated eye was grossed and processed to produce one pupil-
optic nerve (PO) section, which is then studied histopathologically. This practice 
was abandoned following the consensus of the International Retinoblastoma 
Staging Working Group (IRSWG) in 2009 where the efforts of 85 members from 
Figure 1. 
Grossing an enucleated eye with retinoblastoma: (A) vertical corneal measurements; (B) inferior oblique 
muscle insertion located temporal (lateral) to the optic nerve (asterisk); (C, D) pupil-optic nerve (PO) 
section; (E) cassettes containing both calottes cut in bread-loaf pattern (red arrows), while the PO section is 
submitted in a separate cassette.
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24 different countries were joined to establish guidelines for tissue processing and 
handlining as well as staging. They concluded that the entire enucleated globe 
should be examined microscopically. This can be achieved by dividing the eye into 
four blocks. The optic nerve, tumor, and anterior chamber structures are included 
in the central pupil-optic nerve (PO) section composing one block as demonstrated 
in (Figure 1C, D). Two mirrored blocks composed of the calottes, representing the 
remaining eye tissue after harvesting the PO section, are usually cut consecutively 
in a bread-loaf fashion and embedded on edge to increase the examined surface 
area of the choroid, and this will subsequently improve the chances of detection 
of choroidal involvement (Figure 1E). The last block comprises the optic nerve 
margin cross section, and this is usually taken initially before cutting the eye. 
The optic nerve head, lamina cribrosa, and optic nerve posterior to the lamina 
cribrosa in a single section plane are usually displayed in the PO section as shown 
in (Figure 1D) [9].
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counseling and prognosis prediction. To facilitate this, guidelines and protocols 
were proposed to ensure preservation of the harvested ocular tissue for examination 
to obtain the best histopathological and molecular testing results. This guideline 
states that the enucleated globe should be processed and opened soon after surgery 
in order to prevent proteins and nucleic acid denaturation. Then, the optic nerve 
length is measured and documented in mm, and this is followed by preparing the 
block of the optic nerve margin cut section before proceeding with opening the eye. 
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collection of the PO section. Opening the eye can be accomplished using one of two 
techniques. The first proposed technique involves creating a window opening in the 
sclera adjacent to the edge of the bulk of the tumor. This scleral window is ideally 
created using a trephine. The second method is done utilizing a large bore 22-gauge 
needle that is used under sterile conditions to aspirate fresh tumor cells/tissue. The 
needle is inserted obliquely under direct visualization via the sclera into the poste-
rior chamber behind the lens, and aspiration takes place once it is inside the tumor 
mass. Finally, the globe is fixed in an adequate amount of formalin for a minimum 
of 48 hours [10].
Figure 2. 
(A) Gross photo showing the encephaloid appearance of the tumor. (B) White flecks representing the 
calcification.
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Macroscopically, the tumor has an encephaloid appearance, and this is not 
surprising given that it arises from the retina which resembles the neurological 
tissue (Figure 2A). The tumor is typically white in color, and it encompasses lightly 
colored flecks. In fact, these flecks are analogous to the dystrophic calcification 
within the necrotic tissue microscopically (Figure 2A) [10].
3. Histopathology
3.1 Tumor origin
Embryologically, retinoblastoma tumors initiate from the inner layer of the optic 
cup that is derived from the neuroectoderm which is a neurological tissue. At the 
cellular level, the retinoblastoma constituent cells appear as small, roundish blue 
cells. Retinal differentiation in RB is categorized as the following: differentiated, 
undifferentiated, or necrotic. Differentiated tumors are furtherly subdivided into 
(1) “fleurettes” exhibiting advanced photoreceptor differentiation, (2) the classic 
Flexner-Wintersteiner rosettes representing early retinal differentiation, (3) Homer 
Wright rosettes with primitive neuroblastic differentiation, or (4) poorly differenti-
ated [11]. These rosettes in an ascending order of differentiation include Homer 
Wright, Flexner-Wintersteiner rosettes, and fleurettes providing examples of these 
histologic structures (Figure 3) [2, 10, 12–14]. The Flexner-Wintersteiner rosettes 
when examined by high magnification microscopy demonstrate a ring of nuclei sur-
rounding a central clear lumen corresponding to the subretinal space (Figure 3A). In 
comparison, the Homer Wright rosettes surround a central tangle of neural filaments 
with no clear distinct lumen (Figure 3A) [10, 11]. The different types of rosettes and/
or fleurettes (Figure 3B) observed in RB tumors represent varying degrees of differ-
entiation, and these are recognized based on the histologic architectural pattern.
3.2 General histopathology
On microscopic examination, the neuroblastic tumor cells are mitotically active 
with scanty cytoplasm and irregular basophilic nuclei. Apoptosis leading to necrosis 
Figure 3. 
(A) Different types of rosettes noted by low power. High-power slide showing two types of rosettes: Flexner-
Wintersteiner rosettes (arrow) and Homer Wright rosettes (asterisk). (B) Bland-looking pinkish tumor cells 
with fleurettes (arrow) (original magnification ×1000 stained with hematoxylin and eosin).
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is also frequently seen in these tumors. Necrotic areas may develop dystrophic calci-
fication which is the source of the red purple color seen on sections stained with the 
hematoxylin and eosin (H&E) stain (Figure 4) [2, 10, 15]. These calcifications are 
of great clinical value, and they are usually detected by B-scan ultrasonography.
The level of differentiation of these cells varies, and there is a negative correlation 
between advancing age and the level of differentiation (less differentiation in older 
children). Notably, an inverse relationship was detected between retinal differentia-
tion and age, where older infants present with poorer retinal differentiation than 
young infants in whom microscopic examination of their enucleated eyes revealed 
good differentiation with the presence of Flexner-Wintersteiner rosettes [11, 16].
Histopathological examination of removed tumors showed that one-fifth of the 
cases have foci of differentiated photoreceptors. This condition is attributed to a lesser 
degree of apoptosis and cellular turnover in highly differentiated tumors as photorecep-
tor differentiation, which persist regardless of the age, unlike Flexner-Wintersteiner 
rosettes, which were noted to decrease with older age [10, 11]. It was hypothesized that 
retinoblastomas originate from retinomas or retinocytomas, which are benign tumors 
entirely formed of differentiated photoreceptors and what proves this theory is the 
presence of well-differentiated photoreceptor foci at the base of endophytic retinoblas-
tomas. Moreover, Dimaras demonstrated the presence of both RB1 gene mutation in 
these benignly behaving precursor tumors mentioned above [10, 17].
3.3 High-risk histopathological features
Detecting the presence of high-risk features on histopathological examination 
is of utmost significance. This is because of the implications these factors have 
on the risk of systemic metastasis and overall survival. Moreover, the presence of 
these factors dictates the institution of post-enucleation systemic chemotherapy to 
improve survival rates and limit the risk of metastasis [9, 11, 18–22].
Several studies from different parts of the world attempted to identify and 
evaluate these high-risk factors that include the following: retrolaminar optic 
nerve invasion (Figure 5), massive choroidal invasion (Figures 6 and 7), ante-
rior segment tumor invasion, and extraocular/extra-scleral tumor extension 
(Figure 8) [9, 11, 18–20, 23].
Optic nerve invasion is usually classified as prelaminar (anterior the lamina 
cribrosa), laminar (involving the lamina cribrosa but not extending beyond it), 
retrolaminar (extending beyond the lamina cribrosa), and tumor at the surgical cut 
margin (Figure 5A–C). In addition to the length of invasion, the focus of tumor 
Figure 4. 
Low-power histopathological appearance of the tumor demonstrating pseudorosettes. Note the extensive 
necrosis (N) and calcification (arrow) (original magnification ×40 hematoxylin and eosin).
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Figure 6. 
(A) Microscopic photos showing focal choroidal invasion <3 mm, (hematoxylin and eosin ×100). (B) Massive 
choroidal invasion>3 mm, (hematoxylin and eosin ×12.5). Note the postlaminar optic nerve invasion (arrow).
invasion must be determined by measuring the maximum depth of invasion into 
the optic nerve. This is achieved by measuring from the internal limiting membrane 
(ILM) of the optic disc or Bruch’s membrane if ILM was destroyed by the tumor to 
the deepest area of invasion as demonstrated in (Figure 5C) [24, 25]. On the other 
hand, experts defined massive as more than 3 mm foci of choroidal invasion whether 
in thickness or width, whereas focal choroidal invasion was defined as less than 
3 mm foci of choroidal invasion whether in thickness or width (Figures 6 and 7). 
Another helpful anatomical definition is whether the tumor cells are reaching the 
inner scleral layers in massive invasion or not reaching the sclera in focal invasion [9, 
11, 18, 19, 26]. It is important not to misinterpret artificial tumor seeding of the cho-
roid or other ocular structures as invasion. This will prevent over-reporting of high-
risk features (such as choroidal invasion) and will consequently avoid additional 
Figure 5. 
Histopathological photos of several retinoblastoma tumors showing various degrees of optic nerve invasion: 
(A) prelaminar, (B) intralaminar, and (C) postlaminar, measuring the depth from Bruch’s membrane 
(hematoxylin and eosin ×40).
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unnecessary treatments in these vulnerable children. Artificial seeding classically 
consists of tumor cells clustered in small groups along with many necrotic cells in 
natural or potential ocular spaces (e.g., suprachoroidal space, anterior chamber, or 
subarachnoid space of the optic nerve), sectioning artifacts created during tissue 
preparation and/or ocular surfaces (e.g., episclera, optic nerve meningeal sheath). 
On the other hand, truly existent invasion consists of solid nests of infiltrative tumor 
cells that anatomically destroy and substitute the area of invasion; however, necrosis 
is rarely seen except if the tumor is massive [9, 10].
In the literature, there are several key studies that looked at these high-risk 
factors. A large study conducted by Eagle et al. from the USA looked at the over-
all occurrence of high-risk features in children with unilateral retinoblastoma 
(n = 387), whether treated preoperatively or not, and found an incidence of 
20.4%. Further evaluation of the untreated group (n = 297) revealed that high-risk 
features were present in 18.5% of the enucleated eyes. Among these, retrolaminar 
optic nerve invasion was the commonest feature occurring in 10.4% followed by 
massive choroidal invasion in 8.1%, and lastly a combination of both features was 
observed in 3.4% [11]. In fact, these percentages were similar to those (11.6 and 
9.3% for retrolaminar optic nerve invasion and massive uveal invasion, respec-
tively) reported previously by large specialized American treatment centers [11, 
27]. The incidence of high-risk features is to the lower side in developed countries 
(e.g., 20% in the USA); yet, higher rates were observed in developing countries 
Figure 7. 
(A) Massive choroidal invasion noted grossly (G). (B) Corresponding histopathology massive choroidal 
invasion (H). Note the postlaminar optic nerve invasion (arrow) (hematoxylin and eosin, scanned slide).
Figure 8. 
Extraocular extension identified during surgery (A), grossing (B), and by microscopy (C). Note tumor cells on 
the outer surface of the sclera (EOE, hematoxylin and eosin ×40).
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subarachnoid space of the optic nerve), sectioning artifacts created during tissue 
preparation and/or ocular surfaces (e.g., episclera, optic nerve meningeal sheath). 
On the other hand, truly existent invasion consists of solid nests of infiltrative tumor 
cells that anatomically destroy and substitute the area of invasion; however, necrosis 
is rarely seen except if the tumor is massive [9, 10].
In the literature, there are several key studies that looked at these high-risk 
factors. A large study conducted by Eagle et al. from the USA looked at the over-
all occurrence of high-risk features in children with unilateral retinoblastoma 
(n = 387), whether treated preoperatively or not, and found an incidence of 
20.4%. Further evaluation of the untreated group (n = 297) revealed that high-risk 
features were present in 18.5% of the enucleated eyes. Among these, retrolaminar 
optic nerve invasion was the commonest feature occurring in 10.4% followed by 
massive choroidal invasion in 8.1%, and lastly a combination of both features was 
observed in 3.4% [11]. In fact, these percentages were similar to those (11.6 and 
9.3% for retrolaminar optic nerve invasion and massive uveal invasion, respec-
tively) reported previously by large specialized American treatment centers [11, 
27]. The incidence of high-risk features is to the lower side in developed countries 
(e.g., 20% in the USA); yet, higher rates were observed in developing countries 
Figure 7. 
(A) Massive choroidal invasion noted grossly (G). (B) Corresponding histopathology massive choroidal 
invasion (H). Note the postlaminar optic nerve invasion (arrow) (hematoxylin and eosin, scanned slide).
Figure 8. 
Extraocular extension identified during surgery (A), grossing (B), and by microscopy (C). Note tumor cells on 
the outer surface of the sclera (EOE, hematoxylin and eosin ×40).
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ranging between 29 and 48% [28, 29]. Gupta studied retrospectively 142 cases of 
retinoblastoma eye enucleated over a 5-year period and found that the high-risk 
histopathologic features were present in 54.2% of these eyes. Choroidal invasion 
was the most frequent where it was detected in 40% followed by retrolaminar optic 
nerve invasion 17% and less commonly other ocular structures such as the iris and 
sclera. This study further linked the identified high-risk features to the clinical 
presentation and reported a positive correlation between age > 24 months and 
choroidal invasion, whereas iris neovascularization correlated with both retrola-
minar optic nerve invasion and choroidal invasion [11, 18]. Furthermore, Kaliki 
evaluated patients with an International Classification of Retinoblastoma (ICRB) 
classes D and E for high-risk features and reported their presence in 17% of class 
D eyes (15/87) and 24% of class E eyes (102/432). The fact that high-risk features 
were more likely to be present in advanced disease is evidently supported by the 
fact that 10% of patients demonstrating high-risk features on histopathology in the 
previous study developed metastasis which was fatal in two children. To compare, 
none of the children in group D with high-risk features developed metastasis nor 
died [19].
Overall, choroidal and optic nerve invasion reported incidences in the litera-
ture are variable and were noticed to be higher in previous publication than more 
recent ones [23, 28, 30–34]. To add, a trend of higher occurrence was observed 
in developing countries and specific geographic locations such as Asia and India, 
and this is explained by the later presentation and unique biological behavior 
of tumors in these areas. This variability in incidence was looked at by Eagle 
where he attributed it to multiple factors including diagnosis to enucleation time, 
reporting institute location and ununified assessing techniques of enucleating 
specimens [11].
The survival rates in the presence of these high-risk features are usually 
decreased. In general, patients with massive choroidal invasion had a 70% survival 
rate, while patients with tumor extending up to the optic nerve cut margin had an 
obviously lower survival rate of approximately 35%. On the contrary, those with 
prelaminar optic nerve invasion had excellent survival rates reaching more than 
90% [2, 24, 35].
3.4 Other histopathological features
3.4.1 Necrosis
Another characteristic feature seen in RB cases is tumor or ocular tissue necrosis. 
This condition occurs secondary to mitotically active tumor cells that grow 90–110 
micron from the tumor-feeding vessels resulting in ischemia and necrosis. Papillary 
appearance may be seen in necrotic tissue termed as pseudorosettes (wrong nomen-
clature) consisting of basophilic viable tissue resembling sleeves and cuffs measur-
ing 100um from the central blood vessels separated by eosinophilic necrotic sheets 
(Figure 9) [10, 15, 20].
Chong studied the association between extensive tumor and ocular tissue necro-
sis in RB enucleated eyes with high-risk histopathological features. Extensive tissue 
necrosis was defined as more than 95% of ocular tissue or tumor to be necrotic 
in enucleated samples. The total number of eyes showing extensive necrosis is 11 
(25.6%) out of 43 enucleated eyes. Histopathological high-risk features were more 
prevalent and statistically significant in enucleated eyes with extensive necrosis. 
On review of histopathological slides, 11 (100%) had optic nerve invasion with 8 
(72.2%) showing retrolaminar invasion and 9 (81.8%) with choroidal invasion. This 
study concluded that the presence of extensive necrosis of tumor or ocular tissue in 
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RB should alert the ocular pathologist to extensively review the slides for high-risk 
histopathological features to improve the survival rate and lower the risk of metas-
tasis [20].
3.4.2 Growth pattern
RB originates and destroys the neurosensory retina. The tumor is subdivided 
into two types based on the growth pattern. Endophytic tumors, which are 
known to be the most common type, arise from the inner layers of the retina 
which maintains its attachment and normally invades into the vitreous chamber 
(Figure 10C, D) [10]. They are clinically visible by ophthalmoscopy as white 
mass lesions surrounded by fine feeding vessels, which may be mistaken for an 
astrocytic hamartoma [36]. These tumors may also occasionally seed the anterior 
chamber. On the other hand, exophytic tumors arise from the outer retinal layers 
in between the sensory retina and the retinal pigment epithelium and grow 
outward typically causing high bullous retinal detachments which may progress 
to total retinal detachment (Figure 10A, B) [10, 36]. They are usually invisible 
by ophthalmoscopy but may initially be identified with difficulty as small gray 
masses [36]. They may also cause anterior displacement of the lens-iris diaphragm 
and secondary angle closure [10]. When presenting with a total retinal detach-
ment, exophytic tumors may be mistaken as Coats disease, persistent hyperplastic 
primary vitreous, retinopathy of prematurity, or retinal dysplasia [36]. The 
two previously mentioned growth patterns may overlap manifesting as a mixed 
endophytic-exophytic retinoblastoma [10]. Rarely, a diffuse infiltrating RB may 
be found which grows diffusely within the retina without forming a discrete mass. 
These usually present with signs suggestive of inflammation and are misdiagnosed 
as uveitis [36].
In 1990, Palazzi classified 297 cases of RB into two types of growth pattern. 
Their study showed that 61% of the cases were endophytic, while 39% of the cases 
were exophytic [37]. Similarly, in a more recent study published in 2014, Nawaiseh 
reported 42 cases of RB where 45% of cases were endophytic, 33% were exophytic, 
and 21% were mixed endophytic-exophytic. The study did not report any cases of 
the diffuse infiltrating type [36]. However, Taktikos reported the diffuse infiltrat-
ing type in 1% of the cases in his published article in 1966 [38].
The growth patterns have different impacts on the pathological features of 
the tumor in the eyes with retinoblastoma and no treatment prior to enucleation. 
Endophytic tumors, which have a direct contact with the vitreous, are more likely 
Figure 9. 
Pseudorosettes with viable blue cell tumor survived for about 100 um from the central blood vessels, surrounded 
by pink necrotic tissue.
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RB should alert the ocular pathologist to extensively review the slides for high-risk 
histopathological features to improve the survival rate and lower the risk of metas-
tasis [20].
3.4.2 Growth pattern
RB originates and destroys the neurosensory retina. The tumor is subdivided 
into two types based on the growth pattern. Endophytic tumors, which are 
known to be the most common type, arise from the inner layers of the retina 
which maintains its attachment and normally invades into the vitreous chamber 
(Figure 10C, D) [10]. They are clinically visible by ophthalmoscopy as white 
mass lesions surrounded by fine feeding vessels, which may be mistaken for an 
astrocytic hamartoma [36]. These tumors may also occasionally seed the anterior 
chamber. On the other hand, exophytic tumors arise from the outer retinal layers 
in between the sensory retina and the retinal pigment epithelium and grow 
outward typically causing high bullous retinal detachments which may progress 
to total retinal detachment (Figure 10A, B) [10, 36]. They are usually invisible 
by ophthalmoscopy but may initially be identified with difficulty as small gray 
masses [36]. They may also cause anterior displacement of the lens-iris diaphragm 
and secondary angle closure [10]. When presenting with a total retinal detach-
ment, exophytic tumors may be mistaken as Coats disease, persistent hyperplastic 
primary vitreous, retinopathy of prematurity, or retinal dysplasia [36]. The 
two previously mentioned growth patterns may overlap manifesting as a mixed 
endophytic-exophytic retinoblastoma [10]. Rarely, a diffuse infiltrating RB may 
be found which grows diffusely within the retina without forming a discrete mass. 
These usually present with signs suggestive of inflammation and are misdiagnosed 
as uveitis [36].
In 1990, Palazzi classified 297 cases of RB into two types of growth pattern. 
Their study showed that 61% of the cases were endophytic, while 39% of the cases 
were exophytic [37]. Similarly, in a more recent study published in 2014, Nawaiseh 
reported 42 cases of RB where 45% of cases were endophytic, 33% were exophytic, 
and 21% were mixed endophytic-exophytic. The study did not report any cases of 
the diffuse infiltrating type [36]. However, Taktikos reported the diffuse infiltrat-
ing type in 1% of the cases in his published article in 1966 [38].
The growth patterns have different impacts on the pathological features of 
the tumor in the eyes with retinoblastoma and no treatment prior to enucleation. 
Endophytic tumors, which have a direct contact with the vitreous, are more likely 
Figure 9. 
Pseudorosettes with viable blue cell tumor survived for about 100 um from the central blood vessels, surrounded 
by pink necrotic tissue.
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to be associated with vitreous seeds than exophytic tumors. On the other hand, 
exophytic tumors characteristically grow toward the choroid with a higher risk of 
choroidal invasion than endophytic tumors. This theory was supported by Palazzi’s 
findings where 71% of tumors with choroidal invasion had an exophytic growth 
pattern [37]. Nawaiseh also found that all cases with massive choroidal invasion 
occurred with tumors of exophytic growth patterns [36].
3.5  Correlation between clinical classifications and the high-risk pathological 
features
Wilson and Kaliki found that group Vb eyes according to the Reese-Ellsworth 
(RE) classification (eyes with vitreous seeds) have higher incidence of high-risk 
features than group Va (eyes without vitreous seeds) [19, 39, 40]. The risk of optic 
nerve invasion (laminar or postlaminar) was found to be 58% in that group, while 
the risk of massive choroid invasion was as low as 29% [39]. Nawaiseh correlated 
the above conclusions by Wilson to his own findings and anticipated that endo-
phytic tumors are more likely to be associated with optic nerve invasion rather than 
choroidal invasion based on the fact that vitreous seeding was more likely to be 
associated with an endophytic growth pattern [36].
A mixed tumor growth pattern indicated a more advanced tumor stage and a 
more damaging tumor. Nawaiseh found that the mixed tumor growth pattern was 
more likely to be associated with neovascular glaucoma and with more advanced 
IIRC groups (67% were associated with IIRC group E, the most advanced stage of 
Figure 10. 
(A) Gross photo of an exophytic growth pattern (posterior to the retina). (B) Low magnification sample 
demonstrating exophytic growth pattern (hematoxylin and eosin). (C) Gross photo of an endophytic growth 
pattern (anterior to the retina) with subretinal fluid. (D) Low magnification sample demonstrating 
endophytic growth pattern with subretinal fluid (hematoxylin and eosin).
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intraocular RB) [36]. On the other hand, Palazzi found that neovascular glaucoma 
was more likely to be associated with the exophytic tumor which may be due to the 
long-standing retinal detachment leading to ischemia. However, in that study, only 
the exophytic and endophytic growth patterns were studied without the mixed 
growth pattern [37].
3.6 Histopathology of retinoblastoma in enucleated globes following treatment
The well-differentiated part of the RB is relatively radioresistant and chemore-
sistant; therefore, photoreceptor differentiation is more common in the enucleated 
eyes after radiotherapy or chemotherapy [11].
The histopathological examination of the enucleated eyes with RB after che-
moreduction therapy may show Type 1, cottage cheese; Type 2, fish flesh; Type 
3, combination of types 1 and 2; and Type 4, complete regression or presumably 
viable histologically intact tumor cells [3, 41, 42]. Type 2 regression pattern may 
have the same histological features as a retinocytoma and result in a retinocytoma-
like clinical appearance, which may be because well-differentiated tumors are 
relatively resistant to chemotherapy and therefore the cells are not cycling [42]. 
Similar regression patterns are also seen in tumors treated by intra-arterial chemo-
therapy (IAC) [43].
4. American Joint Committee on Cancer (AJCC) classification
The American Joint Committee on Cancer and the International Union Against 
Cancer (AJCC/UICC) created a TNM staging scheme system for RB [26, 44–46]. It 
has multiple updated editions where the 8th edition is the latest updated one [45]. It 
is considered one of the extraocular classification systems besides the International 
Retinoblastoma Staging System (IRSS) [47]. Unlike other staging systems, TNM 
and IRSS were developed by multiple specialists and medical centers worldwide 
[48, 49]. The TNM8 system is subclassified into clinical, pathological, and heredi-
tary classifications which stand for cTNM, pTNM, and H, respectively [45]. 
Furthermore, pathological staging necessitates enucleation of the eye to classify 
primary tumor plus examining local extension or distant metastasis by biopsies or 
total resection if present. The pTNM categories are divided to pT, the histological 
staging of the primary tumor after biopsy or enucleation, pN stands for microscopic 
examination of lymph node biopsy, and clinical plus microscopic examination 
of distant metastatic lesions implies as M [45, 49]. However, on initial evaluation 
application of clinical or cTNM, subclassification is wildly used by ophthalmologist 
which subclassify the tumor burden to intraretinal, intraocular, advanced intraocu-
lar, or extraocular [47]. The clinical “cTNM” and hereditary “H” classification are 
beyond the scope of this chapter. Further details of pTNM classification and staging 
are demonstrated in Table 1 [45].
The updated pathological TNM8 version emphasized the importance to define 
focal, massive choroidal invasion and scleral invasion in compression to previ-
ously published TNM7 and TNM6 staging system in 2009 and 2002, respectively 
[45, 46, 49]. Furthermore, newly updated TNM8 staging system officially released 
formal staging group for prognosis. It is subdivided into four stages assigned for 
both clinical and pathological classifications as seen in Table 1 [45]. Guillermo 
reported poor disease-free survival in patients staged by the pTNM7 staging sys-
tem due to omission of scleral invasion. The major event of disease-free survival 
was extraocular relapse [49].
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eyes after radiotherapy or chemotherapy [11].
The histopathological examination of the enucleated eyes with RB after che-
moreduction therapy may show Type 1, cottage cheese; Type 2, fish flesh; Type 
3, combination of types 1 and 2; and Type 4, complete regression or presumably 
viable histologically intact tumor cells [3, 41, 42]. Type 2 regression pattern may 
have the same histological features as a retinocytoma and result in a retinocytoma-
like clinical appearance, which may be because well-differentiated tumors are 
relatively resistant to chemotherapy and therefore the cells are not cycling [42]. 
Similar regression patterns are also seen in tumors treated by intra-arterial chemo-
therapy (IAC) [43].
4. American Joint Committee on Cancer (AJCC) classification
The American Joint Committee on Cancer and the International Union Against 
Cancer (AJCC/UICC) created a TNM staging scheme system for RB [26, 44–46]. It 
has multiple updated editions where the 8th edition is the latest updated one [45]. It 
is considered one of the extraocular classification systems besides the International 
Retinoblastoma Staging System (IRSS) [47]. Unlike other staging systems, TNM 
and IRSS were developed by multiple specialists and medical centers worldwide 
[48, 49]. The TNM8 system is subclassified into clinical, pathological, and heredi-
tary classifications which stand for cTNM, pTNM, and H, respectively [45]. 
Furthermore, pathological staging necessitates enucleation of the eye to classify 
primary tumor plus examining local extension or distant metastasis by biopsies or 
total resection if present. The pTNM categories are divided to pT, the histological 
staging of the primary tumor after biopsy or enucleation, pN stands for microscopic 
examination of lymph node biopsy, and clinical plus microscopic examination 
of distant metastatic lesions implies as M [45, 49]. However, on initial evaluation 
application of clinical or cTNM, subclassification is wildly used by ophthalmologist 
which subclassify the tumor burden to intraretinal, intraocular, advanced intraocu-
lar, or extraocular [47]. The clinical “cTNM” and hereditary “H” classification are 
beyond the scope of this chapter. Further details of pTNM classification and staging 
are demonstrated in Table 1 [45].
The updated pathological TNM8 version emphasized the importance to define 
focal, massive choroidal invasion and scleral invasion in compression to previ-
ously published TNM7 and TNM6 staging system in 2009 and 2002, respectively 
[45, 46, 49]. Furthermore, newly updated TNM8 staging system officially released 
formal staging group for prognosis. It is subdivided into four stages assigned for 
both clinical and pathological classifications as seen in Table 1 [45]. Guillermo 
reported poor disease-free survival in patients staged by the pTNM7 staging sys-
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Retinoblastoma is a subclassification composed of three aspects: pT, pN, and M. Pathological definition of 
primary tumor (pT): stands for histopathological staging of the primary tumor after biopsy or enucleation. 
Pathological definition of lymph node (pN): stands for microscopic examination of lymph node biopsy. Definition 
of distant metastasis (M): stands for grading distant metastatic lesions including both clinical and pathological 
definitions.
The abovementioned aspects of pTNM are categorized to 4 stages demonstrated in the last part of Table 1.
Table 1. 
Pathological TNM classification and staging by the AJCC/UICC for retinoblastoma.
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static rate and improves the survival rate. The high-risk features include retrolaminar 
optic nerve invasion, choroidal invasion, anterior chamber involvement, extraocular 
or extra-scleral spread. Moreover, incidences of previously mentioned high-risk fea-
tures were studied in various articles. TNM staging created by AJCC/UICC provided 
pathological staging scheme for retinoblastoma. The recently released 8th edition 
in 2017 embedded choroidal and scleral invasion definition in tumor pathological 
staging section. In addition, formal prognostic stages were added.
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Abstract
Advances in retinoblastoma treatment in children nowadays and in the last
decades lead to success and adulthood life without problems. Treatment modalities
used in childhood to cure the retinoblastoma can affect health later. Some secondary
malignancies in patients with retinoblastoma may be long-term side effects of
radiation and chemotherapy. However, rates of second cancers in people treated for
hereditary retinoblastoma are higher than in people who had sporadic retinoblas-
toma. The survivors of retinoblastoma in whom second malignant neoplasms
develop are at a higher risk for the development of additional tumors than they
were for the development of a second tumor. The standardized incidence rate of
secondary malignancies is about 15% in inherited cases and about 1.5% in
nonheritable retinoblastoma. However, today there is no clear consensus on what, if
any, screening protocol would be most appropriate and effective.
Keywords: retinoblastoma, secondary malignancies, secondary tumors after
radiotherapy, chemotherapy
1. Retinoblastoma and secondary malignancies
With major advances in retinoblastoma treatment in recent decades, most chil-
dren treated for retinoblastoma are now expected to have a normal life [1]. Some of
the treatment modalities used in childhood to cure the retinoblastoma can affect a
child’s health later in life, so watching for health effects as they get older has become
more of a concern in recent years [2]. The prognosis for survival is excellent. The
current therapy includes an improved survival rate and decreased iatrogenic side
effects [2–4].
The most common primary intraocular malignant tumor in children is retino-
blastoma. Hereditary retinoblastoma with gene Rb1 has bilateral tumor infiltration
most frequently. Also children with positive family history are presumed to have a
germline Rb1 mutation [3]. Screening of mutations in the Rb1 gene can help to
identify heritable retinoblastoma and contribute to clinical management and
genetic counseling for affected families [5]. The main criteria in determining the
result of a mutation is its location in the 3D structure. The altered 3D model
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1. Retinoblastoma and secondary malignancies
With major advances in retinoblastoma treatment in recent decades, most chil-
dren treated for retinoblastoma are now expected to have a normal life [1]. Some of
the treatment modalities used in childhood to cure the retinoblastoma can affect a
child’s health later in life, so watching for health effects as they get older has become
more of a concern in recent years [2]. The prognosis for survival is excellent. The
current therapy includes an improved survival rate and decreased iatrogenic side
effects [2–4].
The most common primary intraocular malignant tumor in children is retino-
blastoma. Hereditary retinoblastoma with gene Rb1 has bilateral tumor infiltration
most frequently. Also children with positive family history are presumed to have a
germline Rb1 mutation [3]. Screening of mutations in the Rb1 gene can help to
identify heritable retinoblastoma and contribute to clinical management and
genetic counseling for affected families [5]. The main criteria in determining the
result of a mutation is its location in the 3D structure. The altered 3D model
structures of the Rb1 novel mutant proteins are also available today [6, 7].
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Improvements in survival, from a 3-year survival rate of 76% in the 1970s to a
5-year survival rate of 97% since the mid-1990s, are due to advances in treatment
[2, 8, 9]. But children who survive and have hereditary retinoblastoma have an
increased risk for secondary malignant neoplasms (SMN). The most common sub-
sequent malignancies are in bony tissues like sarcomas. Also secondary melanoma
can develop most frequently [10, 11]. The authors of several studies in retinoblas-
toma survivors have reported an increased risk of SMN associated with previous
treatment, particularly in radiotherapy (RT) which showed an increased risk when
it was indicated in children under the age of 1 year [12–14]. In retinoblastoma
survivors increased incidence of common epithelial cancers (especially in the lungs
and breast) has been observed [15–18].
Young people treated in childhood for retinoblastoma are at risk, to some
degree, for several possible late effects of their cancer treatment. The risk of late
effects depends on a number of factors, such as the specific treatments used, the
doses of treatment, the type of retinoblastoma (heritable or nonheritable), and the
age of the patient when the therapy was used. The late effects of the retinoblastoma
treatment are:
• Enucleation of the eye globe leads to loss of vision and cosmetic defects.
• Radiotherapy, especially external radiotherapy, of the affected eye leads to
visual acuity loss or reduction and can lead also to deformities of the bony
orbit.
• Kidney function reduction.
• Chemotherapy leads to heart problems.
• In children with retinoblastoma, generally, slowed growth and development
are observed.
• In children with retinoblastoma generally changes in sexual development and
ability to have children are observed.
• In survivors of retinoblastoma in adult age, an increased risk of SMN,
especially in children with hereditary retinoblastoma, is present.
2. Secondary cancers after retinoblastoma treatment
Although the risk for a second retinoblastoma decreases significantly after 5 years
of age, follow-up on all children after treatment is critical and particularly for those
who carry the Rb1 mutation. Retinoblastoma survivors are at increased risk for local
secondary complications after treatment, e.g., retinal detachment and cataracts, in
later life because of the retinal changes caused by the cancer and therapy modalities.
Although the general risk for secondary cancers associated with intravenous chemo-
therapies is high, it’s thought to be lower than the risk from radiation therapy.
2.1 Hereditary retinoblastoma (heritable)
Children with the heritable form of retinoblastoma have a much higher risk of
developing other types of cancer throughout their lives. The most common second-
ary cancers among hereditary retinoblastoma survivors include:
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• Cancers in the head region, mouth, or nose
The risk for these cancers is even higher in any parts of the body that got
radiation during treatment for retinoblastoma in childhood. This is because each cell
in the body has an abnormal Rb1 tumor suppressor gene, which, if it were normal,
would help stop some of these cancers from forming. Most of these cancers are very
treatable if detected early, which is why it’s very important that these children
(young people) are followed closely throughout their lives. Retinoblastoma survi-
vors in adult age have the increased risk of SMN, and it is necessary to teach them
and their relatives and speak with them about other factors that might increase their
risk of secondary malignancies in adult age. Increased risk of skin melanoma may be
due to higher sun exposure, and smoking can increase lung cancer risk. These young
survivors have to avoid the risk factors. It is necessary to inform the relatives also
about screening tests in adulthood of retinoblastoma survivors.
Children who got the heritable form of retinoblastoma also have a small risk of
developing a tumor in the pineal gland within a few years. Magnetic resonance
imaging (MRI) scans of the head in retinoblastoma survivors should be done regu-
larly for several years after retinoblastoma treatment in childhood with the aim of
detecting secondary tumors as soon as possible.
2.2 Sporadic retinoblastoma (nonheritable)
Patients with the nonheritable form of retinoblastoma who do not have the Rb1
gene change in all of their cells do not have such a high risk of secondary malignan-
cies. Still, the risk of some types of secondary malignancies might be higher as a
long-term effect of chemotherapy or external radiation therapy.
2.3 Follow-up
The whole long-life follow-up is necessary to retinoblastoma survivors. Long-
term follow-up guidelines for survivors of childhood cancers and also retinoblas-
toma were invented by the Children’s Oncology Group (COG). These guidelines are
helpful for relatives but also doctors to send the patient regularly for screening tests,
and they help to realize how late effects of, e.g., radiotherapy, can be treated [3].
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In child’s healthcare team, it is very important to discuss possible long-term
complications after treatment and to inform also parents and relatives, if these
problems appear, how to treat them. The guidelines of COG are available for
healthcare professionals, but also patients’ version is available (as “Health Links”)
on the webpage as well.
2.4 Emotional and social issues
Even though most children with retinoblastoma are very young at the time of
diagnosis, under the age of 4, they may have emotional or psychological problems
that need to be addressed during the treatment and also after the treatment.
Depending on the age of retinoblastoma, these children have some problems at
school work due to visual acuity loss or reduction.
The factors can lead to problems in their life and they need help. Doctors,
ophthalmologists, oncologists, and other members of the healthcare team like psy-
chologists can recommend special support programs and services to help children
during and after treatment and to avoid misdiagnosed secondary malignancies in
adulthood. Parents and relatives can also be affected with the situation of primary
retinoblastoma treatment and also secondary tumors which appear later. The family
situation is worsened; financial stress and traveling to and staying near the cancer
center are complicated for the family. Social programs and psychologists can help
families deal with these problems. Oncology centers for patients with retinoblas-
toma may have programs to introduce new patients and their relatives to patients
who have finished retinoblastoma therapy.
Loss of visual acuity is serious but enucleation leads to defect in the face. In
patients with these problems, social groups and programs for the visually impaired
can help. Most children treated for retinoblastoma can have good visual acuity in
the unaffected eye, but it can happen that the surrounding tissues around the
treated eye and the area of the orbit might have changes and later can lead to
secondary malignancies. Such changes can be treated by reconstructive surgery.
Early intervention can help to avoid psychological problems and also avoid second-
ary tumors in soft tissues in the orbit [3].
3. Secondary malignancies
In patients with retinoblastoma, secondary malignancies can be the result of the
long-term side effect of radiation and chemotherapy. The incidence of secondary
malignancies in children treated for hereditary retinoblastoma is higher than in
children with sporadic retinoblastoma. In the study of MacCarthy et al. in 1927,
retinoblastoma patients are diagnosed in Britain from 1951 to 2004; standardized
incidence rate of secondary malignancies was reported: it was significantly higher in
inherited retinoblastoma children—13.7% cases compared to 1.5% in nonheritable
cases [19].
Osteosarcoma as the most frequent secondary malignancy following retinoblas-
toma treatment can be associated with the Rb1 gene and/or induced by radiother-
apy. Studies have consistently demonstrated increased risks for bone cancers and
soft tissue sarcomas among retinoblastoma survivors who received radiotherapy,
but by investigations of chemotherapy, subsequent malignant neoplasm develop-
ment has been limited. Previous reports among hereditary retinoblastoma survivors
in studies have suggested that increased risks of bone cancers and soft tissue sarco-
mas are associated with chemotherapy [20, 21], but in the study of Wong et al., they
were results of first comprehensive analysis of chemotherapy-related SMN risk [22].
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In a study of 46 survivors of retinoblastoma who received triethylenemelamine and
radiotherapy, 7 secondary malignancies were reported. This malignancies were
sarcomas of the bones (femur and orbit), as well as other cancers of the brain,
parotid gland, pineal gland, and cervix [23]. In other studies in 18 retinoblastoma
survivors who developed a subsequent osteosarcoma, 7 and 6 survivors had
received triethylenemelamine or cyclophosphamide, respectively [24].
In retinoblastoma survivors after receiving cyclophosphamide, secondary
malignancy as osteosarcoma was frequently reported in other studies [25–27]. In a
study of 25 survivors who received RT and developed subsequent soft tissue or bone
sarcomas, they received cyclophosphamide, either alone or in combination with
other agents [11]. Individual cases of bone cancers have also been reported in
patients who received triethylenemelamine [28]. One study reported few secondary
malignancies after retinoblastoma treatment with carbocisplatin, vincristine, and
etoposide, but the mean follow-up time for hereditary survivors was only up to
7 years [29]. Additional follow-up in the future is needed to capture the typical age
groups and intervals after retinoblastoma therapy for adults for SMN development.
In a study of 15 retinoblastoma survivors with secondary acute myelogenous leuke-
mia, 12 of them had been treated with adjuvant chemotherapy, including topo-
isomerase II inhibitors, epipodophyllotoxins, and alkylating agents [30].
Studies of chemotherapy treatment for retinoblastoma and related SMN risks
among retinoblastoma survivors are limited. But some results of previous studies
reported CT-related risks of bone cancers among childhood cancer survivors. A
case-control study of the UK National Registry of Childhood Tumors reported a
nonsignificant 2.1-fold increased risk for bone cancers in the chemotherapy plus RT
group relative to the group receiving RT only [26]. Childhood cancer survivors who
had an alkylator score ≥ 3 and had received irradiation ≥1000 rad had a 1.6-fold
increased risk for bone cancers as it was reported in another case-control analysis
[31]. In both abovementioned studies, a supra-additive effect was observed when
comparing the chemotherapy plus RT relative risk with the independent risks for
RT and chemotherapy. There was a greater risk when survivors were treated with
both as opposed to RT or chemotherapy alone [26, 27, 31]. The result in study of
Wong et al. was limited to the small number of retinoblastoma survivors who were
treated with chemotherapy but no RT, and there are no reported SMNs in this
treatment group. But they were unable to estimate SMN risks associated with CT
alone [22]. These studies also demonstrate a positive dose-response relationship for
the alkylator score with bone sarcoma risk among childhood cancer survivors
treated with chemotherapy only.
In studies among retinoblastoma survivors who received chemotherapy and RT,
risk is increased for soft tissue sarcomas, especially leiomyosarcomas. A case-
control analysis of a UK-based cohort of childhood cancer survivors reported a
positive dose-response relationship for soft tissue sarcoma among survivors treated
with alkylating agents [32]. Previous studies among retinoblastoma survivors have
reported higher SMN risk with RT administered before the age of 1 year [12, 14, 33].
Although the alkylating agent-related risk estimate for leiomyosarcomas was higher
for receipt of alkylating agents at age < 1 than for age ≥ 1 year, this difference was
not statistically significant, and thus, it remains unclear whether treatment-related
risks differ by age. Further research is needed to understand whether younger
individuals may be more susceptible to alkylating agent-related SMNs. Other stud-
ies also noted a particularly elevated risk for leiomyosarcomas compared with other
soft tissue sarcomas after retinoblastoma treatment, but those studies lacked data
on retinoblastoma treatments [7, 15, 30, 31]. Loss of heterozygosity in Rb1 and in
other major tumor suppressor genes, as well as deletions of chromosome 13, that
contain the Rb1 gene has been reported in individuals who developed uterine
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In child’s healthcare team, it is very important to discuss possible long-term
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toma treatment can be associated with the Rb1 gene and/or induced by radiother-
apy. Studies have consistently demonstrated increased risks for bone cancers and
soft tissue sarcomas among retinoblastoma survivors who received radiotherapy,
but by investigations of chemotherapy, subsequent malignant neoplasm develop-
ment has been limited. Previous reports among hereditary retinoblastoma survivors
in studies have suggested that increased risks of bone cancers and soft tissue sarco-
mas are associated with chemotherapy [20, 21], but in the study of Wong et al., they
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In a study of 46 survivors of retinoblastoma who received triethylenemelamine and
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leiomyosarcomas. Future genetic studies in this population could elucidate the
predisposition for leiomyosarcomas in patients with retinoblastoma [35, 36].
Children with the heritable form of retinoblastoma also have a very small risk to
develop within a few years a tumor in the pineal gland; it is referred as a trilateral
retinoblastoma. Tumors can start there, while the pineal gland can have cells similar
to retina cells. That is why it is important to perform MRI of the head for several
years after treatment of retinoblastoma to detect these tumors as early as possible.
Trilateral retinoblastoma has been the principal cause of death from retinoblastoma
in the United States during the first decade of life [37]. Yamanaka, Hayno, and
Takashima analyzed 211 cases of trilateral retinoblastomas. The average latency
period between the onset of retinoblastomas and trilateral retinoblastomas was
1.5  1.8 years. Pineal tumors were found in almost 74% and sellar tumors in 22%.
The overall median survival was 10.3 months, and the 5-year survival rate was 16%,
while in patients receiving high-dose chemotherapy by stem cell transplantation,
the survival time was significantly longer than with conventional chemotherapy.
The authors conclude that trilateral retinoblastoma patients with an irradiation
history had shorter survival than those without irradiation history for retinoblas-
toma, and high-dose chemotherapy should be considered as a potential treatment
option for trilateral retinoblastomas [38].
Among patients with hereditary disease, treatment with radiotherapy in 95%
was associated with a further increase in the risk of a subsequent cancer. After
30 years of follow-up, elevated risks of epithelial cancers (lung, bladder, and breast)
were observed among survivors of hereditary retinoblastoma [18]. In the study of
Wong et al., it was found that the incidence of secondary cancer after retinoblas-
toma treatment is higher due to the genetic predisposition. Genetic predisposition
has a substantial impact on risk of subsequent cancers in retinoblastoma survivors,
and radiation treatment increases it. A radiation dose-response relationship is dem-
onstrated in all types of soft tissue sarcomas. Retinoblastoma patients should be
examined for new cancers and followed into later life also in whole adulthood due to
extraordinary secondary cancer risk [39].
The development of lung cancer is affected to a considerable extent by somatic
mutations in the Rb1 gene in patients with an elevated risk for lung cancer. Higher
risk of developing lung cancer is in patients undergoing chemotherapy and radio-
therapy in retinoblastoma treatment [40, 41]. Some studies suggested there might
also be an increased risk for lung cancer in non-irradiated patients [15].
Bladder tumors are distinguished between malignant and nonmalignant. In this
case, there is only a small difference between them that is difficult to determine
microscopically. The most common bladder cancer is papilloma and papillomavirus,
which together account for about 90% of all tumors. The borderline between
malignant and nonmalignant bladder tumors is very thin [42]. Study of Marees
et al. significantly elevated risk of bladder cancer among hereditary retinoblastoma
patients after prolonged follow-up, whose prevalence is mostly 30 years after reti-
noblastoma treatment [18]. Alterations in an Rb1 pathway have been established as
a major contributor to bladder tumorigenesis, and carriers of an Rb1 mutation have
an elevated risk of bladder cancer, when they reach the ages at which these malig-
nancies occur in the population at large [43].
All available studies on the occurrence of secondarymalignity after retinoblastoma
treatment indicate that the most important risk factor remains the Rb1 genemutation.
Kleinerman describes in his study the risks of new cancers after radiotherapy in
long-term survivors of retinoblastoma. Radiation increases the risk of another can-
cer in hereditary patients by 3.1-fold. Hereditary patients continue to have at sig-
nificantly increased risk for sarcomas, melanoma, and cancers of the brain and nasal
cavities [44].
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3.1 Case report 1
Girl with bilateral retinoblastoma treated in 1989 in Bratislava by enucleation of
the right eye and chemotherapy plus RT on the left side. Due to secondary compli-
cation, she underwent cataract surgery in 1993 and was aphakic and got glasses. In
2011 secondary tumor developed in the orbit region with infiltration to the brain.
She underwent surgery three times by a neurosurgeon with adjuvant chemotherapy
and high-dose RT due to verified leiomyosarcoma. In 2015 due to progression of the
leiomyosarcoma, she underwent photon beam irradiation with gamma knife.
Tumor masses infiltrating the orbit lead to exenteration of the orbit (Figures 1–3).
The risk of secondary malignancies after retinoblastoma treatment is high, but in
contrast to bone cancers and leiomyosarcomas, chemotherapy was not associated
with increased melanoma risk [10, 17]. The development of skin melanoma may be
related to an underlying genetic predisposition associated with retinoblastoma
rather than treatment modality. Major susceptibility genes for melanoma include
CDKN2A and CDK4 which are both upstream from the Rb1 gene. In the future an
additional investigation is necessary to understand the association between the
development of melanoma and retinoblastoma treatment [45].
The leukemogenicity of certain chemotherapeutic agents is well established, and
there are connections between alkylating agents and a range of development of solid
Figure 1.
Case report 1: Patient after enucleation of her right eye in childhood; conjunctival sac clear; in her left eye,
aphakia (clinical findings in 2015).
Figure 2.
Case report 1: Preoperative findings in 2017 by partial exenteration of the left orbit due to secondary tumor—
Histopathologically confirmed leiomyosarcoma grade 2.
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The overall median survival was 10.3 months, and the 5-year survival rate was 16%,
while in patients receiving high-dose chemotherapy by stem cell transplantation,
the survival time was significantly longer than with conventional chemotherapy.
The authors conclude that trilateral retinoblastoma patients with an irradiation
history had shorter survival than those without irradiation history for retinoblas-
toma, and high-dose chemotherapy should be considered as a potential treatment
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onstrated in all types of soft tissue sarcomas. Retinoblastoma patients should be
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which together account for about 90% of all tumors. The borderline between
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treatment indicate that the most important risk factor remains the Rb1 genemutation.
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SMNs. Chemotherapy has also been associated with an increased risk for other types
of malignancies, e.g., lung cancer after Hodgkin and non-Hodgkin lymphomas,
stomach cancer after Hodgkin lymphoma in combination with high-dose abdominal
RT, and colorectal cancer after childhood cancer [46, 47]. Increased sarcoma risk
after childhood cancer is associated with anthracyclines therapy, especially after
Hodgkin lymphoma or a primary sarcoma in childhood [48].
Hereditary retinoblastoma survivors who were treated with alkylating agents
plus RT have a significantly higher risk of developing bone cancers and
leiomyosarcomas than those treated with single RT. Excess risks of secondary can-
cers associated with alkylating agents plus RT persist for decades. Significantly
higher incidence of leiomyosarcomas is diagnosed at a median age of 34 years.
These risks are present during long-term follow-up of retinoblastoma survivors.
Guide recommendations for future treatment protocols will define chemo-related
SMN risk among retinoblastoma survivors, particularly in patients treated with
chemotherapy without RT.
Current chemotherapy agents recommended for retinoblastoma include cyclo-
phosphamide, ifosfamide, carboplatin, vincristine, etoposide, topotecan, and doxo-
rubicin [49–51]. Most retinoblastoma survivors who received an alkylating agent
received TEM, which is no longer used in clinical practice [52]. On the basis of the
recently developed cyclophosphamide equivalent dose, TEM has substantially lower
hematologic toxicity than agents used in current clinical practice. Generally there is
the long latency period of SMN development and potentially different CT drug-
related adverse effect. In the future studies have to evaluate SMN risk with long-
term follow-up of patients with retinoblastoma treated with current agents. The
cyclophosphamide equivalent dose can be easily calculated, facilitating its use for
patient counseling. It is independent of the drug dose distribution of a particular
patient population, a characteristic that will allow direct comparisons of outcomes
among epidemiological cohorts. The use of the cyclophosphamide equivalent dose is
promising in future research, assessing cumulative alkylating agent exposure [53].
Several limitations of certain studies dealing with SMNs should be taken into
account. On reports of family history of retinoblastoma and laterality to define
hereditary status, some unilateral retinoblastoma survivors could have had a
germline Rb1 mutation and should have been included into analysis [17, 34].
Although some survivors in studies are lost to follow-up due to different reasons,
SMN risk estimates are unlikely to be affected, because response was not related to
Figure 3.
Case report 1: Clinical findings next month after surgery of the left orbit, healing without complications.
114
Retinoblastoma - Past, Present and Future
treatment received for retinoblastoma [54]. Due to results of Wong et al., although
SMNs are more likely to be misclassified because histology is not specified, sensitivity
analyses including 1-year versus 5-year survivors also yielded comparable results [22].
Skin malignancies are rare but usually are in the head region. Orbital malignan-
cies are more frequent. In the study was presented a 22-year-old young man with
history of bilateral retinoblastoma initially in childhood treated by enucleation of
his left eye. The histopathology findings showed a moderately differentiated tumor
with vitreous seeding. The patient received chemotherapy in addition to radiother-
apy to his right eye. More than 20 years later, he got proptosis due to the right
orbital tumor. The excisional biopsy of his orbital mass verified a spindle cell
sarcoma with features of malignant fibrous histiocytoma [55].
3.2 Case report 2
Boy with unilateral retinoblastoma treated in 1988 in Bratislava with enucleation
of the left eye globe and chemotherapy and RT. He got individual prosthesis
Figure 4.
Case report 2: Secondary tumor in his upper right eye lid (histopathologically confirmed squamous cell
carcinoma of the eyelid).
Figure 5.
Case report 2: Patient 2 months after surgery due to secondary malignancy—Squamous cell carcinoma, in his
upper left eyelid.
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without complications. In 2017 he developed “inflammation” of the right eye upper
eye lid and was sent to an ophthalmologist for chalazion excochleation. By exci-
sional biopsy was confirmed squamous cell carcinoma (Figures 4 and 5).
4. Conclusion
Retinoblastoma survivors as carriers of the retinoblastoma gene have a long life
and increased incidence for secondary tumors. Ophthalmologists should always
keep this in mind to be able to provide these patients with proper counseling, plan
for close long-term follow-up, and update their knowledge in the therapy modali-
ties of retinoblastoma current management and possible secondary malignancies in
adulthood. A clear consensus on the form of a screening protocol would be most
appropriate and effective in preventing future malignancies.
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and increased incidence for secondary tumors. Ophthalmologists should always
keep this in mind to be able to provide these patients with proper counseling, plan
for close long-term follow-up, and update their knowledge in the therapy modali-
ties of retinoblastoma current management and possible secondary malignancies in
adulthood. A clear consensus on the form of a screening protocol would be most
appropriate and effective in preventing future malignancies.
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